
<html lang="en"     class="pb-page"  data-request-id="7ac093e2-94a8-498a-b723-47791114ea56"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2017.60.issue-19;article:article:10.1021/acs.jmedchem.7b00631;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656)" /></meta><meta name="dc.Creator" content="Xianfeng  Li" /></meta><meta name="dc.Creator" content="Vincent  Hernandez" /></meta><meta name="dc.Creator" content="Fernando L.  Rock" /></meta><meta name="dc.Creator" content="Wai  Choi" /></meta><meta name="dc.Creator" content="Yvonne S. L.  Mak" /></meta><meta name="dc.Creator" content="Manisha  Mohan" /></meta><meta name="dc.Creator" content="Weimin  Mao" /></meta><meta name="dc.Creator" content="Yasheen  Zhou" /></meta><meta name="dc.Creator" content="Eric E.  Easom" /></meta><meta name="dc.Creator" content="Jacob J.  Plattner" /></meta><meta name="dc.Creator" content="Wuxin  Zou" /></meta><meta name="dc.Creator" content="Esther  Pérez-Herrán" /></meta><meta name="dc.Creator" content="Ilaria  Giordano" /></meta><meta name="dc.Creator" content="Alfonso  Mendoza-Losana" /></meta><meta name="dc.Creator" content="Carlos  Alemparte" /></meta><meta name="dc.Creator" content="Joaquín  Rullas" /></meta><meta name="dc.Creator" content="Iñigo  Angulo-Barturen" /></meta><meta name="dc.Creator" content="Sabrinia  Crouch" /></meta><meta name="dc.Creator" content="Fátima  Ortega" /></meta><meta name="dc.Creator" content="David  Barros" /></meta><meta name="dc.Creator" content="M. R. K.  Alley" /></meta><meta name="dc.Description" content="There is an urgent need to develop new and safer antitubercular agents that possess a novel mode of action. We synthesized and evaluated a novel series of 3-aminomethyl 4-halogen benzoxaboroles as ..." /></meta><meta name="Description" content="There is an urgent need to develop new and safer antitubercular agents that possess a novel mode of action. We synthesized and evaluated a novel series of 3-aminomethyl 4-halogen benzoxaboroles as ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 27, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00631" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00631" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00631" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00631" /></link>
        
    
    

<title>Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00631" /></meta><meta property="og:title" content="Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0011.jpeg" /></meta><meta property="og:description" content="There is an urgent need to develop new and safer antitubercular agents that possess a novel mode of action. We synthesized and evaluated a novel series of 3-aminomethyl 4-halogen benzoxaboroles as Mycobacterium tuberculosis (Mtb) leucyl-tRNA synthetase (LeuRS) inhibitors. A number of Mtb LeuRS inhibitors were identified that demonstrated good antitubercular activity with high selectivity over human mitochondrial and cytoplasmic LeuRS. Further evaluation of these Mtb LeuRS inhibitors by in vivo pharmacokinetics (PK) and murine tuberculosis (TB) efficacy models led to the discovery of GSK3036656 (abbreviated as GSK656). This molecule shows potent inhibition of Mtb LeuRS (IC50 = 0.20 μM) and in vitro antitubercular activity (Mtb H37Rv MIC = 0.08 μM). Additionally, it is highly selective for the Mtb LeuRS enzyme with IC50 of &gt;300 μM and 132 μM for human mitochondrial LeuRS and human cytoplasmic LeuRS, respectively. In addition, it exhibits remarkable PK profiles and efficacy against Mtb in mouse TB infection models with superior tolerability over initial leads. This compound has been progressed to clinical development for the treatment of tuberculosis." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00631"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00631">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00631&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00631&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00631&amp;href=/doi/10.1021/acs.jmedchem.7b00631" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 19</span><span class="cit-fg-pageRange">, 8011-8026</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/19" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00476" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00745" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Potent and Specific <i>M. tuberculosis</i> Leucyl-tRNA Synthetase Inhibitor: (<i>S</i>)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol (GSK656)</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xianfeng++Li">Xianfeng Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vincent++Hernandez">Vincent Hernandez</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fernando+L.++Rock">Fernando L. Rock</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wai++Choi">Wai Choi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yvonne+S.+L.++Mak">Yvonne S. L. Mak</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Manisha++Mohan">Manisha Mohan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Weimin++Mao">Weimin Mao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yasheen++Zhou">Yasheen Zhou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eric+E.++Easom">Eric E. Easom</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jacob+J.++Plattner">Jacob J. Plattner</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wuxin++Zou">Wuxin Zou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Esther++P%C3%A9rez-Herr%C3%A1n">Esther Pérez-Herrán</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ilaria++Giordano">Ilaria Giordano</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alfonso++Mendoza-Losana">Alfonso Mendoza-Losana</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carlos++Alemparte">Carlos Alemparte</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joaqu%C3%ADn++Rullas">Joaquín Rullas</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=I%C3%B1igo++Angulo-Barturen">Iñigo Angulo-Barturen</a></span><span class="author-xref-symbol "><sup>∥</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sabrinia++Crouch">Sabrinia Crouch</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=F%C3%A1tima++Ortega">Fátima Ortega</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Barros">David Barros</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-4099-0438" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=M.+R.+K.++Alley">M. R. K. Alley</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Anacor Pharmaceuticals, Inc., 1020 E. Meadow Circle, Palo Alto, California 94303, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">BioDuro LLC, Building E, No. 29, Life Science Park Road, Beijing 102206, P. R. China</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">GlaxoSmithKline, Tres Cantos Medicines Development Campus, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain</span></div><div class="corresp-info"><strong>*</strong>Phone: (+34) 629170293. Fax: (+34) 918070550. E-mail: <a href="/cdn-cgi/l/email-protection#7115100718155f105f131003031e023116021a5f121e1c"><span class="__cf_email__" data-cfemail="8ce8edfae5e8a2eda2eeedfefee3ffccebffe7a2efe3e1">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00631&amp;href=/doi/10.1021%2Facs.jmedchem.7b00631" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 19</span><span class="cit-pageRange">, 8011–8026</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 27, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>5 May 2017</li><li><span class="item_label"><b>Published</b> online</span>27 September 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 October 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00631" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00631</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8011%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXianfeng%2BLi%252C%2BVincent%2BHernandez%252C%2BFernando%2BL.%2BRock%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D19%26contentID%3Dacs.jmedchem.7b00631%26title%3DDiscovery%2Bof%2Ba%2BPotent%2Band%2BSpecific%2BM.%2Btuberculosis%2BLeucyl-tRNA%2BSynthetase%2BInhibitor%253A%2B%2528S%2529-3-%2528Aminomethyl%2529-4-chloro-7-%25282-hydroxyethoxy%2529benzo%255Bc%255D%255B1%252C2%255Doxaborol-1%25283H%2529-ol%2B%2528GSK656%2529%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8026%26publicationDate%3DOctober%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00631"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3404</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">59</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00631" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xianfeng&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Vincent&quot;,&quot;last_name&quot;:&quot;Hernandez&quot;},{&quot;first_name&quot;:&quot;Fernando&quot;,&quot;last_name&quot;:&quot;L. Rock&quot;},{&quot;first_name&quot;:&quot;Wai&quot;,&quot;last_name&quot;:&quot;Choi&quot;},{&quot;first_name&quot;:&quot;Yvonne&quot;,&quot;last_name&quot;:&quot;S. L. Mak&quot;},{&quot;first_name&quot;:&quot;Manisha&quot;,&quot;last_name&quot;:&quot;Mohan&quot;},{&quot;first_name&quot;:&quot;Weimin&quot;,&quot;last_name&quot;:&quot;Mao&quot;},{&quot;first_name&quot;:&quot;Yasheen&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Eric&quot;,&quot;last_name&quot;:&quot;E. Easom&quot;},{&quot;first_name&quot;:&quot;Jacob&quot;,&quot;last_name&quot;:&quot;J. Plattner&quot;},{&quot;first_name&quot;:&quot;Wuxin&quot;,&quot;last_name&quot;:&quot;Zou&quot;},{&quot;first_name&quot;:&quot;Esther&quot;,&quot;last_name&quot;:&quot;Pérez-Herrán&quot;},{&quot;first_name&quot;:&quot;Ilaria&quot;,&quot;last_name&quot;:&quot;Giordano&quot;},{&quot;first_name&quot;:&quot;Alfonso&quot;,&quot;last_name&quot;:&quot;Mendoza-Losana&quot;},{&quot;first_name&quot;:&quot;Carlos&quot;,&quot;last_name&quot;:&quot;Alemparte&quot;},{&quot;first_name&quot;:&quot;Joaquín&quot;,&quot;last_name&quot;:&quot;Rullas&quot;},{&quot;first_name&quot;:&quot;Iñigo&quot;,&quot;last_name&quot;:&quot;Angulo-Barturen&quot;},{&quot;first_name&quot;:&quot;Sabrinia&quot;,&quot;last_name&quot;:&quot;Crouch&quot;},{&quot;first_name&quot;:&quot;Fátima&quot;,&quot;last_name&quot;:&quot;Ortega&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Barros&quot;},{&quot;first_name&quot;:&quot;M.&quot;,&quot;last_name&quot;:&quot;R. K. Alley&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;19&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;8011-8026&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00631&quot;},&quot;abstract&quot;:&quot;There is an urgent need to develop new and safer antitubercular agents that possess a novel mode of action. We synthesized and evaluated a novel series of 3-aminomethyl 4-halogen benzoxaboroles as Mycobacterium tuberculosis (Mtb) leucyl-tRNA synthetase (LeuRS) inhibitors. A number of Mtb LeuRS inhibitors were identified that demonstrated good antitubercular activity with high selectivity over human mitochondrial and cytoplasmic LeuRS. Further evaluation of these Mtb LeuRS inhibitors by in vivo pharmacokinetics (PK) and murine tuberculosis (TB) efficacy models led to the discovery of GSK3036656 (abbreviated as GSK656). This molecule shows potent inhibition of Mtb LeuRS (IC50 = 0.20 μM) and in vitro antitubercular activity (Mtb H37Rv MIC = 0.08 μM). Additionally, it is highly selective for the Mtb LeuRS enzyme with IC50 of &gt;300 μM and 132 μM for human mitochondrial LeuRS and human cytoplasmic LeuRS, respectively. In addition, it exhibits remarkable PK profiles and efficacy against Mtb in mouse TB infection mode&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00631&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00631" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00631&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00631" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00631&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00631" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00631&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00631&amp;href=/doi/10.1021/acs.jmedchem.7b00631" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00631" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00631" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00631%26sid%3Dliteratum%253Aachs%26pmid%3D28953378%26genre%3Darticle%26aulast%3DLi%26date%3D2017%26atitle%3DDiscovery%2Bof%2Ba%2BPotent%2Band%2BSpecific%2BM.%2Btuberculosis%2BLeucyl-tRNA%2BSynthetase%2BInhibitor%253A%2B%2528S%2529-3-%2528Aminomethyl%2529-4-chloro-7-%25282-hydroxyethoxy%2529benzo%255Bc%255D%255B1%252C2%255Doxaborol-1%25283H%2529-ol%2B%2528GSK656%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D19%26spage%3D8011%26epage%3D8026%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291430" title="Infectious diseases">Infectious diseases</a>,</li><li><a href="/action/doSearch?ConceptID=291011" title="High-performance liquid chromatography">High-performance liquid chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/19" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/jmcmar.2017.60.issue-19/20171012/jmcmar.2017.60.issue-19.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/medium/jm-2017-00631g_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00631&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">There is an urgent need to develop new and safer antitubercular agents that possess a novel mode of action. We synthesized and evaluated a novel series of 3-aminomethyl 4-halogen benzoxaboroles as <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>) leucyl-tRNA synthetase (LeuRS) inhibitors. A number of <i>Mtb</i> LeuRS inhibitors were identified that demonstrated good antitubercular activity with high selectivity over human mitochondrial and cytoplasmic LeuRS. Further evaluation of these <i>Mtb</i> LeuRS inhibitors by in vivo pharmacokinetics (PK) and murine tuberculosis (TB) efficacy models led to the discovery of GSK3036656 (abbreviated as GSK656). This molecule shows potent inhibition of <i>Mtb</i> LeuRS (IC<sub>50</sub> = 0.20 μM) and in vitro antitubercular activity (<i>Mtb</i> H37Rv MIC = 0.08 μM). Additionally, it is highly selective for the <i>Mtb</i> LeuRS enzyme with IC<sub>50</sub> of >300 μM and 132 μM for human mitochondrial LeuRS and human cytoplasmic LeuRS, respectively. In addition, it exhibits remarkable PK profiles and efficacy against <i>Mtb</i> in mouse TB infection models with superior tolerability over initial leads. This compound has been progressed to clinical development for the treatment of tuberculosis.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83377" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83377" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Tuberculosis (TB) is a life-threatening infectious disease caused by the bacteria <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>). The World Health Organization (WHO) estimates that one-third of the world’s population is infected with <i>Mtb</i>, resulting in 1.4 million deaths in 2015.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In the same year, there were additional 0.4 million people infected with HIV who also died of TB disease.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The current treatment for TB infection requires a combination therapy of four front-line drugs rifampin, isoniazid, pyrazinamide, and ethambutol for 6–9 months, often leading to significant side effects and poor patient compliance. In addition, emergence of multidrug-resistant TB (MDR-TB)<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and extensively drug-resistant TB (XDR-TB)<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> has rendered many front-line and second-line drugs ineffective. Furthermore, totally drug-resistant TB (TDR-TB) has recently emerged that is resistant to all clinical drugs.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Therefore, there is an urgent need to develop new antitubercular agents that are effective against TB, which possess a novel mode of action that circumvents these resistances.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8">(5-8)</a></div><div class="NLM_p">Bedaquiline and delamanid have recently been approved by the Food and Drug Administration (FDA) or the European Medicines Agency (EMA) to treat MDR-TB, representing the first new TB drugs in more than 40 years.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> Bedaquiline acts by the novel mechanism of mycobacterial adenosine 5′-triphosphate (ATP) synthase inhibition,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> while delamanid is a nitroimidazole derivative that primarily inhibits synthesis of methoxymycolic and ketomycolic acid, which are components of the mycobacterial cell wall.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> However, bedaquiline has a boxed warning related to possible cardiac toxicity<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and delamanid (OPC-67683) induces QTc prolongation.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> In addition there is cross-resistance between clofazimine and bedaquiline<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> as well as some of pre-existing resistance to delamanid.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> There has been an increased activity toward the discovery of new antitubercular agents.<a onclick="showRef(event, 'ref17 ref18 ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20 ref21 ref22">(17-22)</a> Other TB drug candidates that are in the clinical development include moxifloxacin, sutezolid, SQ109, and Q203<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/medium/jm-2017-00631g_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0001.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Bedaquiline, delamanid, and selected TB drug candidates in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00631&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We recently identified a series of 3-aminomethylbenzoxaboroles that target <i>Mtb</i> LeuRS (<b>1</b>–<b>4</b>, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> These <i>Mtb</i> LeuRS inhibitors require the boron atom for <i>Mtb</i> LeuRS activity since it forms a bidentate covalent adduct with the terminal nucleotide of tRNA, Ade76. The resulting covalent adduct traps the 3′ end of tRNA<sup>Leu</sup> in the editing site in a nonproductive complex, inhibiting leucylation and thus protein synthesis. The amino group of the (<i>S</i>)-aminomethyl side chain at C-3 is critical for binding as it makes three hydrogen bonding interactions. An important finding from this work is that 4-halogen atom (especially Cl and Br) significantly improves <i>Mtb</i> LeuRS activity, antitubercular activity against <i>Mtb</i> H37Rv, and selectivity against other bacteria. This effort led to the discovery of potent <i>Mtb</i> LeuRS inhibitors <b>3a</b> and <b>4a</b> that are orally bioavailable and effective against <i>Mtb</i> in mouse TB infection models but with potential toxicity issues from inhibition of mammalian cytoplasmic LeuRS.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Furthermore, a once daily dose of 50 mg/kg <b>4a</b> in a mouse acute TB infection model was not tolerated and was a concern for an indication that involved long-term therapy.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/medium/jm-2017-00631g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. 3-Aminomethyl 4-halogen benzoxaborole inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00631&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Therefore, we set out to expand structure–activity relationship (SAR) of this 3-aminomethyl 4-halogen benzoxaborole series with the goal to improve the selectivity of the <i>Mtb</i> LeuRS inhibitors suitable for further development. From the binding pharmacophore revealed by the crystal structure of <b>3a</b> complexed with <i>Mtb</i> LeuRS,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> the C-7 or C-6 position of the benzoxaborole appears to be solvent-exposed and may be open for structural modification. In the present work, we used <b>3a</b> and <b>4a</b> as lead compounds and focused on three modification sites which are C-7, C-6, and C-6/C-7 positions. We investigated various 7-substituted analogues represented by target compounds <b>5</b>–<b>24</b> (class A) and a number of 6-substituted compounds <b>25</b>–<b>32</b> (class B) as well as C-6/C-7 fused compounds <b>33</b>–<b>36</b> (class C). In this study, we intentionally made and evaluated both 4-Cl and 4-Br compounds in parallel, providing useful SAR information on their relative magnitudes in activity and selectivity. Further PK evaluation and efficacy studies of these <i>Mtb</i> LeuRS inhibitors led to the identification of a first-in-class boron-containing antitubercular agent <b>23a</b> (GSK656),<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> which had a much better safety profile than <b>3a</b> and <b>4a</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Activity of Compounds <b>1</b>–<b>36</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/medium/jm-2017-00631g_0009.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/medium/jm-2017-00631g_0010.gif" alt="" id="GRAPHIC-d97e586-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">All compounds were prepared as HCl or TFA salts. Experimental procedures are described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Values are the mean of duplicate or more experiments.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Desired product with 7-phenoxy group (R = Ph) was not formed during the bromination step, and dibrominated product <b>12</b> with 7-(4-bromophenoxy) group was isolated instead.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro Selectivity Data for Representative Compounds<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">human mito LeuRS IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">human cytoplasm LeuRS IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">HepG2 protein synthesis EC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">selectivity index<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">HepG2 cell 48 h EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3a</b></td><td class="colsep0 rowsep0" align="left">>300</td><td class="colsep0 rowsep0" align="left">38.8</td><td class="colsep0 rowsep0" align="left">19.6</td><td class="colsep0 rowsep0" align="left">196</td><td class="colsep0 rowsep0" align="left">65.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4a</b></td><td class="colsep0 rowsep0" align="left">>300</td><td class="colsep0 rowsep0" align="left">66.9</td><td class="colsep0 rowsep0" align="left">30.5</td><td class="colsep0 rowsep0" align="left">305</td><td class="colsep0 rowsep0" align="left">47.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5a</b></td><td class="colsep0 rowsep0" align="left">>300</td><td class="colsep0 rowsep0" align="left">260</td><td class="colsep0 rowsep0" align="left">105</td><td class="colsep0 rowsep0" align="left">1050</td><td class="colsep0 rowsep0" align="left">327</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="left">>300</td><td class="colsep0 rowsep0" align="left">>300</td><td class="colsep0 rowsep0" align="left">97</td><td class="colsep0 rowsep0" align="left">970</td><td class="colsep0 rowsep0" align="left">74.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23a</b></td><td class="colsep0 rowsep0" align="left">>300</td><td class="colsep0 rowsep0" align="left">132</td><td class="colsep0 rowsep0" align="left">137</td><td class="colsep0 rowsep0" align="left">1713</td><td class="colsep0 rowsep0" align="left">381</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24a</b></td><td class="colsep0 rowsep0" align="left">>300</td><td class="colsep0 rowsep0" align="left">118</td><td class="colsep0 rowsep0" align="left">116</td><td class="colsep0 rowsep0" align="left">1450</td><td class="colsep0 rowsep0" align="left">292</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35a</b></td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">96.6</td><td class="colsep0 rowsep0" align="left">82.8</td><td class="colsep0 rowsep0" align="left">1035</td><td class="colsep0 rowsep0" align="left">69.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36a</b></td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">118</td><td class="colsep0 rowsep0" align="left">39.5</td><td class="colsep0 rowsep0" align="left">1317</td><td class="colsep0 rowsep0" align="left">43.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">The human biological samples were sourced ethically, and their research use was in accord with the terms of the informed consents.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Selectivity index is defined as a ratio of HepG2 protein synthesis EC<sub>50</sub> over MIC against <i>Mtb</i> H37Rv. Values are the mean of duplicate or more experiments.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Readout performed with CellTiter Glo luminescent viability assay kit (Promega).</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">NT = not tested.</p></div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Physicochemical Properties and PK Parameters<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center"><b>4a</b><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><b>4a</b><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center"><b>6a</b><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><b>23a</b><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center"><b>35a</b><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MW</td><td class="colsep0 rowsep0" colspan="2" align="center">285.9</td><td class="colsep0 rowsep0" align="left">271.9</td><td class="colsep0 rowsep0" align="left">239.5</td><td class="colsep0 rowsep0" align="left">255.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">clogD<sub>7.4</sub></td><td class="colsep0 rowsep0" colspan="2" align="center">0.95</td><td class="colsep0 rowsep0" align="left">0.60</td><td class="colsep0 rowsep0" align="left">–0.4</td><td class="colsep0 rowsep0" align="left">–0.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PSA</td><td class="colsep0 rowsep0" colspan="2" align="center">64.71</td><td class="colsep0 rowsep0" align="left">64.71</td><td class="colsep0 rowsep0" align="left">53.71</td><td class="colsep0 rowsep0" align="left">73.94</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose (mg/kg), iv</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">28.5</td><td class="colsep0 rowsep0" align="left">5.0</td><td class="colsep0 rowsep0" align="left">5.5</td><td class="colsep0 rowsep0" align="left">30.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">3.2</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mL min<sup>–1</sup> kg<sup>–1</sup>), iv</td><td class="colsep0 rowsep0" align="left">11.45</td><td class="colsep0 rowsep0" align="left">6.6</td><td class="colsep0 rowsep0" align="left">14.2</td><td class="colsep0 rowsep0" align="left">8.5</td><td class="colsep0 rowsep0" align="left">6.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">3.4</td><td class="colsep0 rowsep0" align="left">3.1</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">3.6</td><td class="colsep0 rowsep0" align="left">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–inf</sub> (h·μg/mL), iv</td><td class="colsep0 rowsep0" align="left">43.4</td><td class="colsep0 rowsep0" align="left">72.3</td><td class="colsep0 rowsep0" align="left">5.84</td><td class="colsep0 rowsep0" align="left">11.12</td><td class="colsep0 rowsep0" align="left">76.32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DNAUC<sub>0–inf</sub> (h·μg/mL per mg/kg), iv</td><td class="colsep0 rowsep0" align="left">1.45</td><td class="colsep0 rowsep0" align="left">2.54</td><td class="colsep0 rowsep0" align="left">1.17</td><td class="colsep0 rowsep0" align="left">2.03</td><td class="colsep0 rowsep0" align="left">2.54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose (mg/kg), po</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">26.1</td><td class="colsep0 rowsep0" align="left">5.0</td><td class="colsep0 rowsep0" align="left">30.0</td><td class="colsep0 rowsep0" align="left">30.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μg/mL)</td><td class="colsep0 rowsep0" align="left">6.3</td><td class="colsep0 rowsep0" align="left">11.14</td><td class="colsep0 rowsep0" align="left">0.98</td><td class="colsep0 rowsep0" align="left">17.76</td><td class="colsep0 rowsep0" align="left">6.21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–24h</sub> (h·μg/mL), po</td><td class="colsep0 rowsep0" align="left">57.6</td><td class="colsep0 rowsep0" align="left">77.86</td><td class="colsep0 rowsep0" align="left">4.21</td><td class="colsep0 rowsep0" align="left">88.24</td><td class="colsep0 rowsep0" align="left">37.67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DNAUC<sub>0–24h</sub> (h·μg/mL), po</td><td class="colsep0 rowsep0" align="left">1.92</td><td class="colsep0 rowsep0" align="left">2.98</td><td class="colsep0 rowsep0" align="left">0.84</td><td class="colsep0 rowsep0" align="left">2.94</td><td class="colsep0 rowsep0" align="left">1.26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">∼100</td><td class="colsep0 rowsep0" align="left">∼100</td><td class="colsep0 rowsep0" align="left">72</td><td class="colsep0 rowsep0" align="left">∼100</td><td class="colsep0 rowsep0" align="left">50</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">All animal studies were ethically reviewed and carried out in accordance with European Directive 2010/63/EU and the GSK Policy on the Care, Welfare and Treatment of Animals.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Mouse PK studies were conducted by using CD-1 mice as described in ref <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">23</a>. PK values for <b>4a</b> by using CD-1 mice were from ref <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">23</a> and are presented for comparison.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">Mouse PK studies were conducted by using C57 mice as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Efficacy in a Mouse Model of Acute TB Infection<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>4a</b><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><b>6a</b></th><th class="colsep0 rowsep0" align="center"><b>23a</b></th><th class="colsep0 rowsep0" align="center"><b>35a</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ED<sub>99</sub> (mg/kg)</td><td class="colsep0 rowsep0" align="left"><1.0</td><td class="colsep0 rowsep0" align="left">3.8</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">70</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Efficacy of compounds in a mouse model of acute TB infection under QD dosing regimen (once a day). C57BL/6J mice were infected with <i>M. tuberculosis</i> H37Rv intratracheally (∼10<sup>5</sup> CFU) and were dosed starting on the following day after infection for 8 days. Mice were sacrificed at least 24 h after the last drug administration. All animal studies were ethically reviewed and carried out in accordance with European Directive 2010/63/EU and the GSK Policy on the Care, Welfare and Treatment of Animals.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Efficacy data for <b>4a</b> was reported previously in ref <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">23</a>.</p></div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Efficacy in a Mouse Model of Chronic TB Infection<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" colspan="2" align="center">no treatment</th><th class="colsep0 rowsep0" align="center">linezolid</th><th class="colsep0 rowsep0" colspan="6" align="center"><b>23a</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose (mg/kg)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log<sub>10</sub> CFU</td><td class="colsep0 rowsep0" align="left">5.8<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a> (0.3)</td><td class="colsep0 rowsep0" align="left">6.4<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a> (0.3)</td><td class="colsep0 rowsep0" align="left">3.9<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a> (0.2)</td><td class="colsep0 rowsep0" align="left">6.4 (0.6)</td><td class="colsep0 rowsep0" align="left">6.0 (0.1)</td><td class="colsep0 rowsep0" align="left">4.7<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a> (0.2)</td><td class="colsep0 rowsep0" align="left">4.6<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a> (0.2)</td><td class="colsep0 rowsep0" align="left">4.3<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a> (0.1)</td><td class="colsep0 rowsep0" align="left">4.4<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a> (0.2)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Efficacy of compounds in a mouse model of chronic TB infection under QD dosing regimen (once a day). C57BL/6J mice were infected with <i>M. tuberculosis</i> H37Rv intratracheally (∼10<sup>2</sup> CFU) and were dosed once daily for 8 weeks starting 6 weeks after infection. Mice were sacrificed at least 24 h after the last drug administration. Every data point represents the mean values (±standard deviations) from 7 mice per group for untreated and linezolid-treated groups and from 3 mice for <b>23a</b>-treated groups. All animal studies were ethically reviewed and carried out in accordance with European Directive 2010/63/EU and the GSK Policy on the Care, Welfare and Treatment of Animals.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">6 weeks after infection.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">14 weeks after infection.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">Statistically significant difference compared to 14-week untreated mice (<i>p</i> < 0.05, ANOVA, Dunnett’s multiple comparison test).</p></div></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15463" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15463" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Chemistry</h3><div class="NLM_p">Throughout the article, compounds have been numbered using the format <b>23</b>, <b>23a</b>, and <b>23b</b> for the racemate, the (<i>S</i>)-isomer, and the (<i>R</i>)-isomer of compound <b>23</b>, respectively. The chemistry used to synthesize racemic 7-substituted compounds <b>11</b>–<b>20</b> and <b>23</b>–<b>24</b> (class A) is described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, starting from 2-bromo-3-hydroxybenzaldehyde <b>37</b>. Phenol <b>37</b> was converted to phenyl ether <b>38</b> by alkylation with alkyl bromide or alkyl iodide (when R is an alkyl group) or through copper-mediated arylation with arylboronic acid (when R is an aryl group). Incorporation of boron was accomplished by reaction of <b>38</b> with pinacol diborane in the presence of a palladium catalyst to give boronate <b>39</b> or by reaction of <b>41</b> with <i>n</i>-butyllithium and trimethyl borate followed by acidic workup to give boronic acid <b>42</b>. The Henry reaction of <b>39</b> or <b>42</b> with nitromethane afforded 3-nitromethylbenzoxaborole <b>40</b>.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Chlorination or bromination can be achieved through 3-nitromethylbenzoxaborole <b>40</b> or through <i>tert</i>-butoxycarbonyl (Boc) protected 3-aminomethylbenzoxaborole <b>43</b>. The removal of Boc group of compound <b>44</b> or the reduction of nitro group in compound <b>45</b> provided corresponding C-4 chloro or bromo analogues (<b>11</b>–<b>20</b>, <b>23</b>, <b>24</b>) as racemates. Compounds <b>23</b> and <b>24</b> were further resolved by chiral supercritical fluid chromatography (SFC) separation to provide active enantiomers <b>23a</b> and <b>24a</b>, respectively.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/medium/jm-2017-00631g_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0004.jpeg" id="GRAPHIC-d97e1604-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00631&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) when R = alkyl, alkyl bromide or alkyl iodide, K<sub>2</sub>CO<sub>3</sub>, DMF, heat; when R = aryl, arylboronic acid, Cu(OAc)<sub>2</sub>, TEA, DCM; (b) (Pin)<sub>2</sub>B<sub>2</sub>, KOAc, PdCl<sub>2</sub>(dppf), THF, reflux; (c) CH<sub>3</sub>NO<sub>2</sub>, NaOH, water/THF; (d) ethylene glycol, TsOH, toluene, Dean–Stark apparatus, reflux; (e) (1) BuLi, B(OMe)<sub>3</sub>, THF, −78 °C; (2) 2 N HCl, rt; (f) CH<sub>3</sub>NO<sub>2</sub>, NaOH, water/THF; (g) (1) Raney Ni, H<sub>2</sub>, NH<sub>3</sub>/EtOH, then HCl/Et<sub>2</sub>O; (2) di-<i>tert</i>-butyl dicarbonate, TEA, DCM, 0 °C; (h) when X = Cl, NCS, DMF, heat or SO<sub>2</sub>Cl<sub>2</sub>, AcOH, rt; when X = Br, NBS, CH<sub>3</sub>CN, heat; (i) TFA, DCM, then HCl; (j) when X = Cl, NCS, DMF, heat; when X = Br, NBS, CH<sub>3</sub>CN, heat; (k) Raney Ni, H<sub>2</sub>, NH<sub>3</sub>/EtOH, then HCl/Et<sub>2</sub>O; (l) chiral SFC separation.</p></p></figure><div class="NLM_p">The chemistry used to synthesize enantiopure 7-substituted compounds <b>5a</b>–<b>10a</b>, <b>21a</b>, and <b>22a</b> (class A) is described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. This modular approach would introduce C-7 substitution in appropriate enantiopure benzoxaborole intermediates at a late stage of the synthesis and give active enantiomers, thus avoiding a lengthy multistep route and chiral separation. The enantiopure compound <b>46</b> with 3-hydroxypropoxy substitution at C-7 position was made according to literature procedure.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Dealkylation of <b>46</b> with BBr<sub>3</sub> followed by Boc protection provided the key intermediate <b>51</b> with 7-hydroxy substitution. Initial attempts to alkylate phenol <b>51</b> with an alkyl bromide under standard conditions (K<sub>2</sub>CO<sub>3</sub>, DMSO, room temperature) failed to give any desired 7-alkyoxy product, presumably due to the presence of the neighboring boron atom that forms an intramolecular complex and protects the phenol from further reaction. Finally we found that the reaction of <b>51</b> with an alkyl bromide in the presence of potassium <i>tert</i>-butoxide at 90 °C in DMSO afforded 7-substituted compound <b>52</b>. Subsequent chlorination or bromination of compound <b>52</b>, followed by Boc removal, provided the C-4 chloro or bromo analogs <b>7a</b>–<b>10a</b>. Compounds <b>21a</b> and <b>22a</b> were made by chlorination or bromination of Boc-protected intermediate <b>48</b>, followed by Boc removal. Compounds <b>5a</b> and <b>6a</b> were made similarly from the enantiopure material <b>47</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/medium/jm-2017-00631g_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0005.jpeg" id="GRAPHIC-d97e1767-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00631&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) di-<i>tert</i>-butyl dicarbonate, TEA, DCM, 0 °C; (b) (1) when X = Cl, NCS, DMF, heat; when X = Br, NBS, CH<sub>3</sub>CN, heat; (2) TFA, DCM, then HCl; (c) BBr<sub>3</sub>, DCM, −78 °C; (d) di-<i>tert</i>-butyl dicarbonate, TEA, DCM, 0 °C; (e) alkyl bromide, <i>t</i>-BuOK, DMSO, 90 °C; (f) (1) when X = Cl, NCS, DMF, heat or SO<sub>2</sub>Cl<sub>2</sub>, AcOH, rt; when X = Br, NBS, CH<sub>3</sub>CN, heat; (2) TFA, DCM, then HCl.</p></p></figure><div class="NLM_p">The chemistry used to make 6-substituted analogues (class B) is described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> and <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. For this series of compounds, 4-halogen substituent needs to be incorporated at an early stage of the synthesis. As shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, the 4-Cl analogues were synthesized starting from 2-chloro-4,6-dihydroxybenzaldehyde <b>53</b>. After selected protection of 4-hydroxy group, reaction of phenol <b>54</b> with triflic anhydride in the presence of pyridine gave triflate <b>55</b>. Borylation was accomplished by reaction of triflate <b>55</b> with pinacol diborane in the presence of a palladium catalyst. Subsequent multistep manipulation of boronate <b>56</b> including Henry reaction, nitro reduction, and alkylation provided the final 4-Cl compounds (<b>25</b>, <b>27</b>, <b>29</b>, and <b>31</b>). On the other hand, the 4-Br analogues were synthesized starting from 2,6-dibromo-4-hydroxybenzaldehyde <b>60</b> as shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Alkylation of <b>60</b> followed by protection of aldehyde group provided symmetric dibromide <b>62</b>. Reaction of <b>62</b> with <i>n</i><b>-</b>butyllithium and trimethyl borate followed by acidic workup converted one bromide to boronic acid <b>63</b>. Subsequent multistep manipulation of boronic acid <b>63</b> including Henry reaction and nitro reduction provided the final 4-Br compounds (<b>26</b>, <b>28</b>, <b>30</b>, and <b>32</b>).</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/medium/jm-2017-00631g_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0006.jpeg" id="GRAPHIC-d97e1889-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00631&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) dihydropyran, PPTS (cat.), DCM; (b) Tf<sub>2</sub>O, pyridine, DCM, 0 °C; (c) (Pin)<sub>2</sub>B<sub>2</sub>, PdCl<sub>2</sub>(dppf), KOAc, THF, reflux; (d) CH<sub>3</sub>NO<sub>2</sub>, NaOH, THF; (e) conc HCl; (f) (1) Raney Ni, H<sub>2</sub>, NH<sub>3</sub>/EtOH, then HCl/EtOH; (2) di-<i>tert</i>-butyl dicarbonate, TEA, DCM, 0 °C; (g) alkyl bromide or alkyl iodide, K<sub>2</sub>CO<sub>3</sub>, DMF, heat; (h) TFA, DCM, then HCl.</p></p></figure><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/medium/jm-2017-00631g_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0007.jpeg" id="GRAPHIC-d97e1936-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00631&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) alkyl bromide, K<sub>2</sub>CO<sub>3</sub>, DMF, heat; (b) CH(OMe)<sub>3</sub>, H<sub>2</sub>SO<sub>4</sub>, MeOH, reflux; (c) (1) BuLi, B(OMe)<sub>3</sub>, THF, −78 °C; (2) 2 N HCl, rt; (d) CH<sub>3</sub>NO<sub>2</sub>, NaOH, water/THF; (e) Raney Ni, H<sub>2</sub>, NH<sub>3</sub>/EtOH, then HCl/EtOH.</p></p></figure><div class="NLM_p">The chemistry used to synthesize C-6/C-7 fused analogues <b>33</b>–<b>36</b> (class C) is described in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. Reaction of 2-bromo-3,4-dihydroxybenzaldehyde <b>65</b> with dibromomethane provided five-membered dioxolane containing benzaldehyde <b>66</b> (<i>n</i> = 1). Similarly, reaction of <b>65</b> with 1,1,2,2-tetrabromoethane provided six-membered dioxolane-containing benzaldehyde <b>66</b> (<i>n</i> = 2). Incorporation of boron in compound <b>66</b> was accomplished by reaction with pinacol diborane in the presence of a palladium catalyst to give boronate <b>67</b>. The Henry reaction of boronate <b>67</b> with nitromethane provided 3-nitromethylbenzoxaborole <b>68</b>. Chlorination or bromination of <b>68</b> gave corresponding C-4 chloro- or bromobenzoxaborole <b>69</b>. The reduction of nitro group in compound <b>69</b> gave the C-4 chloro or bromo C-6/C-7 fused analogs <b>33</b>–<b>36</b>. Compounds <b>35</b> and <b>36</b> were further separated into their active enantiomers <b>35a</b> and <b>36a</b> by chiral SFC separation.</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/medium/jm-2017-00631g_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0008.jpeg" id="GRAPHIC-d97e2052-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00631&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) CH<sub>2</sub>Br<sub>2</sub> (<i>n</i> = 1) or BrCH<sub>2</sub>CH<sub>2</sub>Br (<i>n</i> = 2), K<sub>2</sub>CO<sub>3</sub>, DMF, heat; (b) (Pin)<sub>2</sub>B<sub>2</sub>, KOAc, PdCl<sub>2</sub>(dppf), dioxane, reflux; (c) CH<sub>3</sub>NO<sub>2</sub>, NaOH, THF; (d) when X = Cl, NCS, DMF, heat or SO<sub>2</sub>Cl<sub>2</sub>, AcOH, rt; when X = Br, NBS, CH<sub>3</sub>CN; (e) Raney Ni, H<sub>2</sub>, NH<sub>3</sub>/EtOH, then HCl/EtOH; (f) chiral SFC separation.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Structure–Activity Relationships</h3><div class="NLM_p">The compounds were evaluated in the <i>Mtb</i> LeuRS aminoacylation assay as well as in a whole cell activity assay against <i>Mtb</i> H37Rv (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Since cell penetration can vary between series, the MIC values of these <i>Mtb</i> LeuRS inhibitors against <i>Mtb</i> H37Rv were used to optimize the potency and drive SAR, while the biochemical inhibition was used to gauge whether the inhibitors were on target. Representative compounds with good antitubercular activity (<i>Mtb</i> H37Rv MIC < 0.2 μM) were selected and tested for selectivity in the human mitochondrial and cytoplasmic LeuRS biochemical assays as well as activity against cytoplasmic protein synthesis in intact human HepG2 cells (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) to see if we could improve on the safety profile of the initial leads.</div><div class="NLM_p">Most of compounds were made and tested as racemates first and separated into active (<i>S</i>)-isomers when racemates were very active (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Generally, the (<i>S</i>)-enantiomer is 2-fold more potent compared to the racemate and the (<i>R</i>)-enantiomer is completely inactive as exemplified by compounds <b>23</b>, <b>24</b>, <b>35</b>, and <b>36</b>. For these four compounds, the results from the racemate and both enantiomers were given for comparison.</div><div class="NLM_p">We first explored the size of 7-alkoxyl side chain of the <i>Mtb</i> LeuRS inhibitors. The smaller 7-methoxy compounds <b>5a</b> and <b>6a</b> showed similar <i>Mtb</i> LeuRS potency and antitubercular activity, compared to 7-ethoxy leads <b>3a</b> and <b>4a</b>. Increasing the length of 7-alkoxy group provided 7-propoxy compounds <b>7a</b>/<b>8a</b> and butoxy compounds <b>9a</b>/<b>10a</b>. These analogues with larger 7-alkoxy substitutions exhibited decreased <i>Mtb</i> LeuRS potency and antitubercular activity by 2- to 5-fold, suggesting that adding size and lipophilicity at 7-position is not beneficial for biochemical and antitubercular activity. We also incorporated aromatic moieties in 7-substitution and made six analogues with one-, two, or three-atom linker between the two aromatics (<b>11</b>–<b>16</b>). These large compounds showed decent <i>Mtb</i> LeuRS activity; however, all of them lost antitubercular activity, suggesting that adding hydrophobic aromatics in the molecule was detrimental to their antitubercular activity. <b>5a</b> and <b>6a</b> were selected for in vitro selectivity evaluation.</div><div class="NLM_p">Since the addition of fluorine atoms to drugs is well-known to have the potential to acquire additional interactions, modulate potency and selectivity of bioactive compounds, we did a fluorine scan of the 7-ethoxy side chain and explored the effects of C-7 fluorine substitution on <i>Mtb</i> LeuRS and antitubercular activity. Introduction of one fluorine atom in the 7-ethoxy group (<b>17</b> and <b>18</b>) resulted in approximately equivalent MIC values (considering compounds <b>17</b> and <b>18</b> are racemates). Introduction of two fluorine atoms in the 7-ethoxy group of compounds <b>19</b> and <b>20</b> resulted in slight decrease in antitubercular activity.</div><div class="NLM_p">We also explored the impacts of a hydrophilic side chain at C-7 position on the potency of the <i>Mtb</i> LeuRS inhibitors. <b>21a</b> and <b>22a</b> with 3-hydroxypropoxy group at C-7 position maintained <i>Mtb</i> LeuRS and antitubercular activity. To further reduce the lipophilicity, the size of the three-carbon linker was reduced to a two-carbon linker giving <b>23</b> and <b>24</b>, both of which were very active. After chiral separation, their corresponding <i>S</i> enantiomers <b>23a</b> and <b>24a</b> were found to exhibit excellent antitubercular activity (MIC = 0.08 μM and 0.08 μM, respectively). Both <b>23a</b> and <b>24a</b> were selected for in vitro selectivity determinations. It is interesting to note that <b>23a</b> or <b>24a</b> is present as a seven-membered tricyclic ring form based on <sup>1</sup>H NMR in deuterated DMSO (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>), suggesting that an equilibrium exists between open and close forms depending on solvent and environment. This dynamic equilibrium between open and closed forms of the benzoxaborole pharmacophore and its six- and seven-membered analogues has been studied by Hall and his group.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><figure id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/medium/jm-2017-00631g_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. 3-Aminomethyl 4-halogen benzoxaborole inhibitors <b>23a</b> and <b>24a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00631&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We also expanded chemical space and synthesized a number of 6-substituted compounds <b>25</b>–<b>32</b> (class B), as described in <a class="ref internalNav" href="#sch3" aria-label="Schemes 3">Schemes 3</a> and <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. These 6-substituted analogs showed decent <i>Mtb</i> LeuRS activity in the range of 0.25–1.11 μM. However, they exhibited poor antitubercular activity compared to the corresponding 7-substituted analogs. Although <b>27</b> and <b>28</b> showed some MIC against <i>Mtb</i> H37Rv (0.6–1.3 μM), further investigation of this subseries of <i>Mtb</i> LeuRS inhibitors was discontinued due its poor antitubercular activity.</div><div class="NLM_p last">In another subseries to expand chemical space (class C), we investigated a C-6/C-7 fused ring in the scaffold to determine the structure–activity relationship by making compounds <b>33</b><i>–</i><b>36</b>, as described in <a class="ref internalNav" href="#sch5" aria-label="Schemes 5">Schemes 5</a>. While <b>33</b> and <b>34</b> with a five-membered dioxolane ring failed to demonstrate antitubercular activity (MIC > 5 μM), compounds <b>35</b> and <b>36</b> with a six-membered dioxane ring exhibited potent <i>Mtb</i> LeuRS and antitubercular activity. Presumably the dioxolane-containing compound <b>33</b> or <b>34</b> has an unfavorable conformation and/or electronics that resulted in their poor cellular activity. The dioxane-containing compounds <b>35</b> and <b>36</b> were separated into their respective enantiomers <b>35a</b> and <b>36a</b>, both of which exhibited potent antitubercular activity (MIC = 0.08 μM and 0.03 μM, respectively). <b>35a</b> and <b>36a</b> were selected for in vitro selectivity evaluation.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> In Vitro Selectivity</h3><div class="NLM_p last">Although in vitro potency against <i>Mtb</i> was not significantly improved over the initial analogs <b>3a</b> and <b>4a</b>, we evaluated the inhibitors against several different in vitro selectivity assays in order to improve their safety profile including a cell-based protein synthesis assay (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Fortunately these series were effectively inactive against human mitochondrial LeuRS with IC<sub>50</sub> > 300 μM, which is presumably due to this enzyme being editing defective.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Compared to the leads <b>3a</b> and <b>4a</b>, the new inhibitors <b>5a</b>, <b>6a</b>, <b>23a</b>, <b>24a</b>, <b>35a</b> all exhibited improved selectivity against human cytoplasmic LeuRS and HepG2 protein synthesis assay by 2- to 9-fold, suggesting that decreasing lipophilicity or adding polarity in the molecule could translate into improved selectivity profiles. These results were consistent with and further supported by our HepG2 cell toxicity EC<sub>50</sub> data (48 h) obtained with these <i>Mtb</i> LeuRS inhibitors. The compounds <b>5a, 23a</b>, and <b>24a</b> exhibited the least activity against HepG2 cells and thus were advanced further for in vivo testing. Also, it is worthy to note that little difference exists in activity and selectivity profiles between 4-Cl compound and 4-Br counterpart, as exemplified by <b>3a</b> vs <b>4a</b> and <b>23a</b> vs <b>24a</b>. Compounds <b>6a</b>, <b>23a</b>, and <b>35a</b> with different structural features (7-methoxy, 7-hydroxyethoxy, and 6-/7-fused analog) were chosen for drug metabolism and pharmacokinetics (DMPK) studies.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> DMPK</h3><div class="NLM_p last">The PK of new compounds <b>6a</b>, <b>23a</b>, and <b>35a</b> were evaluated in mice (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). All three new compounds exhibited low clearance and excellent exposure, which are consistent with previous PK results of <b>4a</b>. The dose-normalized (DN) AUC values for <b>6a</b>, <b>23a</b>, and <b>35a</b> were 1.17, 2.03, and 2.54 h·μg/mL, respectively. After oral administration, the DNAUC values of <b>6a</b>, <b>23a</b>, and <b>35a</b> were 0.84, 2.96, and 1.26 h·μg/mL, corresponding to bioavailability of 72%, 100%, and 50%, respectively. These <i>Mtb</i> LeuRS inhibitors show low molecular weight, low polar surface area (PSA), and clogD<sub>7.4</sub> value similar to frontline TB drugs isoniazid, pyrazinamide, and ethambutol. We believe that the physicochemical properties of these compounds (such as low molecular weight, low PSA, and favorable clogD<sub>7.4</sub>) contribute to their remarkable exposure and bioavailability in the in vivo PK assays.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> In Vivo Efficacy</h3><div class="NLM_p last">To evaluate the ability of these <i>Mtb</i> LeuRS inhibitors to treat tuberculosis, we examined <b>6a</b>, <b>23a</b>, and <b>35a</b> in an animal TB efficacy model. The results from a murine acute TB infection model are shown in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. In this TB infection model, <b>23a</b> showed the best efficacy with ED<sub>99</sub> (efficacious dose that gives 2 log colony-forming units (CFU) reduction compared to the untreated control) of 0.4 mg/kg among the four compounds evaluated. <b>6a</b> is 10-fold less potent in terms of dose with ED<sub>99</sub> of 3.8 mg/kg, compared to <b>23a</b>. <b>35a</b> showed a significant decrease in efficacy with ED<sub>99</sub> of 70 mg/kg (>100-fold). The reason for an in vitro and in vivo disconnect of <b>35a</b> is not clear and is apparently not related to a lack of in vitro potency or in vivo exposure. Unlike with <b>4a</b>, which was not tolerated at 50 mg/kg QD, <b>23a</b> was well tolerated at the maximum dose tested of 100 mg/kg. In a maximum single tolerated dose study in healthy mice, <b>23a</b> was well tolerated at 300 mg/kg and <b>4a</b> was not tolerated at the lowest dose tested of 150 mg/kg. Therefore, further evaluations of <b>23a</b> in a murine chronic TB infection model were performed in parallel with the protein synthesis inhibitor linezolid (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). <b>23a</b> exhibited a dose-dependent reduction in CFU from 0.1 mg/kg to 10 mg/kg QD. Importantly, 10 mg/kg QD resulted in 2.1 log<sub>10</sub> reduction in CFU compared with a 2.5 log<sub>10</sub> reduction in CFU for 100 mg/kg of linezolid QD. From these studies, <b>23a</b> was identified as having the best overall profiles, with remarkable oral bioavailability and in vivo efficacy at low doses in acute and chronic mouse TB infection models.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65704" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65704" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In this work, we designed and synthesized a new series of <i>Mtb</i> LeuRS inhibitors by investigating various substituents in the aromatic ring of the 3-aminomethyl 4-halogen benzoxaborole scaffold. The SARs which include the influence of substitution size, nature, and pattern at positions 6 and 7 were explored, leading to the identification of a number of <i>Mtb</i> LeuRS inhibitors with excellent antitubercular potency in the mid-nanomolar range. These <i>Mtb</i> LeuRS inhibitors exhibited improved selectivity over human cytoplasmic LeuRS as well as protein synthesis inhibition in intact human cells over the initial leads. Moreover, the superior tolerability of the new compounds has enabled their further progression and ultimately the selection of a clinical candidate. These <i>Mtb</i> LeuRS inhibitors exhibited remarkable oral exposure, with small molecular weight and low clogD similar to frontline TB drugs isoniazid, pyrazinamide, and ethambutol. From these compounds, <b>23a</b> was identified as having the best overall profiles, with excellent in vivo efficacy at low doses in acute and chronic mouse TB infection models. As a result, <b>23a</b> has been progressed to clinical development for the treatment of tuberculosis (ClinicalTrials.gov identifier NCT03075410). Future publications will report other preclinical studies and clinical trial results.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56162" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56162" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> LeuRS Aminoacylation Assay</h3><div class="NLM_p last">An N-terminal six histidine-tagged LeuRS from <i>M. tuberculosis</i> H37Rv and humans (cytoplasmic and mitochondrial) were codon-optimized for <i>E. coli</i> (GenScript, Piscataway, NJ, USA) and overexpressed and purified according to Novagen (Madison, WI, USA) using an <i>E. coli</i> BL21(DE3) T7 RNA polymerase overexpression strain. Aminoacylation assay was performed in 96-well microtiter plates, using 80 μL of reaction mixtures containing 50 mM HEPES–KOH (pH 8.0), 30 mM MgCl<sub>2</sub> 30 mM KCl, 13 μM <span class="smallcaps smallerCapital">l</span>-[<sup>14</sup>C]leucine (306 mCi/mmol, PerkinElmer), 15 μM total <i>E. coli</i> tRNA (Roche, Switzerland), 0.02% (w/v) BSA, 1 mM DTT, 0.2 pM LeuRS, and 4 mM ATP at 30 °C. Reactions were started by the addition of 4 mM ATP. After 7 min, reactions were quenched and tRNA was precipitated by the addition of 50 μL of 10% (w/v) TCA and transferred to 96-well nitrocellulose membrane filter plates (Millipore Multiscreen HTS, MSHAN4B50). Each well was then washed three times with 100 μL of 5% TCA. Filter plates were then dried under a heat lamp, and the precipitated <span class="smallcaps smallerCapital">l</span>-[<sup>14</sup>C]leucine tRNA<sup>Leu</sup> was quantified by liquid scintillation counting using a Wallac MicroBeta Trilux model 1450 liquid scintillation counter (PerkinElmer, Waltham, MA, USA). To determine the inhibitor concentration, which reduces enzyme activity by 50% (IC<sub>50</sub>), increasing concentrations of compound inhibitors that covered the IC<sub>50</sub> value were incubated with LeuRS enzyme, tRNA, and <span class="smallcaps smallerCapital">l</span>-leucine for 20 min. Reactions were initiated by the addition of 4 mM ATP. Reactions were stopped after 7 min and then precipitated and counted to quantify radioactivity. IC<sub>50</sub> values were determined using a four-parameter logistic nonlinear regression model (GraphPad Software Inc. (La Jolla, CA, USA). The only difference was with the human cytoplasmic LeuRS aminoacylation assay when we used tRNA isolated from Brewer’s yeast (Roche Diagnostics GmbH).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Determination of MIC for <i>M. tuberculosis</i></h3><div class="NLM_p last"><i>Mycobacterium tuberculosis</i> H37Rv was grown at 37 °C in Middlebrook 7H9 broth (Difco) supplemented with 0.025% Tween 80 and 10% albumin-dextrose-catalase (ADC) or on Middlebrook 7H10 plates supplemented with 10% oleic acid-albumin-dextrose-catalase (OADC). The antitubercular activity against extracellular of intracellular <i>Mycobacterium</i> strains was performed as previously described.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> HepG2 Protein Synthesis EC<sub>50</sub> Determination</h3><div class="NLM_p last">Human liver carcinoma HepG2 cells were grown in Dulbecco’s modified Eagle’s medium containing 10% (v/v) fetal calf serum, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, and 50 units/mL penicillin–streptomycin at 37 °C with 5% CO<sub>2</sub>. HepG2 cells were seeded in 96-well plates at 3000 cells/200 μL/well in cell culture medium. Stock solutions of compounds were made in DMSO. Increasing concentrations of compounds were added with the final DMSO concentration being 0.5%. Vehicle-treated samples had DMSO added at 0.5% with no compound. Cells were then grown in the presence of the compounds at 37 °C in 10% CO<sub>2</sub> for 2 days. After 48 h, the medium was removed and then replaced by fresh medium containing 0.5 μCi of <span class="smallcaps smallerCapital">l</span>-[<sup>14</sup>C]leucine and the same concentrations of compounds. After incubation for 3 h, the medium was removed and 50 μL of trypsin–EDTA solution was added to each well. After 15 min, the trypsinzed cells were transferred to a 96-well plate containing ice-cold 20% (w/v) TCA. After 60 min on ice the samples were collected over vacuum on 96-well glass fiber filter plate (Millipore, MSFBNB50) and washed three times with 150 μL of ice-cold 10% (w/v) TCA. To the dried filter plate 40 μL of scintillation cocktail was added, and counts were obtained in Wallac MicroBeta Trilux model 1450 liquid scintillation counter (PerkinElmer, Waltham, MA). IC<sub>50</sub> values were determined by curve-fitting using the Prism by GraphPad (San Diego, CA, USA).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> HepG2 Cytotoxicity Assay</h3><div class="NLM_p last">HepG2 (HB-8065) cells were cultured with fresh medium (essential minimum Eagle medium, EMEM, supplemented with 5% fetal calf serum and 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine) the day before subculturing the plates. On the day of the assay, cells (10 000 cells/well) were seeded in a black 96-well collagen coated microplate with clear bottom, (Becton Dickinson) except in column 11, which was dispensed only 100 mL of culture medium. Stock solution from each test substances was prepared in 100% DMSO. Ten serial 1:2 dilutions were prepared of each test compound, and finally, a 1:200 dilution was made, in medium, to achieve a final concentration of 0.5% of DMSO. Resazurin tablets (Merck) were dissolved in phosphate buffer saline at a concentration of 0.0042%. After 24 h of incubation of the cells (37 °C, 5% CO<sub>2</sub>, 95% relative humidity), a volume of 150 μL of culture medium containing the appropriate test concentrations of the compounds dilutions was added to cells in two replicates. In column 12, only 150 μL of 0.5% DMSO was added (blank control). Then, cells were exposed to test compounds for 48 h. After that, medium was removed and resazurin solution was added to each well and incubated for further 1.5 h. Fluorescence was measured at an excitation wavelength of 515 nm and an emission wavelength of 590 nm in a Microplate reader 1420 Multilabel HTS counter, Victor 2 (Wallac). Data were processed using an Excel spreadsheet and GraphPad software analysis. Tox50 values were calculated from the Sigmoidal dose–response (variable slope) curves by nonlinear regression analysis.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Procedure for PK Studies</h3><div class="NLM_p">For pharmacokinetic studies, C57BL/6 female mice (18–20 g) were used, and compound concentrations were determined using peripheral whole blood. All animal studies were ethically reviewed and carried out in accordance with European Directive 2010/63/EU and the GSK Policy on the Care, Welfare and Treatment of Animals.</div><div class="NLM_p"><b>4a</b> was administered by intravenous route at 30 mg/kg single dose in saline and by oral gavage at 30 mg/kg single dose in 1% methylcellulose (1% MC). For iv route aliquots of 25 μL of blood were taken from the lateral tail vein by puncture from each mouse (<i>n</i> = 5) at 5, 15, and 30 min and 1, 2, 4, and 8 h postdose; for oral route aliquots of 25 μL of blood were taken by cardiac puncture for each mouse (euthanized by CO<sub>2</sub>, <i>n</i> = 3 mice per time point) at 15, 30, and 45 min and 1, 1.5, 2, 3, 4, 8, and 24 h postdose.</div><div class="NLM_p"><b>23a</b> was administered by intravenous route at 5 mg/kg single dose in saline and by oral gavage at 30 mg/kg single dose in 1% methylcellulose (1% MC). For iv route aliquots of 15 μL of blood were taken from the lateral tail vein by puncture from each mouse (<i>n</i> = 3) at 5, 15, and 30 min and 1, 2, 4, 8, and 24 h postdose; for oral route aliquots of 15 μL of blood were taken from the lateral tail vein by puncture from each mouse (<i>n</i> = 3) at 15, 30, and 45 min and 1, 2, 4, 8, and 24 h postdose.</div><div class="NLM_p"><b>35a</b> was administered by intravenous route at 30 mg/kg single dose in saline and by oral gavage at 30 mg/kg single dose in 1% methylcellulose (1% MC). For iv route aliquots of 15 μL of blood were taken from the lateral tail vein by puncture from each mouse (<i>n</i> = 3) at 5, 15, and 30 min and 1, 2, 4, 8, and 24 h postdose; for oral route aliquots of 15 μL of blood were taken from the lateral tail vein by puncture from each mouse (<i>n</i> = 3) at 15, 30, and 45 min and 1, 2, 4, 8, and 24 h postdose.</div><div class="NLM_p last">LC–MS/MS was used as the analytical method for the establishment of compound concentration in blood. Pharmacokinetic analysis was performed by noncompartmental data analysis (NCA) with Phoenix WinNonlin 6.3 (Pharsight, Certara L.P.), and supplementary analysis was performed with GraphPad Prism 6 (GraphPad Software, Inc.).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Murine Model of Acute and Chronic TB Infections</h3><div class="NLM_p last">Specific pathogen-free, 8- to 10-week-old female C57BL/6 mice were purchased from Harlan Laboratories and were allowed to acclimate for 1 week. The experimental design for the acute assay has been previously described.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> In brief, mice were intratracheally infected with 100 000 CFU/mouse of <i>M. tuberculosis</i> H37Rv. Compounds were administered for 8 consecutive days starting 1 day after infection. For the chronic assay, mice were intratracheally infected with 100 CFU/mouse and the products administered daily (7 days a week) for 8 consecutive weeks starting 6 weeks after infection. Lungs were harvested 24 h after the last administration, and all lung lobes were aseptically removed, homogenized, and frozen. Homogenates were plated onto 10% OADC–Middlebrook 7H11 medium and incubated for 21 days at 37 °C. All animal studies were ethically reviewed and carried out in accordance with European Directive 2010/63/EU and the GSK Policy on the Care, Welfare and Treatment of Animals. The viable CFU were converted to logarithms, which were then evaluated by one-way analysis of variance, followed by multiple-comparison analysis of variance by a one-way Tukey test (SigmaStat software program). Differences were considered significant at the 95% level of confidence.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Chemical Synthesis</h3><div class="NLM_p last">Starting materials used were either commercially available or prepared according to literature procedures and had experimental data in accordance with those reported. High performance liquid chromatography (HPLC) was used to determine the purity of the compounds synthesized. The data confirmed that the target compounds generally had ≥95% of purity with the exception of compounds <b>8</b> and <b>30</b>. <sup>1</sup>H NMR spectra were recorded on a Varian or Bruker 300 or 400 MHz spectrometer. Chemical shifts were reported in ppm and were referenced to the appropriate residual solvent signals, such as 2.49 ppm for DMSO-<i>d</i><sub>6</sub> and 7.26 ppm for CDCl<sub>3</sub>. LC–MS data were obtained using an Agilent LC–MS 1200 with 6110 MS detector. The mass spectrometer was equipped with an electrospray ion source (ESI) operated in a positive or negative mode. Flash column chromatography was typically preformed using silica gel 60 (230–400 mesh). Typical solvents used for flash chromatography or thin layer chromatography (TLC) were mixtures of MeOH/DCM and EtOAc/petroleum ether. HPLC analysis was performed on a Gilson HPLC system using a Gemini 5 μm C18 column (150 mm × 4.6 mm i.d.) or a Venusil MP C18 3 μm C18 column (100 mm × 4.6 mm i.d.). Purification using prep-HPLC was accomplished using a Gilson HPLC system with a Gemini 5 μm C18 column (150 mm × 21.2 mm i.d.). Typically, the mobile phase used for HPLC was a linear gradient of water (A) and acetonitrile (B). The water and acetonitrile were mixed with 0.1% TFA or 0.1% HCOOH. The flow rate was maintained at 0.8–1.2 mL/min for analytic HPLC and 20 mL/min for prep-HPLC, and the eluent was monitored with UV detector at 220 nm. Chiral separation was performed on a Thar preparative SFC 80 system with a Daicel Chiralpak AD-H 5 μm (250 mm × 20 mm i.d.), eluted with carbon dioxide and methanol mobile phase. The flow rate was maintained at 65–70 mL/min, and eluent was monitored with UV detector at 220 nm. For enantiomeric excess determination, chiral HPLC analysis was performed on a Thar analytical SFC system with a Chiralpak AD-H 5 μm (150 mm × 4.6 mm i.d.) or a ChiralCel OJ-H 5 μm (150 mm × 4.6 mm i.d.) or a ChiralPak AY-H 5 μm (150 mm × 4.6 mm i.d.), eluted with carbon dioxide and methanol mobile phase at a flow rate of approximately 2.4–4 mL/min. The ee of all tested enantiomers was >97%.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> (<i>S</i>)-3-(Aminomethyl)-4-chloro-7-methoxybenzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>5a</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described below for the synthesis of <b>21a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.22 (b, 1H), 8.20 (b, 3H), 7.54 (d, 1H, <i>J</i> = 9.0 Hz), 7.01 (d, 1H, <i>J</i> = 9.0 Hz), 5.33 (m, 1H), 3.82 (s, 3H), 3.56 (m, 1H), 2.92 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 228 [M + H]<sup>+</sup>. HPLC purity: 99.9% (220 nm). <b>5a</b> had >99% ee based on starting material <b>47</b>.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> (<i>S</i>)-3-(Aminomethyl)-4-bromo-7-methoxybenzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>6a</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described below for the synthesis of <b>22a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.21 (b, 1H), 8.41 (b, 3H), 7.66 (d, 1H, <i>J</i> = 8.8 Hz), 6.94 (d, 1H, <i>J</i> = 8.4 Hz), 5.34 (m, 1H), 3.81 (s, 3H), 3.62 (m, 1H), 2.85 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 272 [M + H]<sup>+</sup>. HPLC purity: 99.7% (220 nm). <b>6a</b> had >99% ee based on starting material <b>47</b>.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> (<i>S</i>)-3-(Aminomethyl)-4-chloro-7-propoxybenzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>7a</b>)</h3><div class="NLM_p last">To a solution of (<i>S</i>)-3-(aminomethyl)-7-(3-hydroxypropoxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol hydrochloride <b>46</b> (30 g, 0.11 mol) and triethylamine (33.3 g, 0.33 mol) in DCM (300 mL) at 0 °C was added di-<i>tert</i>-butyl dicarbonate (36 g, 0.165 mol). The mixture was stirred at rt for overnight. The solvent was removed to afford (<i>S</i>)-<i>tert</i>-butyl (1-hydroxy-7-(3-hydroxypropoxy)-1,3-dihydrobenzo[<i>c</i>][1,2]oxaborol-3-yl)methylcarbamate as a white solid (38 g, yield 100%). To a stirred solution of the above compound (10 g, 29.7 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) at −78 °C was added BBr<sub>3</sub> (8.3 mL, 89.1 mmol) dropwise. The reaction was stirred at −78 °C for 2 h and stirred at rt overnight. The mixture was poured into ice–water and extracted with DCM. The aqueous layer was adjusted to pH = 8 with sat. NaHCO<sub>3</sub>, and di-<i>tert</i>-butyl dicarbonate (6.5 g, 29.7 mmol) was added. The reaction mixture was stirred at rt overnight and then extracted with EtOAc (3 × 50 mL). The organic layer was dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give (<i>S</i>)-<i>tert</i>-butyl (1,7-dihydroxy-1,3-dihydrobenzo[<i>c</i>][1,2]oxaborol-3-yl)methylcarbamate (3 g, 36%). To a solution of the above compound (600 mg, 2.15 mmol) in 10 mL of DMSO at 0 °C under N<sub>2</sub> was added <i>t</i>-BuOK (362 mg, 3.2 mmol). The reaction mixture was stirred at rt for 30 min, followed by the addition of 1-bromopropane (1.1 mL, 1.4 g, 10.7 mmol). The reaction mixture was stirred at rt for 12 h. After the reaction was quenched with ice–water, the mixture was extracted with EtOAc (50 mL). The organic layer was washed with brine (50 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel chromatography, eluting with EtOAc and petroleum ether (1:3) to give (<i>S</i>)-<i>tert</i>-butyl (1-hydroxy-7-propoxy-1,3-dihydrobenzo[<i>c</i>][1,2]oxaborol-3-yl)methylcarbamate as colorless oil (110 mg, 16%). A solution of the above compound (440 mg, 1.37 mmol) and <i>N</i>-chlorosuccinimide (183 mg, 1.37 mmol) in 20 mL of CH<sub>3</sub>CN was stirred at 90 °C for 1 h. The mixture was concentrated in vacuo. The residue was purified by prep-HPLC, eluting with water/acetonitrile gradient to give (<i>S</i>)-<i>tert</i>-butyl (4-chloro-1-hydroxy-7-propoxy-1,3-dihydrobenzo[<i>c</i>][1,2]oxaborol-3-yl)methylcarbamate as a white solid (89 mg, 18%). To a solution of the above compound (89 mg, 0.25 mmol) in 10 mL of DCM was added TFA (1 mL). The reaction mixture was stirred at rt for 1 h and then concentrated in vacuo. After 1 M HCl in Et<sub>2</sub>O (10 mL) was added, it was stirred for 1 h. The residue was filtered and dried in vacuo to give (<i>S</i>)-<b>7</b> as a white solid (71 mg, 97%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.13 (b, 1H), 8.19 (b, 3H), 7.50 (d, 1H, <i>J</i> = 8.6 Hz), 6.99 (d, 1H, <i>J</i> = 8.7 Hz), 5.38 (m, 1H), 4.00 (t, 2H), 3.57 (m, 1H), 2.94 (m, 1H), 1.75 (m, 2H), 0.99 (t, 3H). MS (ESI) <i>m</i>/<i>z</i> = 256 [M + H]<sup>+</sup>. HPLC purity: 96.3% (220 nm). <b>7a</b> had >99% ee based on the use of starting material <b>46</b>.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (<i>S</i>)-3-(Aminomethyl)-4-bromo-7-propoxybenzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>8a</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described above for the synthesis of <b>7a</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.09 (b, 1H), 8.03 (b, 3H), 7.63 (d, 1H, <i>J</i> = 8.6 Hz), 6.93 (d, 1H, <i>J</i> = 8.7 Hz), 5.26 (m, 1H), 3.98 (t, 2H), 3.63 (m, 1H), 3.00 (m, 1H), 1.75 (m, 2H), 0.98 (t, 3H). MS (ESI) <i>m</i>/<i>z</i> = 300 [M + H]<sup>+</sup>. HPLC purity: 93.1% (220 nm). <b>8a</b> had >99% ee based on starting material <b>46</b>.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (<i>S</i>)-3-(Aminomethyl)-7-butoxy-4-chlorobenzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>9a</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described above for the synthesis of <b>7a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.11 (b, 1H), 8.11 (b, 3H), 7.50 (d, 1H, <i>J</i> = 8.4 Hz), 6.99 (d, 1H, <i>J</i> = 8.4 Hz), 5.36 (m, 1H), 4.04 (t, 2H), 3.57 (m, 1H), 2.96 (m, 1H), 1.72 (m, 2H), 1.47 (m, 2H), 0.94 (t, 3H). MS (ESI) <i>m</i>/<i>z</i> = 270 [M + H]<sup>+</sup>. HPLC purity: 97.2% (220 nm). <b>9a</b> had >99% ee based on starting material <b>46</b>.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (<i>S</i>)-3-(Aminomethyl)-7-butoxy-4-bromobenzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>10a</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described above for the synthesis of <b>7a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.10 (b, 1H), 8.11 (b, 3H), 7.64 (d, 1H, <i>J</i> = 8.8 Hz), 6.96 (d, 1H, <i>J</i> = 8.4 Hz), 5.28 (m, 1H), 4.04 (t, 2H), 3.61 (m, 1H), 2.96 (m, 1H), 1.71 (m, 2H), 1.45 (m, 2H), 0.94 (t, 3H). MS (ESI) <i>m</i>/<i>z</i> = 314 [M + H]<sup>+</sup>. HPLC purity: 99.2% (220 nm). <b>10</b> had >99% ee based on starting material <b>46</b>.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 3-(Aminomethyl)-4-chloro-7-phenoxybenzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>11</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described below for the synthesis of <b>23</b>. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 7.57–7.29 (m, 3H), 7.17 (t, 1H, <i>J</i> = 7.4 Hz,), 7.06–6.97 (m, 2H), 6.79 (d, 1H, <i>J</i> = 8.6 Hz,), 5.51 (m, 1H), 3.88 (m, 1H), 3.08 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 290 [M + H]<sup>+</sup>. HPLC purity: 98.0% (220 nm).</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 3-(Aminomethyl)-4-bromo-7-(4-bromophenoxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>12</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described below for the synthesis of <b>24</b>. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 7.66–7.63 (d, 1H, <i>J</i> = 8.5 Hz), 7.51–7.46 (t, 2H, <i>J</i> = 7.9 Hz), 6.94–6.91 (d, 2H, <i>J</i> = 8.8 Hz), 6.85–6.80 (t, 1H, <i>J</i> = 9.0 Hz), 5.44 (m, 1H), 3.94 (m, 1H), 3.09 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 414 [M + H]<sup>+</sup>. HPLC purity: 98.0% (220 nm).</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 3-(Aminomethyl)-7-(benzyloxy)-4-chlorobenzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>13</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described below for the synthesis of <b>23</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.20 (<i>b</i>, 1H), 8.29 (<i>b</i>, 3H), 7.49–7.31 (m, 6H), 7.04 (d, 1H, <i>J</i> = 8.8 Hz), 5.41 (m, 1H), 5.23 (s, 2H), 3.57 (m, 1H), 2.94 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 304 [M + H]<sup>+</sup>. HPLC purity: 96.8% (220 nm).</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 3-(Aminomethyl)-7-(benzyloxy)-4-bromobenzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>14</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described below for the synthesis of <b>24</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.62 (d, 1H, <i>J</i> = 8.0 Hz), 7.52–7.32 (m, 5H), 7.00 (d, 1H, <i>J</i> = 8.0 Hz), 5.41 (m, 1H), 5.21 (s, 2H), 3.94 (m, 1H), 3.07 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 348 [M + H]<sup>+</sup>. HPLC purity: 99.6% (220 nm).</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 3-(Aminomethyl)-4-chloro-7-phenethoxybenzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>15</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described below for the synthesis of <b>23</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.45 (d, 1H, <i>J</i> = 8.0 Hz), 7.38 (d, 2H, <i>J</i> = 8.0 Hz), 7.31 (<i>m</i>, 2H), 7.22 (<i>m</i>, 1H), 6.97 (d, 1H, <i>J</i> = 8.0 Hz), 5.43 (<i>m</i>, 1H), 4.27 (t, 2H), 3.83 (<i>m</i>, 1H), 3.11 (t, 3H), 3.03 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 318 [M + H]<sup>+</sup>. HPLC purity: 99.6% (220 nm).</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 3-(Aminomethyl)-4-bromo-7-phenethoxybenzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>16</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described below for the synthesis of <b>24</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.60 (d, 1H, <i>J</i> = 8.0 Hz), 7.37 (d, 2H, <i>J</i> = 8.0 Hz), 7.30 (<i>m</i>, 2H), 7.22 (<i>m</i>, 1H), 6.91 (d, 1H, <i>J</i> = 8.0 Hz), 5.37 (<i>m</i>, 1H), 4.25 (t, 2H), 3.91 (<i>m</i>, 1H), 3.10 (t, 3H), 3.01 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 362 [M + H]<sup>+</sup>. HPLC purity: 100% (220 nm).</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 3-(Aminomethyl)-4-chloro-7-(2-fluoroethoxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>17</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described below for the synthesis of <b>23</b>. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 7.46 (d, 1H, <i>J</i> = 9.0 Hz), 7.00 (d, 1H, <i>J</i> = 9.0 Hz), 5.43 (m, 1H), 4.81 (m, 1H), 4.65 (m, 1H), 4.35 (m, 1H), 4.28 (m, 1H), 3.81 (m, 1H), 3.04 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 260 [M + H]<sup>+</sup>. HPLC purity: 100% (220 nm).</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 3-(Aminomethyl)-4-bromo-7-(2-fluoroethoxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>18</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described below for the synthesis of <b>24</b>. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 7.61 (d, 1H, <i>J</i> = 9.0 Hz), 6.94 (d, 1H, <i>J</i> = 9.0 Hz), 5.36 (m, 1H), 4.81 (m, 1H), 4.65 (m, 1H), 4.37 (m, 1H), 4.27 (m, 1H), 3.89 (m, 1H), 3.04 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 304 [M + H]<sup>+</sup>. HPLC purity: 97.8% (220 nm).</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 3-(Aminomethyl)-4-chloro-7-(2,2-difluoroethoxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>19</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described below for the synthesis of <b>23</b>. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 7.48 (d, 1H, <i>J</i> = 9.0 Hz), 7.02 (d, 1H, <i>J</i> = 9.0 Hz), 6.35 (m, 1H), 5.44 (m, 1H), 4.35 (m, 2H), 3.80 (m, 1H), 3.05 (m, 1H). MS (ESI) <i>m/z</i> = 278 [M + H]<sup>+</sup>. HPLC purity: 99.4% (220 nm).</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 3-(Aminomethyl)-4-bromo-7-(2,2-difluoroethoxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>20</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described below for the synthesis of <b>24</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.27 (b, 1H), 8.32 (b, 3H), 7.65 (d, 1H, <i>J</i> = 9.0 Hz), 7.00 (d, 1H, <i>J</i> = 9.0 Hz), 6.40 (m, 1H), 5.33 (m, 1H), 4.40 (m, 2H), 3.58 (m, 1H), 2.92 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 322 [M + H]<sup>+</sup>. HPLC purity: 98.3% (220 nm).</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (<i>S</i>)-3-(Aminomethyl)-4-chloro-7-(3-hydroxypropoxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>21a</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described above for the synthesis of <b>7a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.00 (b, 3H), 7.43–7.41 (d, 1H, <i>J</i> = 8 Hz), 6.96–6.94 (d, 1H, <i>J</i> = 8 Hz), 5.45 (m, 1H), 4.39 (m, 2H), 4.16 (m, 2H), 3.60 (m, 1H), 3.10–2.80 (m, 1H), 2.00 (m, 2H). MS (ESI) <i>m</i>/<i>z</i> = 272 [M + H]<sup>+</sup>. HPLC purity: 98.3% (220 nm). <b>21a</b> had >99% ee based on starting material <b>46</b>.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (<i>S</i>)-3-(Aminomethyl)-4-bromo-7-(3-hydroxypropoxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>22a</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described above for the synthesis of <b>8a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.31 (b, 3H), 7.65–7.63 (d, 1H, <i>J</i> = 8.0 Hz), 6.96–6.93 (d, 1H, <i>J</i> = 8.4 Hz), 5.29 (m, 1H), 4.11 (m, 2H), 3.70–3.50 (m, 3H), 2.91 (m, 1H), 1.89 (m, 2H). MS (ESI) <i>m</i>/<i>z</i> = 316 [M + H]<sup>+</sup>. HPLC purity: 97.3% (220 nm). <b>22a</b> had >99% ee based on starting material <b>46</b>.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>23</b>)</h3><div class="NLM_p last">To 2-bromoethanol (1.88 g, 15 mmol) was added dihydropyran (1.26 g, 15 mmol) dropwise at 0 °C. The mixture was stirred for 30 min at 0 °C and then 2 h at rt. Subsequently, 2-bromo-3-hydroxybenzaldehyde (2.0 g, 10 mmol) was added, followed by potassium carbonate (1.52 g, 11 mmol), potassium iodide (332 mg, 2 mmol), and dry DMF (20 mL). The reaction was stirred at 70 °C overnight. The mixture was cooled to rt and diluted with diethyl ether (100 mL). After the inorganic salts were removed by filtration, the filtrate was diluted with hexane (100 mL). The organic layer was washed with water (3 × 50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography, eluting with EtOAc and petroleum ether (1:3) to give 2-bromo-3-(2-(tetrahydro-2<i>H</i>-pyran-2-yloxy)ethoxy)benzaldehyde as yellow oil (3.0 g, yield 91%). A mixture of the above compound (160 g, 0.49 mol), bis(pinacolato)diborane (249 g, 0.98 mol), PdCl<sub>2</sub>(dppf) (20 g, 24.5 mmol), and KOAc (144 g, 1.47 mol) in DMF (2.0 L) was degassed and stirred at 90 °C overnight. After the reaction was quenched with ice–water (4 L), the reaction mixture was extracted with EtOAc (3 × 1.5 L). The combined organic layers were washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel chromatography, eluting with EtOAc and petroleum ether (1:10 to 1:2) to give 3-(2-(tetrahydro-2<i>H</i>-pyran-2-yloxy)ethoxy)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde as yellow oil (88 g, yield 48%). To a solution of NaOH (4.8 g, 0.12 mol) in water (100 mL) was added nitromethane (18.3 g, 0.3 mol) at 5–10 °C. After stirring for 15 min at 5–10 °C, cetyltrimethylammonium bromide (2.2 g, 6.0 mmol) was added. After the above compound (45 g, 0.12 mol) was added slowly at 5–10 °C, the reaction mixture was stirred at rt for 5 h. Subsequently, the reaction mixture was acidified to pH = 1 using diluted hydrochloric acid and stirred at rt overnight. The residue was filtered and dried in vacuo to give 7-(2-hydroxyethoxy)-3-(nitromethyl)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol as a white solid (14.5 g, yield 48%). To a solution of the above compound (29 g, 115 mmol) in DMF (250 mL) at 80 °C was added a solution of <i>N</i>-chlorosuccinimide (16.5 g, 123 mmol) in DMF (100 mL). The mixture was stirred for 30 min at 80 °C. After cooling down to rt, the reaction mixture was poured into ice–water and extracted with EtOAc (3 × 200 mL). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by recrystallization from EtOAc and petroleum ether (1:10) to give crude product 4-chloro-7-(2-hydroxyethoxy)-3-(nitromethyl)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol (24 g). A solution of the above compound (24 g, 83.5 mmol), Raney Ni (4.0 g), and 7 M NH<sub>3</sub> in MeOH (20 mL) in MeOH (300 mL) was shaken under an atmosphere of hydrogen for 2 h at rt. The mixture was filtered through a bed of Celite, and the filtrate was concentrated in vacuo. The crude amine was dissolved in MeOH (20 mL), and 1 M HCl in Et<sub>2</sub>O (30 mL) was added. After stirring for 1 h, the residue was filtered, washed with acetonitrile/hexane (2:1, 2 × 200 mL), and dried in vacuo to give <b>23</b> as a white solid (12 g, yield 49%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.19 (b, 3H), 7.51–7.48 (d, 1H, <i>J</i> = 9 Hz), 6.99–6.96 (d, 1H, <i>J</i> = 9 Hz), 5.54 (m, 1H), 4.69 (m, 1H), 4.36–4.23 (m, 3H), 3.58 (m, 1H), 3.03 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 258 [M + H]<sup>+</sup>. HPLC purity: 99.7% (220 nm).</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (<i>S</i>)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>23a</b>) and (<i>R</i>)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>23b</b>)</h3><div class="NLM_p last">To a mixture of <b>23</b> (8.0 g, 27.2 mmol) and triethylamine (10.2 g, 101 mmol) in dichloromethane (250 mL) at 0 °C was added di-<i>tert</i>-butyl dicarbonate (11 g, 50.6 mmol). The reaction mixture was stirred for 2 h at rt. After the reaction was quenched with sat. NaHCO<sub>3</sub> (150 mL), the resulting mixture was extracted with EtOAc (2 × 200 mL). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by prep-HPLC, eluting with water/acetonitrile gradient to give the Boc-protected <b>23</b> (4.6 g, yield 47%). The racemic Boc-protected <b>23</b> was separated on a Thar preparative SFC 80 system with a Daicel Chiralpak AD-H 5 μm (250 mm × 20 mm i.d.), eluting with carbon dioxide and methanol mobile phase. The two isomers were obtained. Each compound (4.6 g, 12.9 mmol) was dissolved in 1 M HCl/Et<sub>2</sub>O (80 mL) and stirred at rt for 1 h and concentrated in vacuo. The residue was washed with acetonitrile (2 × 5 mL) and dried in vacuo to give the desired product as a white solid. <b>23a</b> (1.2 g, yield 32%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.31 (b, 3H), 7.51–7.48 (d, 1H, <i>J</i> = 9 Hz), 6.98–6.95 (d, 1H, <i>J</i> = 9 Hz), 5.59 (m, 1H), 4.70 (m, 1H), 4.36–4.23 (m, 3H), 3.57 (m, 1H), 3.02 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 258 [M + H]<sup>+</sup>. HPLC purity: 99.7% (220 nm). Analysis of the Boc-derivatized material using a ChiralCel OJ-H analytical column showed the (<i>S</i>) enantiomer with a retention time of 2.94 min and 99.9% ee. <b>23b</b> (1.3 g, yield 34%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.28 (b, 3H), 7.51–7.48 (d, 1H, <i>J</i> = 9 Hz), 6.98–6.95 (d, 1H, <i>J</i> = 9 Hz), 5.58 (m, 1H), 4.69 (m, 1H), 4.36–4.23 (m, 3H), 3.59 (m, 1H), 3.02 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 258 [M + H]<sup>+</sup>. HPLC purity: 100% (220 nm). Analysis of the Boc-derivatized material using a ChiralCel OJ-H analytical column showed the (<i>R</i>) enantiomer with a retention time of 2.67 min and 97.8% ee.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 3-(Aminomethyl)-4-bromo-7-(2-hydroxyethoxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>24</b>)</h3><div class="NLM_p last">A solution of 7-(2-hydroxyethoxy)-3-(nitromethyl)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol (1.5 g, 5.9 mmol), Raney Ni (200 mg), and 2 M NH<sub>3</sub> in EtOH (5 mL) in ethanol (40 mL) was shaken under an atmosphere of hydrogen for 2 h at rt. The mixture was filtered through a bed of Celite, and the filtrate was concentrated in vacuo. The crude amine was dissolved in EtOH (20 mL), and 1 M HCl in Et<sub>2</sub>O (30 mL) was added. After stirring for 1 h, the residue was filtered, washed with acetonitrile/hexane (2:1, 2 × 20 mL), and dried in vacuo to give 3-(aminomethyl)-7-(2-hydroxyethoxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol hydrochloride as a white solid (700 mg, yield 46%). To a mixture of the above compound (700 mg, 2.7 mmol) and triethylamine (879 mg, 8.7 mmol) in dichloromethane (10 mL) at 0 °C was added di-<i>tert</i>-butyl dicarbonate (948 mg, 4.4 mmol). The mixture was stirred at rt for 2 h. The reaction was quenched with sat. NaHCO<sub>3</sub> (15 mL), and the mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue was purified by flash-column chromatography to give <i>tert</i>-butyl (1-hydroxy-7-(2-hydroxyethoxy)-1,3-dihydrobenzo[<i>c</i>][1,2]oxaborol-3-yl)methylcarbamate (500 mg, yield 57%). To a solution of the above compound (0.5 mg, 1.5 mmol) and <i>N</i>-bromosuccinimide (354 mg, 2.0 mmol) in CH<sub>3</sub>CN (15 mL) was added 2,2′-azobis(2-methylpropionitrile) (27 mg). The mixture was stirred for 1 h at 90 °C. The reaction mixture was concentrated in vacuo, and the residue was purified by prep-HPLC, eluting with water/acetonitrile gradient to give <i>tert</i>-butyl (4-bromo-1-hydroxy-7-(2-hydroxyethoxy)-1,3-dihydrobenzo[<i>c</i>][1,2]oxaborol-3-yl)methylcarbamate (300 mg, yield 50%). A mixture of the above compound (0.2 g, 0.5 mmol) in 1 M HCl/Et<sub>2</sub>O (10 mL) was stirred at rt for 1 h and then concentrated in vacuo. The residue was washed with acetonitrile (2 × 5 mL) and dried in vacuo to give <b>24</b> as a white solid (140 mg, yield 83%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.36 (b, 3H), 7.64–7.61 (d, 1H, <i>J</i> = 9 Hz), 6.93–6.60 (d, 1H, <i>J</i> = 9 Hz), 5.51 (m, 1H), 4.69 (m, 1H), 4.36–4.23 (m, 3H), 3.62 (m, 1H), 3.01 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 302 [M + H]<sup>+</sup>. HPLC purity: 99.5% (220 nm).</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (<i>S</i>)-3-(Aminomethyl)-4-bromo-7-(2-hydroxyethoxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>24a</b>) and (<i>R</i>)-3-(Aminomethyl)-4-bromo-7-(2-hydroxyethoxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>24b</b>)</h3><div class="NLM_p last">The racemic <i>tert</i>-butyl (4-bromo-1-hydroxy-7-(2-hydroxyethoxy)-1,3-dihydrobenzo[<i>c</i>][1,2]oxaborol-3-yl)methylcarbamate was separated on a Thar preparative SFC 80 system with a Daicel Chiralpak AD-H 5 μm (250 mm × 20 mm i.d.), eluted with carbon dioxide and methanol mobile phase. Two isomers were obtained. Each compound (1.2 g, 3.1 mmol) in 1 M HCl/Et<sub>2</sub>O (20 mL) was stirred at rt for 1 h and concentrated in vacuo. The residue was washed with acetonitrile (2 × 5 mL) and dried in vacuo to give the desired product as a white solid. <b>24a</b> (900 mg, yield 90%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.37 (b, 3H), 7.63–7.60 (d, 1H, <i>J</i> = 9 Hz), 6.92–6.89 (d, 1H, <i>J</i> = 9 Hz), 5.51 (m, 1H), 4.68 (m, 1H), 4.36–4.23 (m, 3H), 3.61 (m, 1H), 3.01 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 302 [M + H]<sup>+</sup>. HPLC purity: 98.4% (220 nm). Analysis of the Boc-derivatized material using a ChiralCel AD-H analytical column showed the (<i>S</i>) enantiomer with a retention time of 3.79 min and 98.0% ee. <b>24b</b> (900 mg, yield 90%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.38 (b, 3H), 7.63–7.60 (d, 1H, <i>J</i> = 9 Hz), 6.92–6.89 (d, 1H, <i>J</i> = 9 Hz), 5.50 (m, 1H), 4.68 (m, 1H), 4.35–4.23 (m, 3H), 3.61 (m, 1H), 3.00 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 302 [M + H]<sup>+</sup>. HPLC purity: 99.5% (220 nm). Analysis of the Boc-derivatized material using a ChiralCel AD-H analytical column showed the (<i>R</i>) enantiomer with a retention time of 3.34 min and 98.1% ee.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 3-(Aminomethyl)-4-chloro-6-ethoxybenzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>25</b>)</h3><div class="NLM_p last">A solution of 2-chloro-4,6-dihydroxybenzaldehyde (6.2 g, 35.9 mmol), DHP (6.02 g, 71.7 mmol), and PPTS (0.9 g) in 150 mL of CH<sub>2</sub>Cl<sub>2</sub> was stirred at rt for 1.5 h. After the reaction was quenched with sat. NaHCO<sub>3</sub> solution (50 mL) at 0 °C, the mixture was washed with brine (30 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel chromatography, eluting with EtOAc and petroleum ether (1:100) to give 2-chloro-6-hydroxy-4-(tetrahydro-2<i>H</i>-pyran-2-yloxy)benzaldehyde as colorless oil (7.8 g, 85%). To a stirred solution of the above compound (7.8 g, 30.4 mmol) and pyridine (10.9 mL) in 150 mL of CH<sub>2</sub>Cl<sub>2</sub> at −10 °C was added Tf<sub>2</sub>O (7.66 mL). The reaction was stirred at 0 °C for 2 h. After the reaction was quenched with brine (35 mL), the mixture was extracted with EtOAc (100 mL). The solvent was evaporated in vacuo. The residue was purified by silica gel chromatography, eluting with EtOAc and petroleum ether (1:200) to give 3-chloro-2-formyl-5-(tetrahydro-2<i>H</i>-pyran-2-yloxy)phenyl trifluoromethanesulfonate as yellow oil (7.0 g, 59%). A mixture of the above compound (3.4 g, 8.7 mmol), bis(pinacolato)diborane (4.0 g, 15.8 mmol), KOAc (2.3 g, 23.7 mmol), and PdCl<sub>2</sub>(dppf) (0.58 g) in 120 mL of 1,4-dioxane was degassed with N<sub>2</sub> six times. The reaction was stirred at 80 °C for 1 h. The solvent was evaporated in vacuo. The residue was purified by silica gel chromatography, eluting with EtOAc and petroleum ether (1:10) to give 2-chloro-4-(tetrahydro-2<i>H</i>-pyran-2-yloxy)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde as a white solid (3.1 g, 97%). To a stirred solution of the above compound (2.2 g, 6.0 mmol) and CH<sub>3</sub>NO<sub>2</sub> (1.1 g, 18.0 mmol) in 40 mL of THF was added a solution of NaOH (0.24 g, 6.0 mmol) in 40 mL of water. The reaction was stirred at rt for 3 h. The reaction mixture was treated with citric acid to pH = 6 and was then extracted with EtOAc (120 mL). The organic phase was washed with brine (15 mL) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated in vacuo to give crude 4-chloro-3-(nitromethyl)-6-(tetrahydro-2<i>H</i>-pyran-2-yloxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol. A solution of the above compound (3.3 g, 10.1 mmol) in 33 mL of conc HCl and 66 mL of MeOH was stirred at reflux for 1 h. The solvent was evaporated in vacuo to give 4-chloro-3-(nitromethyl)benzo[<i>c</i>][1,2]oxaborole-1,6(3<i>H</i>)-diol (3 g, crude). It was used directly in the next step without further purification. A mixture of the above compound (1.4 g, 5.8 mmol) and Raney Ni (0.5 g) in 5 mL of ammonium in ethanol (2 M, 5 mL) and 20 mL of ethanol was hydrogenated at an atmosphere of hydrogen for 6 h. The mixture was filtered through a bed of Celite, and the filtrate was concentrated in vacuo. The residue was dissolved in 30 mL of ethanol and treated with 1 mL of conc HCl. The solvent was evaporated in vacuo to give 3-(aminomethyl)-4-chlorobenzo[<i>c</i>][1,2]oxaborole-1,6(3<i>H</i>)-diol hydrochloride as solid (1.3 g, 90%). To a stirred solution of the above compound (1.3 g, 5.2 mmol) and Et<sub>3</sub>N (1.16 g, 11.5 mmol) in 200 mL of CH<sub>2</sub>Cl<sub>2</sub> at 0 °C was added Boc<sub>2</sub>O (2.5 g, 11.5 mmol). The reaction was stirred at rt for 4 h. The mixture was washed with water (20 mL), brine (20 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel chromatography, eluting with MeOH and CH<sub>2</sub>Cl<sub>2</sub> (1:10) to give <i>tert</i>-butyl (4-chloro-1,6-dihydroxy-1,3-dihydrobenzo[<i>c</i>][1,2]oxaborol-3-yl)methylcarbamate (0.4 g, 25%) as oil. A mixture of the above compound (0.4 g, 1.3 mmol), EtI (0.6 g, 3.8 mmol), and K<sub>2</sub>CO<sub>3</sub> (0.5 g, 3.8 mmol) in 30 mL of acetone was stirred at reflux for 16 h. The solvent was evaporated in vacuo. The residue was purified by silica gel chromatography, eluting with MeOH and CH<sub>2</sub>Cl<sub>2</sub> (1:20) to give <i>tert</i>-butyl (4-chloro-6-ethoxy-1-hydroxy-1,3-dihydrobenzo[<i>c</i>][1,2]oxaborol-3-yl)methylcarbamate (0.43 g, 99%). To a stirred solution of the above compound (0.43 g, 1.3 mmol) in 4 mL of CH<sub>2</sub>Cl<sub>2</sub> was added TFA (2 mL). The reaction was stirred at rt for 1 h. The solvent was evaporated in vacuo. The residue was purified by prep-HPLC followed by treating with conc HCl to give <b>25</b> as a white solid (20 mg, 6%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.17 (s, 1H), 7.14 (s, 1H), 5.47 (m, 1H), 4.10 (q, 2H), 3.82 (m, 1H), 3.04 (m, 1H), 1.42 (t, 3H). MS (ESI) <i>m</i>/<i>z</i> = 242 [M + H]<sup>+</sup>. HPLC purity: 97.0% (220 nm).</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 3-(Aminomethyl)-4-bromo-6-ethoxybenzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>26</b>)</h3><div class="NLM_p last">To a solution of 2,6-dibromo-4-hydroxybenzaldehyde (2 g, 7.1 mmol) and potassium carbonate (2.96 g, 21.4 mmol) in DMF (50 mL) was added CH<sub>3</sub>CH<sub>2</sub>Br (2.3 g, 21.4 mmol). The mixture was stirred at rt for 3 h. After water was added, the mixture was extracted with EtOAc (2 × 100 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo to give 2,6-dibromo-4-ethoxybenzaldehyde as a white solid (2.1 g, 95%). To a stirred solution of the above compound (2 g, 6.5 mmol) and HC(OMe)<sub>3</sub> (1.38 g, 13 mmol) in MeOH (30 mL) was added conc H<sub>2</sub>SO<sub>4</sub> (1 drop) at rt. The reaction was stirred at reflux for 1 h. MeONa was added until pH = 7. After the solvent was removed, the residue was washed with petroleum ether. The organic layer was concentrated in vacuo to afford 1,3-dibromo-2-(dimethoxymethyl)-5-ethoxybenzene as oil (2.0 g, 87%). To a solution of the above compound (500 mg, 1.4 mmol) in anhydrous ether (20 mL) was added <i>n</i>-BuLi (2.5 M, 0.56 mL, 1.4 mmol) dropwise at −78 °C under N<sub>2</sub>. After the mixture was stirred at −78 °C for 15 min, trimethyl borate (176 mg, 1.7 mmol) was added dropwise. The resulting mixture was stirred at −78 °C for 30 min. The reaction was quenched by adding 2 N HCl solution until pH = 1, and the mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with water (10 mL) and brine (10 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo to give 3-bromo-5-ethoxy-2-formylphenylboronic acid (500 mg, crude). A mixture of the above compound (500 mg, 1.8 mmol), NaOH (73 mg, 1.8 mmol) in H<sub>2</sub>O (10 mL) and THF (20 mL) was stirred for 30 min. Nitromethane (558 mg, 9.2 mmol) was added, and the reaction was stirred at rt for 3 h. The mixture was adjusted to pH = 1 by adding diluted HCl (2 N) and then extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo to give 4-bromo-6-ethoxy-3-(nitromethyl)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol as oil (500 mg, crude). A mixture of the above compound (500 mg, 1.6 mmol), NH<sub>3</sub> in MeOH (7 N, 0.2 mL), and Raney Ni (100 mg) in MeOH (40 mL) was stirred under an atmosphere of hydrogen for 4 h at rt. The mixture was filtered through a bed of Celite, and the filtrate was concentrated in vacuo. The residue was purified by prep-HPLC followed by treating with conc HCl to give <b>26</b> as a white solid (120 mg, 24%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.77 (b, 1H), 8.19 (b, 3H), 7.41 (s, 1H), 7.32 (s, 1H), 5.31 (m, 1H), 4.10 (m, 2H), 3.64 (m, 1H), 2.87 (m, 1H), 1.36 (m, 3H). MS (ESI) <i>m</i>/<i>z</i> = 286 [M + H]<sup>+</sup>. HPLC purity: 95.3% (220 nm).</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 3-(Aminomethyl)-4-chloro-6-propoxybenzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>27</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described above for the synthesis of <b>25</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.16 (s, 1H), 7.12 (s, 1H), 5.45 (m, 1H), 3.99 (t, 2H), 3.79 (m, 1H), 3.06 (m, 1H), 1.82 (m, 2H), 1.07 (t, 3H). MS (ESI) <i>m</i>/<i>z</i> = 256 [M + H]<sup>+</sup>. HPLC purity: 96.2% (220 nm).</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 3-(Aminomethyl)-4-bromo-6-propoxybenzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>28</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described above for the synthesis of <b>26</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.71 (b, 1H), 8.09 (b, 3H), 7.36 (s, 1H), 7.31 (s, 1H), 5.28 (m, 1H), 3.97 (m, 2H), 3.60 (m, 1H), 2.86 (m, 1H), 1.74 (m, 2H), 0.98 (t, 3H). MS (ESI) <i>m</i>/<i>z</i> = 300 [M + H]<sup>+</sup>. HPLC purity: 96.5% (220 nm).</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 3-(Aminomethyl)-4-chloro-6-(3-hydroxypropoxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>29</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described above for the synthesis of <b>25</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.36 (s, 1H), 7.18 (s, 1H), 5.48 (m, 1H), 4.13 (t, 2H), 3.80 (m, 1H), 3.75 (t, 2H), 3.05 (m, 1H), 2.02 (m, 2H). MS (ESI) <i>m</i>/<i>z</i> = 272 [M + H]<sup>+</sup>. HPLC purity: 95.3% (220 nm).</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 3-(Aminomethyl)-4-bromo-6-(3-hydroxypropoxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>30</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described above for the synthesis of <b>26</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.72 (b, 1H), 8.13 (b, 3H), 7.39 (s, 1H), 7.33 (s, 1H), 5.29 (m, 1H), 4.08 (t, 2H), 3.63 (m, 1H), 3.57 (m, 2H), 2.86 (m, 1H), 1.87 (m, 2H). MS (ESI) <i>m</i>/<i>z</i> = 316 [M + H]<sup>+</sup>. HPLC purity: 91.3% (220 nm).</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 3-(Aminomethyl)-4-chloro-6-(3-hydroxypropoxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>31</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described above for the synthesis of <b>25</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.22 (s, 1H), 7.20 (s, 1H), 5.48 (m, 1H), 4.11 (t, 2H), 3.91 (t, 2H), 3.85 (m, 1H), 3.05 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 258 [M + H]<sup>+</sup>. HPLC purity: 98.4% (220 nm).</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 3-(Aminomethyl)-4-bromo-6-(3-hydroxypropoxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>32</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described above for the synthesis of <b>26</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.72 (b, 1H), 8.11 (b, 3H), 7.39 (s, 1H), 7.32 (s, 1H), 5.28 (m, 1H), 4.91 (t, 1H), 4.04 (t, 2H), 3.75 (t, 2H), 3.70 (m, 1H), 2.86 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 302 [M + H]<sup>+</sup>. HPLC purity: 98.9% (220 nm).</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 3-(Aminomethyl)-4-chloro[1,3]dioxolo[4′,5′:5,6]benzo[1,2-<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Hydrochloride (<b>33</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described below for the synthesis of <b>35</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.65 (b, 1H), 7.98 (b, 3H), 7.24 (s, 1H), 6.17 (ds, 2H), 5.33 (m, 1H), 3.54 (m, 1H), 2.99 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 242 [M + H]<sup>+</sup>. HPLC purity: 98.9% (220 nm).</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 3-(Aminomethyl)-4-bromo[1,3]dioxolo[4′,5′:5,6]benzo[1,2-<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol Trifluoroacetate (<b>34</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described below for the synthesis of <b>35</b> and obtained as TFA salt after prep-HPLC purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.58 (b, 1H), 7.96 (b, 3H), 7.29 (s, 1H), 6.09 (ds, 2H), 5.18 (m, 1H), 3.52 (m, 1H), 2.90 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 286 [M + H]<sup>+</sup>. HPLC purity: 95.1% (220 nm).</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 3-(Aminomethyl)-4-chloro-7,8-dihydro[1,2]oxaborolo[3′,4′:3,4]benzo[1,2-<i>b</i>][1,4]dioxin-1(3<i>H</i>)-ol Hydrochloride (<b>35</b>)</h3><div class="NLM_p last">A mixture of 2-bromo-3,4-dihydroxybenzaldehyde (4.5 g, 20.7 mmol), 1,2-dibromoethane (4.65 g, 24.8 mmol), and K<sub>2</sub>CO<sub>3</sub> (8.9 g, 64.5 mmol) in DMF (40 mL) was stirred at 50 °C overnight. After H<sub>2</sub>O (80 mL) was added, the mixture was extracted with EtOAc (2 × 80 mL). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue was purified by silica gel chromatography to give 5-bromo-2,3-dihydrobenzo[<i>b</i>][1,4]dioxine-6-carbaldehyde (1.5 g, yield 30%). A mixture of the above compound (2.68 g, 11.0 mmol), bis(pinacolato)diborane (4.0 g, 16.3 mmol), KOAc (4.1 g, 41.8 mmol), and PdCl<sub>2</sub>(dppf) (310 mg, 4.2 mmol) in dioxane (60 mL) was degassed for 15 min with N<sub>2</sub>. The reaction was stirred at 100 °C for 3 h. After the reaction was quenched with ice–water (25 mL), the mixture was extracted with EtOAc (3 × 70 mL). The combined organic layers were washed with water (35 mL) and brine (40 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel chromatography to give 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydrobenzo[<i>b</i>][1,4]dioxine-6-carbaldehyde (1.5 g, yield 47%). A mixture of the above compound (1.52 g, 5.2 mmol), 10% NaOH solution (6 mL), and THF (30 mL) was stirred for 0.5 h at rt. After nitromethane (980 mg 16.1 mmol) was added, the reaction was stirred at rt for 2 h. The mixture was adjusted to pH = 2 by adding diluted HCl (2 N) and extracted with EtOAc (3 × 60 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by prep-HPLC, eluting with water/acetonitrile gradient to give the 6,7-dixoane-3-(nitromethyl)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol (1.3 g, yield 99%). To a mixture of the above compound (200 mg, 0.8 mmol) in glacial acetic acid (15 mL) was added sulfuryl dichloride (64 μL, 0.8 mmol) dropwise. The reaction was stirred at rt for 1.5 h. After the reaction was quenched with water (15 mL), the mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue 6,7-dixoane-4-chloro-3-(nitromethyl)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol was used directly for the next step without purification. A mixture of the above compound, Raney Ni (∼50 mg), and 2 M NH<sub>3</sub> in EtOH (2 mL) in EtOH (10 mL) was shaken under an atmosphere of hydrogen for 3 h. The mixture was filtered through a bed of Celite, and the filtrate was concentrated in vacuo. The crude amine was dissolved in EtOAc (1 mL), and 1 M HCl in Et<sub>2</sub>O (8 mL) was added. After stirring for 1 h, the residue was filtered, washed with hexane, and dried in vacuo to give <b>35</b> as a white solid (90 mg, yield 38%, two steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.29 (b, 1H), 8.25 (b, 3H), 7.08 (s, 1H), 5.30 (m, 1H), 4.27–4.23 (m, 4H), 3.48 (m, 1H), 2.84 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 256 [M + H]<sup>+</sup>. HPLC purity: 98.9% (220 nm).</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> (<i>S</i>)-3-(Aminomethyl)-4-chloro-7,8-dihydro[1,2]oxaborolo[3′,4′:3,4]benzo[1,2-<i>b</i>][1,4]dioxin-1(3<i>H</i>)-ol Hydrochloride (<b>35a</b>) and (<i>R</i>)-3-(Aminomethyl)-4-chloro-7,8-dihydro[1,2]oxaborolo[3′,4′:3,4]benzo[1,2-<i>b</i>][1,4]dioxin-1(3<i>H</i>)-ol Hydrochloride (<b>35b</b>)</h3><div class="NLM_p last">These compounds were prepared by the similar method described above for the synthesis of <b>23a</b> and <b>23b</b>. <b>35a</b>: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.34 (b, 1H), 8.26 (b, 3H), 7.12 (s, 1H), 5.33 (m, 1H), 4.30–4.26 (m, 4H), 3.52 (m, 1H), 2.86 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 256 [M + H]<sup>+</sup>. HPLC purity: 98.1% (220 nm). Analysis of the Boc-derivatized material using a ChiralPak AY-H analytical column showed the (<i>S</i>) enantiomer with a retention time of 1.64 min and >99% ee. <b>35b</b>: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.34 (b, 1H), 8.17 (b, 3H), 7.13 (s, 1H), 5.31 (m, 1H), 4.30–4.26 (m, 4H), 3.54 (m, 1H), 2.90 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 256 [M + H]<sup>+</sup>. HPLC purity: 95.7% (220 nm). Analysis of the Boc-derivatized material using a ChiralPak AY-H analytical column showed the (<i>R</i>) enantiomer with a retention time of 1.95 min and >99% ee.</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 3-(Aminomethyl)-4-bromo-7,8-dihydro[1,2]oxaborolo[3′,4′:3,4]benzo[1,2-<i>b</i>][1,4]dioxin-1(3<i>H</i>)-ol Trifluoroacetate (<b>36</b>)</h3><div class="NLM_p last">This compound was prepared by the similar method described above for the synthesis of <b>35</b> and obtained as TFA salt after prep-HPLC purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.28 (b, 1H), 8.05 (b, 3H), 7.25 (s, 1H), 5.20 (m, 1H), 4.30–4.23 (m, 4H), 3.50 (m, 1H), 2.93 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 300 [M + H]<sup>+</sup>. HPLC purity: 98.8% (220 nm).</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> (<i>S</i>)-3-(Aminomethyl)-4-bromo-7,8-dihydro[1,2]oxaborolo[3′,4′:3,4]benzo[1,2-<i>b</i>][1,4]dioxin-1(3<i>H</i>)-ol Hydrochloride (<b>36a</b>) and (<i>R</i>)-3-(Aminomethyl)-4-bromo-7,8-dihydro[1,2]oxaborolo[3′,4′:3,4]benzo[1,2-<i>b</i>][1,4]dioxin-1(3<i>H</i>)-ol Hydrochloride (<b>36b</b>)</h3><div class="NLM_p last">These compounds were resolved by the similar method described above for the synthesis of <b>23a</b> and <b>23b</b>. <b>36a</b>: <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.28 (b, 1H), 8.19 (b, 3H), 7.23 (s, 1H), 5.22 (m, 1H), 4.29 (m, 4H), 3.56 (m, 1H), 2.88 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 300 [M + H]<sup>+</sup>. HPLC purity: 97.9% (220 nm). Analysis of the Boc-derivatized material using a ChiralCel AD-H analytical column showed the (<i>S</i>) enantiomer with a retention time of 2.79 min and 97.6% ee. <b>36b</b>: <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.28 (b, 1H), 8.15 (b, 3H), 7.23 (s, 1H), 5.23 (m, 1H), 4.29 (m, 4H), 3.54 (m, 1H), 2.89 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> = 300 [M + H]<sup>+</sup>. HPLC purity: 96.5% (220 nm). Analysis of the Boc-derivatized material using a ChiralCel AD-H analytical column showed the (<i>R</i>) enantiomer with a retention time of 2.62 min and 99.6% ee.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00631" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07384" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07384" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Barros</span> - <span class="hlFld-Affiliation affiliation">GlaxoSmithKline, Tres Cantos Medicines Development
Campus, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4099-0438" title="Orcid link">http://orcid.org/0000-0002-4099-0438</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7a1e1b0c131e541b54181b080815093a1d091154191517"><span class="__cf_email__" data-cfemail="1e7a7f68777a307f307c7f6c6c716d5e796d75307d7173">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xianfeng Li</span> - <span class="hlFld-Affiliation affiliation">Anacor
Pharmaceuticals, Inc., 1020 E. Meadow Circle, Palo Alto, California 94303, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vincent Hernandez</span> - <span class="hlFld-Affiliation affiliation">Anacor
Pharmaceuticals, Inc., 1020 E. Meadow Circle, Palo Alto, California 94303, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fernando L. Rock</span> - <span class="hlFld-Affiliation affiliation">Anacor
Pharmaceuticals, Inc., 1020 E. Meadow Circle, Palo Alto, California 94303, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wai Choi</span> - <span class="hlFld-Affiliation affiliation">Anacor
Pharmaceuticals, Inc., 1020 E. Meadow Circle, Palo Alto, California 94303, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yvonne S. L. Mak</span> - <span class="hlFld-Affiliation affiliation">Anacor
Pharmaceuticals, Inc., 1020 E. Meadow Circle, Palo Alto, California 94303, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Manisha Mohan</span> - <span class="hlFld-Affiliation affiliation">Anacor
Pharmaceuticals, Inc., 1020 E. Meadow Circle, Palo Alto, California 94303, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Weimin Mao</span> - <span class="hlFld-Affiliation affiliation">Anacor
Pharmaceuticals, Inc., 1020 E. Meadow Circle, Palo Alto, California 94303, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yasheen Zhou</span> - <span class="hlFld-Affiliation affiliation">Anacor
Pharmaceuticals, Inc., 1020 E. Meadow Circle, Palo Alto, California 94303, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eric E. Easom</span> - <span class="hlFld-Affiliation affiliation">Anacor
Pharmaceuticals, Inc., 1020 E. Meadow Circle, Palo Alto, California 94303, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jacob J. Plattner</span> - <span class="hlFld-Affiliation affiliation">Anacor
Pharmaceuticals, Inc., 1020 E. Meadow Circle, Palo Alto, California 94303, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wuxin Zou</span> - <span class="hlFld-Affiliation affiliation">BioDuro
LLC, Building E, No.
29, Life Science Park Road, Beijing 102206, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Esther Pérez-Herrán</span> - <span class="hlFld-Affiliation affiliation">GlaxoSmithKline, Tres Cantos Medicines Development
Campus, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ilaria Giordano</span> - <span class="hlFld-Affiliation affiliation">GlaxoSmithKline, Tres Cantos Medicines Development
Campus, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alfonso Mendoza-Losana</span> - <span class="hlFld-Affiliation affiliation">GlaxoSmithKline, Tres Cantos Medicines Development
Campus, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carlos Alemparte</span> - <span class="hlFld-Affiliation affiliation">GlaxoSmithKline, Tres Cantos Medicines Development
Campus, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joaquín Rullas</span> - <span class="hlFld-Affiliation affiliation">GlaxoSmithKline, Tres Cantos Medicines Development
Campus, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Iñigo Angulo-Barturen</span> - <span class="hlFld-Affiliation affiliation">GlaxoSmithKline, Tres Cantos Medicines Development
Campus, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sabrinia Crouch</span> - <span class="hlFld-Affiliation affiliation">GlaxoSmithKline, Tres Cantos Medicines Development
Campus, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fátima Ortega</span> - <span class="hlFld-Affiliation affiliation">GlaxoSmithKline, Tres Cantos Medicines Development
Campus, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">M. R. K. Alley</span> - <span class="hlFld-Affiliation affiliation">Anacor
Pharmaceuticals, Inc., 1020 E. Meadow Circle, Palo Alto, California 94303, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i59" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i59"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i60" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i60"> Abbreviations Used</h2><tr><td class="NLM_term">CFU</td><td class="NLM_def"><p class="first last">colony-forming units</p></td></tr><tr><td class="NLM_term">DNAUC</td><td class="NLM_def"><p class="first last">dose-normalized area under the curve</p></td></tr><tr><td class="NLM_term">dppf</td><td class="NLM_def"><p class="first last">1,1′-bis(diphenylphosphino)ferrocene</p></td></tr><tr><td class="NLM_term">i.d.</td><td class="NLM_def"><p class="first last">inside diameter</p></td></tr><tr><td class="NLM_term">LeuRS</td><td class="NLM_def"><p class="first last">leucyl-tRNA synthetase</p></td></tr><tr><td class="NLM_term"><i>Mtb</i></td><td class="NLM_def"><p class="first last"><i>Mycobacterium tuberculosis</i></p></td></tr><tr><td class="NLM_term">(pin)<sub>2</sub></td><td class="NLM_def"><p class="first last">bis(pinacolato)</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TDR-TB</td><td class="NLM_def"><p class="first last">totally drug-resistant tuberculosis</p></td></tr><tr><td class="NLM_term">XDR-TB</td><td class="NLM_def"><p class="first last">extensively drug-resistant tuberculosis</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i61">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15888" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15888" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 30 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">WHO</span><span class="NLM_x">. </span><span> </span><span class="NLM_article-title">Global Tuberculosis Report 2016</span>. <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.who.int/tb/publications/global_report/en/" class="extLink">http://www.who.int/tb/publications/global_report/en/</a> (accessed November 22, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=WHO.+Global+Tuberculosis+Report+2016.+World+Health+Organization%3A+Geneva%2C+2016%3B+http%3A%2F%2Fwww.who.int%2Ftb%2Fpublications%2Fglobal_report%2Fen%2F+%28accessed+November+22%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DGlobal%2520Tuberculosis%2520Report%25202016%26pub%3DWorld%2520Health%2520Organization%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Coker, R. J.</span><span> </span><span class="NLM_article-title">Multidrug-resistant tuberculosis: public health challenges</span> <span class="citation_source-journal">Trop. Med. Int. Health</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span><span class="refDoi"> DOI: 10.1046/j.1365-3156.2003.01156.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1046%2Fj.1365-3156.2003.01156.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=14728604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252FjtVyrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=25-40&author=R.+J.+Coker&title=Multidrug-resistant+tuberculosis%3A+public+health+challenges&doi=10.1046%2Fj.1365-3156.2003.01156.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Review: multidrug-resistant tuberculosis: public health challenges</span></div><div class="casAuthors">Coker Richard J</div><div class="citationInfo"><span class="NLM_cas:title">Tropical medicine & international health : TM & IH</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-40</span>
        ISSN:<span class="NLM_cas:issn">1360-2276</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHu6CcloILkzC850By6mxpfW6udTcc2ebkAKbjrkbIALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252FjtVyrtw%253D%253D&md5=ff2e35bac2f25869857aa72fc7d77238</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-3156.2003.01156.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-3156.2003.01156.x%26sid%3Dliteratum%253Aachs%26aulast%3DCoker%26aufirst%3DR.%2BJ.%26atitle%3DMultidrug-resistant%2520tuberculosis%253A%2520public%2520health%2520challenges%26jtitle%3DTrop.%2520Med.%2520Int.%2520Health%26date%3D2004%26volume%3D9%26spage%3D25%26epage%3D40%26doi%3D10.1046%2Fj.1365-3156.2003.01156.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Esposito, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Ambrosio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadolini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaaf, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caminero Luna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Centis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matteelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blasi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliori, G. B.</span><span> </span><span class="NLM_article-title">ERS/WHO tuberculosis consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">811</span><span class="NLM_x">–</span> <span class="NLM_lpage">815</span><span class="refDoi"> DOI: 10.1183/09031936.00060414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1183%2F09031936.00060414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=24833763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A280%3ADC%252BC2cjjt1OmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2014&pages=811-815&author=S.+Espositoauthor=L.+D%E2%80%99Ambrosioauthor=M.+Tadoliniauthor=H.+S.+Schaafauthor=J.+Caminero+Lunaauthor=B.+Maraisauthor=R.+Centisauthor=M.+Daraauthor=A.+Matteelliauthor=F.+Blasiauthor=G.+B.+Migliori&title=ERS%2FWHO+tuberculosis+consilium+assistance+with+extensively+drug-resistant+tuberculosis+management+in+a+child%3A+case+study+of+compassionate+delamanid+use&doi=10.1183%2F09031936.00060414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use</span></div><div class="casAuthors">Esposito Susanna; D'Ambrosio Lia; Tadolini Marina; Schaaf H Simon; Caminero Luna Jose; Marais Ben; Centis Rosella; Migliori Giovanni Battista; Dara Masoud; Matteelli Alberto; Blasi Francesco</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">811-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrd6ehdbC4EjAyhZbj3lKdfW6udTcc2ebkAKbjrkbIALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjjt1OmtA%253D%253D&md5=b6d47e209f05734b7ea318d13d119908</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1183%2F09031936.00060414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00060414%26sid%3Dliteratum%253Aachs%26aulast%3DEsposito%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Ambrosio%26aufirst%3DL.%26aulast%3DTadolini%26aufirst%3DM.%26aulast%3DSchaaf%26aufirst%3DH.%2BS.%26aulast%3DCaminero%2BLuna%26aufirst%3DJ.%26aulast%3DMarais%26aufirst%3DB.%26aulast%3DCentis%26aufirst%3DR.%26aulast%3DDara%26aufirst%3DM.%26aulast%3DMatteelli%26aufirst%3DA.%26aulast%3DBlasi%26aufirst%3DF.%26aulast%3DMigliori%26aufirst%3DG.%2BB.%26atitle%3DERS%252FWHO%2520tuberculosis%2520consilium%2520assistance%2520with%2520extensively%2520drug-resistant%2520tuberculosis%2520management%2520in%2520a%2520child%253A%2520case%2520study%2520of%2520compassionate%2520delamanid%2520use%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2014%26volume%3D44%26spage%3D811%26epage%3D815%26doi%3D10.1183%2F09031936.00060414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Udwadia, Z. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amale, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajbani, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, C.</span><span> </span><span class="NLM_article-title">Totally drug-resistant tuberculosis in India</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">–</span> <span class="NLM_lpage">581</span><span class="refDoi"> DOI: 10.1093/cid/cir889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1093%2Fcid%2Fcir889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=22190562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A280%3ADC%252BC387ptF2hsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2012&pages=579-581&author=Z.+F.+Udwadiaauthor=R.+A.+Amaleauthor=K.+K.+Ajbaniauthor=C.+Rodrigues&title=Totally+drug-resistant+tuberculosis+in+India&doi=10.1093%2Fcid%2Fcir889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Totally drug-resistant tuberculosis in India</span></div><div class="casAuthors">Udwadia Zarir F; Amale Rohit A; Ajbani Kanchan K; Rodrigues Camilla</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">579-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT2_G3WsdaydUbxh97K6Vt6fW6udTcc2eYb3-n2ixuA0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387ptF2hsQ%253D%253D&md5=237f5c180e0daee51adf5df45a93d428</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcir889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcir889%26sid%3Dliteratum%253Aachs%26aulast%3DUdwadia%26aufirst%3DZ.%2BF.%26aulast%3DAmale%26aufirst%3DR.%2BA.%26aulast%3DAjbani%26aufirst%3DK.%2BK.%26aulast%3DRodrigues%26aufirst%3DC.%26atitle%3DTotally%2520drug-resistant%2520tuberculosis%2520in%2520India%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2012%26volume%3D54%26spage%3D579%26epage%3D581%26doi%3D10.1093%2Fcid%2Fcir889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Hoagland, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. E.</span><span> </span><span class="NLM_article-title">New agents for the treatment of drug-resistant Mycobacterium tuberculosis</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span><span class="refDoi"> DOI: 10.1016/j.addr.2016.04.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1016%2Fj.addr.2016.04.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=27151308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlSns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2016&pages=55-72&author=D.+T.+Hoaglandauthor=J.+Liuauthor=R.+B.+Leeauthor=R.+E.+Lee&title=New+agents+for+the+treatment+of+drug-resistant+Mycobacterium+tuberculosis&doi=10.1016%2Fj.addr.2016.04.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">New agents for the treatment of drug-resistant Mycobacterium tuberculosis</span></div><div class="casAuthors">Hoagland, Daniel T.; Liu, Jiuyu; Lee, Robin B.; Lee, Richard E.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">55-72</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inadequate dosing and incomplete treatment regimens, coupled with the ability of the tuberculosis bacilli to cause latent infections that are tolerant of currently used drugs, have fueled the rise of multidrug-resistant tuberculosis (MDR-TB).  Treatment of MDR-TB infections is a major clin. challenge that has few viable or effective solns.; therefore patients face a poor prognosis and years of treatment.  This review focuses on emerging drug classes that have the potential for treating MDR-TB and highlights their particular strengths as leads including their mode of action, in vivo efficacy, and key medicinal chem. properties.  Examples include the newly approved drugs bedaquiline and delaminid, and other agents in clin. and late preclin. development pipeline for the treatment of MDR-TB.  Herein, we discuss the challenges to developing drugs to treat tuberculosis and how the field has adapted to these difficulties, with an emphasis on drug discovery approaches that might produce more effective agents and treatment regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBEswjNcHj27Vg90H21EOLACvtfcHk0liUUZO-zf5ATw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlSns7c%253D&md5=7c8ca15b9b493cceaf3d51d93b9afcec</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.04.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.04.026%26sid%3Dliteratum%253Aachs%26aulast%3DHoagland%26aufirst%3DD.%2BT.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BB.%26aulast%3DLee%26aufirst%3DR.%2BE.%26atitle%3DNew%2520agents%2520for%2520the%2520treatment%2520of%2520drug-resistant%2520Mycobacterium%2520tuberculosis%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2016%26volume%3D102%26spage%3D55%26epage%3D72%26doi%3D10.1016%2Fj.addr.2016.04.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Zumla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nahid, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, S. T.</span><span> </span><span class="NLM_article-title">Advances in the development of new tuberculosis drugs and treatment regimens</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">388</span><span class="NLM_x">–</span> <span class="NLM_lpage">404</span><span class="refDoi"> DOI: 10.1038/nrd4001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1038%2Fnrd4001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=23629506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Kmsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=388-404&author=A.+Zumlaauthor=P.+Nahidauthor=S.+T.+Cole&title=Advances+in+the+development+of+new+tuberculosis+drugs+and+treatment+regimens&doi=10.1038%2Fnrd4001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the development of new tuberculosis drugs and treatment regimens</span></div><div class="casAuthors">Zumla, Alimuddin; Nahid, Payam; Cole, Stewart T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">388-404</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid, rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to cause considerable morbidity and mortality worldwide.  For the first time since the 1960s, new and novel drugs and regimens for all forms of TB are emerging.  Such regimens are likely to utilize both repurposed drugs and new chem. entities, and several of these regimens are now progressing through clin. trials.  This article covers current concepts and recent advances in TB drug discovery and development, including an update of ongoing TB treatment trials, newer clin. trial designs, TB biomarkers and adjunct host-directed therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs_a1A-oQwcrVg90H21EOLACvtfcHk0liUUZO-zf5ATw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Kmsrk%253D&md5=fbf12f867a19ffff4d7fb74a98699682</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrd4001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4001%26sid%3Dliteratum%253Aachs%26aulast%3DZumla%26aufirst%3DA.%26aulast%3DNahid%26aufirst%3DP.%26aulast%3DCole%26aufirst%3DS.%2BT.%26atitle%3DAdvances%2520in%2520the%2520development%2520of%2520new%2520tuberculosis%2520drugs%2520and%2520treatment%2520regimens%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D388%26epage%3D404%26doi%3D10.1038%2Fnrd4001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Gutierrez-Lugo, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bewley, C. A.</span><span> </span><span class="NLM_article-title">Natural products, small molecules, and genetics in tuberculosis drug development</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2606</span><span class="NLM_x">–</span> <span class="NLM_lpage">2612</span><span class="refDoi"> DOI: 10.1021/jm070719i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070719i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2606-2612&author=M.+T.+Gutierrez-Lugoauthor=C.+A.+Bewley&title=Natural+products%2C+small+molecules%2C+and+genetics+in+tuberculosis+drug+development&doi=10.1021%2Fjm070719i"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm070719i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070719i%26sid%3Dliteratum%253Aachs%26aulast%3DGutierrez-Lugo%26aufirst%3DM.%2BT.%26aulast%3DBewley%26aufirst%3DC.%2BA.%26atitle%3DNatural%2520products%252C%2520small%2520molecules%252C%2520and%2520genetics%2520in%2520tuberculosis%2520drug%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2606%26epage%3D2612%26doi%3D10.1021%2Fjm070719i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Ma, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lienhardt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIlleron, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunn, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span> </span><span class="NLM_article-title">Global tuberculosis drug development pipeline: the need and the reality</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">375</span><span class="NLM_x">, </span> <span class="NLM_fpage">2100</span><span class="NLM_x">–</span> <span class="NLM_lpage">2109</span><span class="refDoi"> DOI: 10.1016/S0140-6736(10)60359-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1016%2FS0140-6736%2810%2960359-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2010&pages=2100-2109&author=Z.+Maauthor=C.+Lienhardtauthor=H.+McIlleronauthor=A.+J.+Nunnauthor=X.+Wang&title=Global+tuberculosis+drug+development+pipeline%3A+the+need+and+the+reality&doi=10.1016%2FS0140-6736%2810%2960359-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2960359-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252960359-9%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DLienhardt%26aufirst%3DC.%26aulast%3DMcIlleron%26aufirst%3DH.%26aulast%3DNunn%26aufirst%3DA.%2BJ.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DGlobal%2520tuberculosis%2520drug%2520development%2520pipeline%253A%2520the%2520need%2520and%2520the%2520reality%26jtitle%3DLancet%26date%3D2010%26volume%3D375%26spage%3D2100%26epage%3D2109%26doi%3D10.1016%2FS0140-6736%2810%2960359-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Cohen, J.</span><span> </span><span class="NLM_article-title">Infectious disease. Approval of novel TB drug celebrated–with restraint</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">339</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="refDoi"> DOI: 10.1126/science.339.6116.130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1126%2Fscience.339.6116.130" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2013&pages=130&author=J.+Cohen&title=Infectious+disease.+Approval+of+novel+TB+drug+celebrated%E2%80%93with+restraint&doi=10.1126%2Fscience.339.6116.130"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1126%2Fscience.339.6116.130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.339.6116.130%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DJ.%26atitle%3DInfectious%2520disease.%2520Approval%2520of%2520novel%2520TB%2520drug%2520celebrated%25E2%2580%2593with%2520restraint%26jtitle%3DScience%26date%3D2013%26volume%3D339%26spage%3D130%26doi%3D10.1126%2Fscience.339.6116.130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Ryan, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, J. H.</span><span> </span><span class="NLM_article-title">Delamanid: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1041</span><span class="NLM_x">–</span> <span class="NLM_lpage">1045</span><span class="refDoi"> DOI: 10.1007/s40265-014-0241-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1007%2Fs40265-014-0241-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=24923253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVagsb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1041-1045&author=N.+J.+Ryanauthor=J.+H.+Lo&title=Delamanid%3A+first+global+approval&doi=10.1007%2Fs40265-014-0241-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Delamanid: First Global Approval</span></div><div class="casAuthors">Ryan, Nicola J.; Lo, Jin Han</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1041-1045</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Delamanid, a nitro-dihydro-imidazooxazole deriv., has been developed by Otsuka Pharmaceutical for the treatment of multidrug-resistant tuberculosis (MDR-TB).  Delamanid received its first global approval for the treatment of MDR-TB in the European Union (EU), for use in combination with optimized background therapy.  It is also under review for marketing in Japan for MDR-TB, the first drug application filed in Japan for this indication.  Delamanid has been granted orphan drug status in both the EU and Japan.  This article summarizes the milestones in the development of delamanid leading to this first approval for MDR-TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxJsQP29JADrVg90H21EOLACvtfcHk0ljTApumLPEEgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVagsb%252FJ&md5=1cce5f24a66b3cd98abaa95466023fc0</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0241-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0241-5%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DN.%2BJ.%26aulast%3DLo%26aufirst%3DJ.%2BH.%26atitle%3DDelamanid%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D1041%26epage%3D1045%26doi%3D10.1007%2Fs40265-014-0241-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Andries, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhasselt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillemont, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Göhlmann, H. W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neefs, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Gestel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timmerman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Chaffoy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huitric, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cambau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truffot-Pernot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lounis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarlier, V.</span><span> </span><span class="NLM_article-title">A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">307</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span><span class="refDoi"> DOI: 10.1126/science.1106753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1126%2Fscience.1106753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=15591164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVKkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=223-227&author=K.+Andriesauthor=P.+Verhasseltauthor=J.+Guillemontauthor=H.+W.+H.+G%C3%B6hlmannauthor=J.-M.+Neefsauthor=H.+Winklerauthor=J.+Van+Gestelauthor=P.+Timmermanauthor=M.+Zhuauthor=E.+Leeauthor=P.+Williamsauthor=D.+de+Chaffoyauthor=E.+Huitricauthor=S.+Hoffnerauthor=E.+Cambauauthor=C.+Truffot-Pernotauthor=N.+Lounisauthor=V.+Jarlier&title=A+diarylquinoline+drug+active+on+the+ATP+synthase+of+Mycobacterium+tuberculosis&doi=10.1126%2Fscience.1106753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis</span></div><div class="casAuthors">Andries, Koen; Verhasselt, Peter; Guillemont, Jerome; Goehlmann, Hinrich W. H.; Neefs, Jean-Marc; Winkler, Hans; Van Gestel, Jef; Timmerman, Philip; Zhu, Min; Lee, Ennis; Williams, Peter; de Chaffoy, Didier; Huitric, Emma; Hoffner, Sven; Cambau, Emmanuelle; Truffot-Pernot, Chantal; Lounis, Nacer; Jarlier, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5707</span>),
    <span class="NLM_cas:pages">223-227</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The incidence of tuberculosis has been increasing substantially on a worldwide basis over the past decade, but no tuberculosis-specific drugs have been discovered in 40 years.  We identified a diarylquinoline, R207910, that potently inhibits both drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro (min. inhibitory concn. 0.06 μg/mL).  In mice, R207910 exceeded the bactericidal activities of isoniazid and rifampin by at least 1 log unit.  Substitution of drugs included in the World Health Organization's first-line tuberculosis treatment regimen (rifampin, isoniazid, and pyrazinamide) with R207910 accelerated bactericidal activity, leading to complete culture conversion after 2 mo of treatment in some combinations.  A single dose of R207910 inhibited mycobacterial growth for 1 wk.  Plasma levels assocd. with efficacy in mice were well tolerated in healthy human volunteers.  Mutants selected in vitro suggest that the drug targets the proton pump of ATP (ATP) synthase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9LY7RSAIXUrVg90H21EOLACvtfcHk0ljTApumLPEEgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVKkug%253D%253D&md5=099b643f173bb77e70cf1aa6e9871ffe</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1126%2Fscience.1106753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1106753%26sid%3Dliteratum%253Aachs%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DVerhasselt%26aufirst%3DP.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DG%25C3%25B6hlmann%26aufirst%3DH.%2BW.%2BH.%26aulast%3DNeefs%26aufirst%3DJ.-M.%26aulast%3DWinkler%26aufirst%3DH.%26aulast%3DVan%2BGestel%26aufirst%3DJ.%26aulast%3DTimmerman%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DWilliams%26aufirst%3DP.%26aulast%3Dde%2BChaffoy%26aufirst%3DD.%26aulast%3DHuitric%26aufirst%3DE.%26aulast%3DHoffner%26aufirst%3DS.%26aulast%3DCambau%26aufirst%3DE.%26aulast%3DTruffot-Pernot%26aufirst%3DC.%26aulast%3DLounis%26aufirst%3DN.%26aulast%3DJarlier%26aufirst%3DV.%26atitle%3DA%2520diarylquinoline%2520drug%2520active%2520on%2520the%2520ATP%2520synthase%2520of%2520Mycobacterium%2520tuberculosis%26jtitle%3DScience%26date%3D2005%26volume%3D307%26spage%3D223%26epage%3D227%26doi%3D10.1126%2Fscience.1106753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Matsumoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashizume, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomishige, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsubouchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimokawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komatsu, M.</span><span> </span><span class="NLM_article-title">OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">e466</span><span class="refDoi"> DOI: 10.1371/journal.pmed.0030466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1371%2Fjournal.pmed.0030466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=17132069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A280%3ADC%252BD28npsFKgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=e466&author=M.+Matsumotoauthor=H.+Hashizumeauthor=T.+Tomishigeauthor=M.+Kawasakiauthor=H.+Tsubouchiauthor=H.+Sasakiauthor=Y.+Shimokawaauthor=M.+Komatsu&title=OPC-67683%2C+a+nitro-dihydro-imidazooxazole+derivative+with+promising+action+against+tuberculosis+in+vitro+and+in+mice&doi=10.1371%2Fjournal.pmed.0030466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice</span></div><div class="casAuthors">Matsumoto Makoto; Hashizume Hiroyuki; Tomishige Tatsuo; Kawasaki Masanori; Tsubouchi Hidetsugu; Sasaki Hirofumi; Shimokawa Yoshihiko; Komatsu Makoto</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e466</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Tuberculosis (TB) is still a leading cause of death worldwide.  Almost a third of the world's population is infected with TB bacilli, and each year approximately 8 million people develop active TB and 2 million die as a result.  Today's TB treatment, which dates back to the 1970s, is long and burdensome, requiring at least 6 mo of multidrug chemotherapy.  The situation is further compounded by the emergence of multidrug-resistant TB (MDR-TB) and by the infection's lethal synergy with HIV/AIDS.  Global health and philanthropic organizations are now pleading for new drug interventions that can address these unmet needs in TB treatment.  METHODS AND FINDINGS:  Here we report OPC-67683, a nitro-dihydro-imidazooxazole derivative that was screened to help combat the unmet needs in TB treatment.  The compound is a mycolic acid biosynthesis inhibitor found to be free of mutagenicity and to possess highly potent activity against TB, including MDR-TB, as shown by its exceptionally low minimum inhibitory concentration (MIC) range of 0.006-0.024 microg/ml in vitro and highly effective therapeutic activity at low doses in vivo.  Additionally, the results of the post-antibiotic effect of OPC-67683 on intracellular Mycobacterium tuberculosis showed the agent to be highly and dose-dependently active also against intracellular M. tuberculosis H37Rv after a 4-h pulsed exposure, and this activity at a concentration of 0.1 microg/ml was similar to that of the first-line drug rifampicin (RFP) at a concentration of 3 microg/ml.  The combination of OPC-67683 with RFP and pyrazinamide (PZA) exhibited a remarkably quicker eradication (by at least 2 mo) of viable TB bacilli in the lung in comparison with the standard regimen consisting of RFP, isoniazid (INH), ethambutol (EB), and PZA.  Furthermore, OPC-67683 was not affected by nor did it affect the activity of liver microsome enzymes, suggesting the possibility for OPC-67683 to be used in combination with drugs, including anti-retrovirals, that induce or are metabolized by cytochrome P450 enzymes.  CONCLUSIONS:  We concluded that based on these properties OPC-67683 has the potential to be used as a TB drug to help combat the unmet needs in TB treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSF0z_BNLNYeRS7coPn-RtfW6udTcc2eYbnxOXg8kSP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28npsFKgug%253D%253D&md5=8a80560cc653b1c76ff4d47430317d18</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0030466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0030466%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumoto%26aufirst%3DM.%26aulast%3DHashizume%26aufirst%3DH.%26aulast%3DTomishige%26aufirst%3DT.%26aulast%3DKawasaki%26aufirst%3DM.%26aulast%3DTsubouchi%26aufirst%3DH.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DShimokawa%26aufirst%3DY.%26aulast%3DKomatsu%26aufirst%3DM.%26atitle%3DOPC-67683%252C%2520a%2520nitro-dihydro-imidazooxazole%2520derivative%2520with%2520promising%2520action%2520against%2520tuberculosis%2520in%2520vitro%2520and%2520in%2520mice%26jtitle%3DPLoS%2520Med.%26date%3D2006%26volume%3D3%26spage%3De466%26doi%3D10.1371%2Fjournal.pmed.0030466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Fox, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzies, D.</span><span> </span><span class="NLM_article-title">A review of the evidence for using bedaquiline (TMC207) to treat multi-drug resistant tuberculosis</span> <span class="citation_source-journal">Infect. Dis. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span><span class="refDoi"> DOI: 10.1007/s40121-013-0009-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1007%2Fs40121-013-0009-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=25134476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FjtV2rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=123-144&author=G.+J.+Foxauthor=D.+Menzies&title=A+review+of+the+evidence+for+using+bedaquiline+%28TMC207%29+to+treat+multi-drug+resistant+tuberculosis&doi=10.1007%2Fs40121-013-0009-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis</span></div><div class="casAuthors">Fox Gregory J; Menzies Dick</div><div class="citationInfo"><span class="NLM_cas:title">Infectious diseases and therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-44</span>
        ISSN:<span class="NLM_cas:issn">2193-8229</span>.
    </div><div class="casAbstract">Existing therapies for multi-drug resistant tuberculosis (MDR-TB) have substantial limitations, in terms of their effectiveness, side-effect profile, and complexity of administration.  Bedaquiline is a novel diarylquinoline antibiotic that has recently been investigated as an adjunct to existing therapies for MDR-TB.  Currently, limited clinical data are available to evaluate the drug's safety and effectiveness.  In two small randomized-controlled clinical studies, bedaquiline given for 8 or 24 weeks has been shown to improve surrogate microbiological markers of treatment response, but trials have not yet evaluated its impact on clinical failure and relapse.  Safety concerns include an increased mortality in the bedaquiline arm of one study, an increased incidence of QT segment prolongation on electrocardiogram, and hepatotoxicity.  Until further research data are available, the use of bedaquiline should be confined to settings where carefully selected patients can be closely monitored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTlWFOQsVg1oaNc3HjJRoFAfW6udTcc2eYbnxOXg8kSP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FjtV2rtg%253D%253D&md5=0cd964c385e6bc327878d5c5203b3f06</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs40121-013-0009-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40121-013-0009-3%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DG.%2BJ.%26aulast%3DMenzies%26aufirst%3DD.%26atitle%3DA%2520review%2520of%2520the%2520evidence%2520for%2520using%2520bedaquiline%2520%2528TMC207%2529%2520to%2520treat%2520multi-drug%2520resistant%2520tuberculosis%26jtitle%3DInfect.%2520Dis.%2520Ther.%26date%3D2013%26volume%3D2%26spage%3D123%26epage%3D144%26doi%3D10.1007%2Fs40121-013-0009-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Field, S. K.</span><span> </span><span class="NLM_article-title">Safety and efficacy of delamanid in the treatment of multidrug-resistant tuberculosis (MDR-TB)</span> <span class="citation_source-journal">Clin. Med. Insights: Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">–</span> <span class="NLM_lpage">149</span><span class="refDoi"> DOI: 10.4137/CMT.S11675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.4137%2FCMT.S11675" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWgsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=137-149&author=S.+K.+Field&title=Safety+and+efficacy+of+delamanid+in+the+treatment+of+multidrug-resistant+tuberculosis+%28MDR-TB%29&doi=10.4137%2FCMT.S11675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of delamanid in the treatment of multidrug-resistant tuberculosis (MDR-TB)</span></div><div class="casAuthors">Field, Stephen K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Medicine Insights: Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">137-149</span>CODEN:
                <span class="NLM_cas:coden">CMITB2</span>;
        ISSN:<span class="NLM_cas:issn">1179-559X</span>.
    
            (<span class="NLM_cas:orgname">Libertas Academica</span>)
        </div><div class="casAbstract">A review.  Globally, the incidence of tuberculosis (TB) is declining but the proportion of drug-resistant cases has increased.  Strains resistant to both isoniazid and rifampin, and possibly other antibiotics, called multidrug-resistant (MDR), are particularly difficult to treat.  Poorer outcomes, including increased mortality, occur in patients infected with MDR strains and the costs assocd. with treatment of MDR-TB are substantially greater.  The recent recognition of MDR-TB and strains with more complex resistance patterns has stimulated the development of new TB medications including fluoroquinolones, oxazolidinones, diarylquinolines, nitroimidazopyrans, ethylenediamines, and benzothiazinones.  Bedaquiline, a diarylquinoline, was approved for the treatment of MDR-TB in 2012.  Addn. of delamanid to WHO-approved treatment improved outcomes for MDR-TB and for extensively drug-resistant TB in a large randomized, controlled phase II clin. trial and is undergoing evaluation in a large international phase III study.  This review will focus on MDR-TB and the role of delamanid in its treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptmzp9Cx13ArVg90H21EOLACvtfcHk0liMlAOoP8-Vjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWgsbfJ&md5=1187f7711003c1af26605d015f4676b3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.4137%2FCMT.S11675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4137%252FCMT.S11675%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DS.%2BK.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520delamanid%2520in%2520the%2520treatment%2520of%2520multidrug-resistant%2520tuberculosis%2520%2528MDR-TB%2529%26jtitle%3DClin.%2520Med.%2520Insights%253A%2520Ther.%26date%3D2013%26volume%3D5%26spage%3D137%26epage%3D149%26doi%3D10.4137%2FCMT.S11675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Hartkoorn, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uplekar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, S. T.</span><span> </span><span class="NLM_article-title">Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2979</span><span class="NLM_x">–</span> <span class="NLM_lpage">2981</span><span class="refDoi"> DOI: 10.1128/AAC.00037-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1128%2FAAC.00037-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=24590481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovV2qsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=2979-2981&author=R.+C.+Hartkoornauthor=S.+Uplekarauthor=S.+T.+Cole&title=Cross-resistance+between+clofazimine+and+bedaquiline+through+upregulation+of+MmpL5+in+Mycobacterium+tuberculosis&doi=10.1128%2FAAC.00037-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis</span></div><div class="casAuthors">Hartkoorn, Ruben C.; Uplekar, Swapna; Cole, Stewart T.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2979-2981, 4 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The antileprosy drug clofazimine is also of interest for the treatment of multidrug-resistant tuberculosis.  To understand possible resistance mechanisms, clofazimine-resistant Mycobacterium tuberculosis mutants were isolated in vitro, and, unexpectedly, found to be cross-resistant to bedaquiline.  Mutations in the transcriptional regulator Rv0678, with concomitant upregulation of the multisubstrate efflux pump, MmpL5, accounted for this cross-resistance.  Mutation in Rv0678 should therefore be considered a confounding factor for the treatment of tuberculosis with clofazimine or bedaquiline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIT-1_Uz5-a7Vg90H21EOLACvtfcHk0liMlAOoP8-Vjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovV2qsLk%253D&md5=ca70e96eceab1d9a8717082ab46d1745</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FAAC.00037-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00037-14%26sid%3Dliteratum%253Aachs%26aulast%3DHartkoorn%26aufirst%3DR.%2BC.%26aulast%3DUplekar%26aufirst%3DS.%26aulast%3DCole%26aufirst%3DS.%2BT.%26atitle%3DCross-resistance%2520between%2520clofazimine%2520and%2520bedaquiline%2520through%2520upregulation%2520of%2520MmpL5%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D2979%26epage%3D2981%26doi%3D10.1128%2FAAC.00037-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Stinson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurepina, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shashkina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreiswirth, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geiter, L.</span><span> </span><span class="NLM_article-title">MIC of delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">3316</span><span class="NLM_x">–</span> <span class="NLM_lpage">3322</span><span class="refDoi"> DOI: 10.1128/AAC.03014-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1128%2FAAC.03014-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=26976868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1entrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=3316-3322&author=K.+Stinsonauthor=N.+Kurepinaauthor=A.+Venterauthor=M.+Fujiwaraauthor=M.+Kawasakiauthor=J.+Timmauthor=E.+Shashkinaauthor=B.+N.+Kreiswirthauthor=Y.+Liuauthor=M.+Matsumotoauthor=L.+Geiter&title=MIC+of+delamanid+%28OPC-67683%29+against+Mycobacterium+tuberculosis+clinical+isolates+and+a+proposed+critical+concentration&doi=10.1128%2FAAC.03014-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">MIC of delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration</span></div><div class="casAuthors">Stinson, Kelly; Kurepina, Natalia; Venter, Amour; Fujiwara, Mamoru; Kawasaki, Masanori; Timm, Juliano; Shashkina, Elena; Kreiswirth, Barry N.; Liu, Yongge; Matsumoto, Makoto; Geiter, Lawrence</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3316-3322</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The increasing global burden of multidrug-resistant tuberculosis (MDR-TB) requires reliable drug susceptibility testing that accurately characterizes susceptibility and resistance of pathogenic bacteria to effectively treat patients with this deadly disease.  Delamanid is an anti-TB agent first approved in the European Union in 2014 for the treatment of pulmonary MDR-TB in adults.  Using the agar proportion method, delamanid MIC was detd. for 460 isolates: 316 from patients enrolled in a phase 2 global clin. trial, 76 from two phase 2 early bactericidal activity trials conducted in South Africa, and 68 isolates obtained outside clin. trials (45 from Japanese patients and 23 from South African patients).  With the exception of two isolates, MICs ranged from 0.001 to 0.05 μg/mL, resulting in an MIC50 of 0.004 μg/mL and an MIC90 of 0.012 μg/mL.  Various degrees of resistance to other anti-TB drugs did not affect the distribution of MICs, nor did origin of isolates from regions/countries other than South Africa.  A crit. concn./breakpoint of 0.2 μg/mL can be used to define susceptible and resistant isolates based on the distribution of MICs and available pharmacokinetic data.  Thus, clin. isolates from delamanid-naive patients with tuberculosis have a very low MIC for delamanid and baseline resistance is rare, demonstrating the potential potency of delamanid and supporting its use in an optimized background treatment regimen for MDR-TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot2O44cdNSm7Vg90H21EOLACvtfcHk0lhjzi-6kUyIqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1entrrL&md5=9a69303ff8d63f8aa0e73c8dd5f068cb</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FAAC.03014-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03014-15%26sid%3Dliteratum%253Aachs%26aulast%3DStinson%26aufirst%3DK.%26aulast%3DKurepina%26aufirst%3DN.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DFujiwara%26aufirst%3DM.%26aulast%3DKawasaki%26aufirst%3DM.%26aulast%3DTimm%26aufirst%3DJ.%26aulast%3DShashkina%26aufirst%3DE.%26aulast%3DKreiswirth%26aufirst%3DB.%2BN.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMatsumoto%26aufirst%3DM.%26aulast%3DGeiter%26aufirst%3DL.%26atitle%3DMIC%2520of%2520delamanid%2520%2528OPC-67683%2529%2520against%2520Mycobacterium%2520tuberculosis%2520clinical%2520isolates%2520and%2520a%2520proposed%2520critical%2520concentration%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D3316%26epage%3D3322%26doi%3D10.1128%2FAAC.03014-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Martínez-Hoyos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Herran, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulten, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Encinas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Álvarez-Gómez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrer-Bazaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Pérez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortega, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angulo-Barturen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rullas-Trincado, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanco Ruano, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castañeda, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernández Menéndez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">González Del Valle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barros, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Signorino-Gelo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKinney, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Bustos, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavandera, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sacchettini, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martín-Casabona, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro-Pichel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendoza-Losana, A.</span><span> </span><span class="NLM_article-title">Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor</span> <span class="citation_source-journal">EBioMedicine.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span><span class="refDoi"> DOI: 10.1016/j.ebiom.2016.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1016%2Fj.ebiom.2016.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=27428438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A280%3ADC%252BC2s3hvVWksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=291-301&author=M.+Mart%C3%ADnez-Hoyosauthor=E.+Perez-Herranauthor=G.+Gultenauthor=L.+Encinasauthor=D.+%C3%81lvarez-G%C3%B3mezauthor=E.+Alvarezauthor=S.+Ferrer-Bazagaauthor=A.+Garc%C3%ADa-P%C3%A9rezauthor=F.+Ortegaauthor=I.+Angulo-Barturenauthor=J.+Rullas-Trincadoauthor=D.+Blanco+Ruanoauthor=P.+Torresauthor=P.+Casta%C3%B1edaauthor=S.+Hussauthor=R.+Fern%C3%A1ndez+Men%C3%A9ndezauthor=S.+Gonz%C3%A1lez+Del+Valleauthor=L.+Ballellauthor=D.+Barrosauthor=S.+Modhaauthor=N.+Dharauthor=F.+Signorino-Geloauthor=J.+D.+McKinneyauthor=J.+F.+Garc%C3%ADa-Bustosauthor=J.+L.+Lavanderaauthor=J.+C.+Sacchettiniauthor=M.+S.+Jimenezauthor=N.+Mart%C3%ADn-Casabonaauthor=J.+Castro-Pichelauthor=A.+Mendoza-Losana&title=Antitubercular+drugs+for+an+old+target%3A+GSK693+as+a+promising+InhA+direct+inhibitor&doi=10.1016%2Fj.ebiom.2016.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor</span></div><div class="casAuthors">Martinez-Hoyos Maria; Perez-Herran Esther; Encinas Lourdes; Alvarez-Gomez Daniel; Alvarez Emilio; Ferrer-Bazaga Santiago; Garcia-Perez Adolfo; Ortega Fatima; Angulo-Barturen Inigo; Rullas-Trincado Joaquin; Blanco Ruano Delia; Torres Pedro; Castaneda Pablo; Huss Sophie; Fernandez Menendez Raquel; Gonzalez Del Valle Silvia; Ballell Lluis; Barros David; Garcia-Bustos Jose Francisco; Lavandera Jose Luis; Castro-Pichel Julia; Gulten Gulcin; Sacchettini James C; Modha Sundip; Signorino-Gelo Francois; McKinney John D; Dhar Neeraj; Jimenez M Soledad; Martin-Casabona Nuria; Mendoza-Losana Alfonso</div><div class="citationInfo"><span class="NLM_cas:title">EBioMedicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">291-301</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Despite being one of the first antitubercular agents identified, isoniazid (INH) is still the most prescribed drug for prophylaxis and tuberculosis (TB) treatment and, together with rifampicin, the pillars of current chemotherapy.  A high percentage of isoniazid resistance is linked to mutations in the pro-drug activating enzyme KatG, so the discovery of direct inhibitors (DI) of the enoyl-ACP reductase (InhA) has been pursued by many groups leading to the identification of different enzyme inhibitors, active against Mycobacterium tuberculosis (Mtb), but with poor physicochemical properties to be considered as preclinical candidates.  Here, we present a series of InhA DI active against multidrug (MDR) and extensively (XDR) drug-resistant clinical isolates as well as in TB murine models when orally dosed that can be a promising foundation for a future treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBKqsJCl5WvbZpSb_XWfMrfW6udTcc2eaM8CzM77CBE7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3hvVWksg%253D%253D&md5=21f1dbf20ad29185ba9c322829755ebb</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ebiom.2016.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ebiom.2016.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25ADnez-Hoyos%26aufirst%3DM.%26aulast%3DPerez-Herran%26aufirst%3DE.%26aulast%3DGulten%26aufirst%3DG.%26aulast%3DEncinas%26aufirst%3DL.%26aulast%3D%25C3%2581lvarez-G%25C3%25B3mez%26aufirst%3DD.%26aulast%3DAlvarez%26aufirst%3DE.%26aulast%3DFerrer-Bazaga%26aufirst%3DS.%26aulast%3DGarc%25C3%25ADa-P%25C3%25A9rez%26aufirst%3DA.%26aulast%3DOrtega%26aufirst%3DF.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DRullas-Trincado%26aufirst%3DJ.%26aulast%3DBlanco%2BRuano%26aufirst%3DD.%26aulast%3DTorres%26aufirst%3DP.%26aulast%3DCasta%25C3%25B1eda%26aufirst%3DP.%26aulast%3DHuss%26aufirst%3DS.%26aulast%3DFern%25C3%25A1ndez%2BMen%25C3%25A9ndez%26aufirst%3DR.%26aulast%3DGonz%25C3%25A1lez%2BDel%2BValle%26aufirst%3DS.%26aulast%3DBallell%26aufirst%3DL.%26aulast%3DBarros%26aufirst%3DD.%26aulast%3DModha%26aufirst%3DS.%26aulast%3DDhar%26aufirst%3DN.%26aulast%3DSignorino-Gelo%26aufirst%3DF.%26aulast%3DMcKinney%26aufirst%3DJ.%2BD.%26aulast%3DGarc%25C3%25ADa-Bustos%26aufirst%3DJ.%2BF.%26aulast%3DLavandera%26aufirst%3DJ.%2BL.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26aulast%3DJimenez%26aufirst%3DM.%2BS.%26aulast%3DMart%25C3%25ADn-Casabona%26aufirst%3DN.%26aulast%3DCastro-Pichel%26aufirst%3DJ.%26aulast%3DMendoza-Losana%26aufirst%3DA.%26atitle%3DAntitubercular%2520drugs%2520for%2520an%2520old%2520target%253A%2520GSK693%2520as%2520a%2520promising%2520InhA%2520direct%2520inhibitor%26jtitle%3DEBioMedicine.%26date%3D2016%26volume%3D8%26spage%3D291%26epage%3D301%26doi%3D10.1016%2Fj.ebiom.2016.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Šink, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosič, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Živec, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Férnandez-Menéndez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turk, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pajk, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Álvarez-Gómez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Román, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales-Cortez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rullas-Triconado, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angulo-Barturen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barros, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballell-Pages, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Encinas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobec, S.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of new thiadiazole-based direct inhibitors of enoyl acyl carrier protein reductase (InhA) for the treatment of tuberculosis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">613</span><span class="NLM_x">–</span> <span class="NLM_lpage">624</span><span class="refDoi"> DOI: 10.1021/jm501029r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501029r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOgsL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=613-624&author=R.+%C5%A0inkauthor=I.+Sosi%C4%8Dauthor=M.+%C5%BDivecauthor=R.+F%C3%A9rnandez-Men%C3%A9ndezauthor=S.+Turkauthor=S.+Pajkauthor=D.+%C3%81lvarez-G%C3%B3mezauthor=E.+M.+Lopez-Rom%C3%A1nauthor=C.+Gonzales-Cortezauthor=J.+Rullas-Triconadoauthor=I.+Angulo-Barturenauthor=D.+Barrosauthor=L.+Ballell-Pagesauthor=R.+J.+Youngauthor=L.+Encinasauthor=S.+Gobec&title=Design%2C+synthesis%2C+and+evaluation+of+new+thiadiazole-based+direct+inhibitors+of+enoyl+acyl+carrier+protein+reductase+%28InhA%29+for+the+treatment+of+tuberculosis&doi=10.1021%2Fjm501029r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of New Thiadiazole-Based Direct Inhibitors of Enoyl Acyl Carrier Protein Reductase (InhA) for the Treatment of Tuberculosis</span></div><div class="casAuthors">Sink, Roman; Sosic, Izidor; Zivec, Matej; Fernandez-Menendez, Raquel; Turk, Samo; Pajk, Stane; Alvarez-Gomez, Daniel; Lopez-Roman, Eva Maria; Gonzales-Cortez, Carolina; Rullas-Triconado, Joaquin; Angulo-Barturen, Inigo; Barros, David; Ballell-Pages, Lluis; Young, Robert J.; Encinas, Lourdes; Gobec, Stanislav</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">613-624</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mycobacterial enoyl acyl carrier protein reductase (InhA) is a clin. validated target for the treatment of tuberculosis infections, a disease that still causes the death of at least a million people annually.  A known class of potent, direct, and competitive InhA inhibitors based on a tetracyclic thiadiazole structure has been shown to have in vivo activity in murine models of tuberculosis infection.  On the basis of this template, we have here explored the medicinal chem. of truncated analogs that have only three arom. rings.  In particular, compds. I [Aryl = 6-methyl-2-pyridyl, 6-bromo-2-pyridyl (8d), 6-(trifluoromethyl)-2-pyridyl, 5-bromo-2-pyridyl and 5-bromo-6-(trifluoromethyl)-2-pyridyl] show interesting features, including low nanomolar InhA IC50, submicromolar antimycobacterial potency, and improved physicochem. profiles in comparison with the tetracyclic analogs.  From this series, 8d is identified as having the best balance of potency and properties, whereby the resolved 8d S-enantiomer shows encouraging in vivo efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMhr0INTijhLVg90H21EOLACvtfcHk0ljj-xYWP98_Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOgsL3O&md5=01311420c022fc076432829c1b1896c8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm501029r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501029r%26sid%3Dliteratum%253Aachs%26aulast%3D%25C5%25A0ink%26aufirst%3DR.%26aulast%3DSosi%25C4%258D%26aufirst%3DI.%26aulast%3D%25C5%25BDivec%26aufirst%3DM.%26aulast%3DF%25C3%25A9rnandez-Men%25C3%25A9ndez%26aufirst%3DR.%26aulast%3DTurk%26aufirst%3DS.%26aulast%3DPajk%26aufirst%3DS.%26aulast%3D%25C3%2581lvarez-G%25C3%25B3mez%26aufirst%3DD.%26aulast%3DLopez-Rom%25C3%25A1n%26aufirst%3DE.%2BM.%26aulast%3DGonzales-Cortez%26aufirst%3DC.%26aulast%3DRullas-Triconado%26aufirst%3DJ.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DBarros%26aufirst%3DD.%26aulast%3DBallell-Pages%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DEncinas%26aufirst%3DL.%26aulast%3DGobec%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520new%2520thiadiazole-based%2520direct%2520inhibitors%2520of%2520enoyl%2520acyl%2520carrier%2520protein%2520reductase%2520%2528InhA%2529%2520for%2520the%2520treatment%2520of%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D613%26epage%3D624%26doi%3D10.1021%2Fjm501029r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Stec, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onajole, O. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lun, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merenbloom, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vistoli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishai, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Indole-2-carboxamide-based MmpL3 Inhibitors show exceptional antitubercular activity in an animal model of tuberculosis infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">6232</span><span class="NLM_x">–</span> <span class="NLM_lpage">6247</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00415</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00415" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVCltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6232-6247&author=J.+Stecauthor=O.+K.+Onajoleauthor=S.+Lunauthor=H.+Guoauthor=B.+Merenbloomauthor=G.+Vistoliauthor=W.+R.+Bishaiauthor=A.+P.+Kozikowski&title=Indole-2-carboxamide-based+MmpL3+Inhibitors+show+exceptional+antitubercular+activity+in+an+animal+model+of+tuberculosis+infection&doi=10.1021%2Facs.jmedchem.6b00415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection</span></div><div class="casAuthors">Stec, Jozef; Onajole, Oluseye K.; Lun, Shichun; Guo, Haidan; Merenbloom, Benjamin; Vistoli, Giulio; Bishai, William R.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6232-6247</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Our team had previously identified certain indolecarboxamides that represented a new chem. scaffold that showed promising anti-TB activity at both an in vitro and in vivo level.  Based on mutational anal. using bacteria found resistant to one of these indolecarboxamides, we identified the trehalose monomycolate transporter MmpL3 as the likely target of these compds.  In the present work, we now further elaborate on the SAR of these compds., which has led in turn to the identification of a new analog, 4,6-difluoro-N-((1R,2R,3R,5S)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-yl)-1H-indole-2-carboxamide (26), that shows excellent activity against drug-sensitive (MIC = 0.012 μM; SI ≥ 16000), multidrug-resistant (MDR), and extensively drug-resistant (XDR) Mycobacterium tuberculosis strains, has superior ADMET properties, and shows excellent activity in the TB aerosol lung infection model.  Compd. 26 is also shown to work in synergy with rifampin.  Because of these properties, we believe that indolecarboxamide 26 is a possible candidate for advancement to human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg0h9TR-VL5rVg90H21EOLACvtfcHk0ljj-xYWP98_Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVCltb8%253D&md5=f9e3d545a65f85deb3f97054dca77c1f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00415%26sid%3Dliteratum%253Aachs%26aulast%3DStec%26aufirst%3DJ.%26aulast%3DOnajole%26aufirst%3DO.%2BK.%26aulast%3DLun%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DMerenbloom%26aufirst%3DB.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DBishai%26aufirst%3DW.%2BR.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DIndole-2-carboxamide-based%2520MmpL3%2520Inhibitors%2520show%2520exceptional%2520antitubercular%2520activity%2520in%2520an%2520animal%2520model%2520of%2520tuberculosis%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6232%26epage%3D6247%26doi%3D10.1021%2Facs.jmedchem.6b00415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Couturier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lair, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellet, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cogo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menegotto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheiper, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagrange, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacqué, E.</span><span> </span><span class="NLM_article-title">Identification and optimization of a new series of anti-tubercular quinazolinones</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">5290</span><span class="NLM_x">–</span> <span class="NLM_lpage">5299</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.09.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1016%2Fj.bmcl.2016.09.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=27671498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFyntbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5290-5299&author=C.+Couturierauthor=C.+Lairauthor=A.+Pelletauthor=A.+Uptonauthor=T.+Kanekoauthor=C.+Perronauthor=E.+Cogoauthor=J.+Menegottoauthor=A.+Bauerauthor=B.+Scheiperauthor=S.+Lagrangeauthor=E.+Bacqu%C3%A9&title=Identification+and+optimization+of+a+new+series+of+anti-tubercular+quinazolinones&doi=10.1016%2Fj.bmcl.2016.09.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and optimization of a new series of anti-tubercular quinazolinones</span></div><div class="casAuthors">Couturier, Cedric; Lair, Christine; Pellet, Alain; Upton, Anna; Kaneko, Takushi; Perron, Corinne; Cogo, Eric; Menegotto, Jerome; Bauer, Armin; Scheiper, Bodo; Lagrange, Sophie; Bacque, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5290-5299</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A high throughput phenotypic screening against Mycobacterium smegmatis led us to the discovery of a new class of bacteriostatic, highly hydrophobic antitubercular quinazolinones that potently inhibited the in vitro growth of either extracellular or intramacrophagic M. tuberculosis (Mtb), via modulation of an unidentified but yet novel target.  Optimization of the initial hit compd. culminated in the identification of potent but poorly sol. Mtb growth inhibitors, three of which were progressed to in vivo efficacy studies.  Despite nanomolar in vitro potency and attractive PK properties, none of these compds. was convincingly potent in the in vivo mouse tuberculosis models.  This lack of efficacy may be linked to the poor drug-likeness of the test mols. and/or to the properties of the target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZQPkqXJ5moLVg90H21EOLACvtfcHk0ljj-xYWP98_Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFyntbzK&md5=95392a67ae9d357cbf44431057268dde</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.09.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.09.043%26sid%3Dliteratum%253Aachs%26aulast%3DCouturier%26aufirst%3DC.%26aulast%3DLair%26aufirst%3DC.%26aulast%3DPellet%26aufirst%3DA.%26aulast%3DUpton%26aufirst%3DA.%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DPerron%26aufirst%3DC.%26aulast%3DCogo%26aufirst%3DE.%26aulast%3DMenegotto%26aufirst%3DJ.%26aulast%3DBauer%26aufirst%3DA.%26aulast%3DScheiper%26aufirst%3DB.%26aulast%3DLagrange%26aufirst%3DS.%26aulast%3DBacqu%25C3%25A9%26aufirst%3DE.%26atitle%3DIdentification%2520and%2520optimization%2520of%2520a%2520new%2520series%2520of%2520anti-tubercular%2520quinazolinones%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D5290%26epage%3D5299%26doi%3D10.1016%2Fj.bmcl.2016.09.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Pethe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiricek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeon, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cechetto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christophe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kempf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenaerts, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pham, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yim, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chua, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanjundappa, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wintjens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonso, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nehrbass, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">No, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span> </span><span class="NLM_article-title">Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1157</span><span class="NLM_x">–</span> <span class="NLM_lpage">1160</span><span class="refDoi"> DOI: 10.1038/nm.3262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1038%2Fnm.3262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=23913123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1WhtrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1157-1160&author=K.+Petheauthor=P.+Bifaniauthor=J.+Jangauthor=S.+Kangauthor=S.+Parkauthor=S.+Ahnauthor=J.+Jiricekauthor=J.+Jungauthor=H.+K.+Jeonauthor=J.+Cechettoauthor=T.+Christopheauthor=H.+Leeauthor=M.+Kempfauthor=M.+Jacksonauthor=A.+J.+Lenaertsauthor=H.+Phamauthor=V.+Jonesauthor=M.+J.+Seoauthor=Y.+M.+Kimauthor=M.+Seoauthor=J.+J.+Seoauthor=D.+Parkauthor=Y.+Koauthor=I.+Choiauthor=R.+Kimauthor=S.+Y.+Kimauthor=S.+Limauthor=S.+A.+Yimauthor=J.+Namauthor=H.+Kangauthor=H.+Kwonauthor=C.+T.+Ohauthor=Y.+Choauthor=Y.+Jangauthor=J.+Kimauthor=A.+Chuaauthor=B.+H.+Tanauthor=M.+B.+Nanjundappaauthor=S.+P.+Raoauthor=W.+S.+Barnesauthor=R.+Wintjensauthor=J.+R.+Walkerauthor=S.+Alonsoauthor=S.+Leeauthor=J.+Kimauthor=S.+Ohauthor=T.+Ohauthor=U.+Nehrbassauthor=S.+J.+Hanauthor=Z.+Noauthor=J.+Leeauthor=P.+Brodinauthor=S.+N.+Choauthor=K.+Namauthor=J.+Kim&title=Discovery+of+Q203%2C+a+potent+clinical+candidate+for+the+treatment+of+tuberculosis&doi=10.1038%2Fnm.3262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis</span></div><div class="casAuthors">Pethe, Kevin; Bifani, Pablo; Jang, Jichan; Kang, Sunhee; Park, Seijin; Ahn, Sujin; Jiricek, Jan; Jung, Juyoung; Jeon, Hee Kyoung; Cechetto, Jonathan; Christophe, Thierry; Lee, Honggun; Kempf, Marie; Jackson, Mary; Lenaerts, Anne J.; Pham, Ha; Jones, Victoria; Seo, Min Jung; Kim, Young Mi; Seo, Mooyoung; Seo, Jeong Jea; Park, Dongsik; Ko, Yoonae; Choi, Inhee; Kim, Ryangyeo; Kim, Se Yeon; Lim, Seung Bin; Yim, Seung-Ae; Nam, Jiyoun; Kang, Hwankyu; Kwon, Haejin; Oh, Chun-Taek; Cho, Yoojin; Jang, Yunhee; Kim, Junghwan; Chua, Adeline; Tan, Bee Huat; Nanjundappa, Mahesh B.; Rao, Srinivasa P. S.; Barnes, Whitney S.; Wintjens, Rene; Walker, John R.; Alonso, Sylvie; Lee, Saeyeon; Kim, Jungjun; Oh, Soohyun; Oh, Taegwon; Nehrbass, Ulf; Han, Sung-Jun; No, Zaesung; Lee, Jinhwa; Brodin, Priscille; Cho, Sang-Nae; Nam, Kiyean; Kim, Jaeseung</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1157-1160</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">New therapeutic strategies are needed to combat the tuberculosis pandemic and the spread of multidrug-resistant (MDR) and extensively drug-resistant (XDR) forms of the disease, which remain a serious public health challenge worldwide.  The most urgent clin. need is to discover potent agents capable of reducing the duration of MDR and XDR tuberculosis therapy with a success rate comparable to that of current therapies for drug-susceptible tuberculosis.  The last decade has seen the discovery of new agent classes for the management of tuberculosis, several of which are currently in clin. trials.  However, given the high attrition rate of drug candidates during clin. development and the emergence of drug resistance, the discovery of addnl. clin. candidates is clearly needed.  Here, we report on a promising class of imidazopyridine amide (IPA) compds. that block Mycobacterium tuberculosis growth by targeting the respiratory cytochrome bc1 complex.  The optimized IPA compd. Q203 inhibited the growth of MDR and XDR M. tuberculosis clin. isolates in culture broth medium in the low nanomolar range and was efficacious in a mouse model of tuberculosis at a dose less than 1 mg per kg body wt., which highlights the potency of this compd.  In addn., Q203 displays pharmacokinetic and safety profiles compatible with once-daily dosing.  Together, our data indicate that Q203 is a promising new clin. candidate for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqNkAj8BKYybVg90H21EOLACvtfcHk0lhhZl5AiMs-tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1WhtrzK&md5=b865009db53f5b4bc15948ded64ef064</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnm.3262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3262%26sid%3Dliteratum%253Aachs%26aulast%3DPethe%26aufirst%3DK.%26aulast%3DBifani%26aufirst%3DP.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DJiricek%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DJ.%26aulast%3DJeon%26aufirst%3DH.%2BK.%26aulast%3DCechetto%26aufirst%3DJ.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DKempf%26aufirst%3DM.%26aulast%3DJackson%26aufirst%3DM.%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DPham%26aufirst%3DH.%26aulast%3DJones%26aufirst%3DV.%26aulast%3DSeo%26aufirst%3DM.%2BJ.%26aulast%3DKim%26aufirst%3DY.%2BM.%26aulast%3DSeo%26aufirst%3DM.%26aulast%3DSeo%26aufirst%3DJ.%2BJ.%26aulast%3DPark%26aufirst%3DD.%26aulast%3DKo%26aufirst%3DY.%26aulast%3DChoi%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DLim%26aufirst%3DS.%26aulast%3DYim%26aufirst%3DS.%2BA.%26aulast%3DNam%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DH.%26aulast%3DKwon%26aufirst%3DH.%26aulast%3DOh%26aufirst%3DC.%2BT.%26aulast%3DCho%26aufirst%3DY.%26aulast%3DJang%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DChua%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DB.%2BH.%26aulast%3DNanjundappa%26aufirst%3DM.%2BB.%26aulast%3DRao%26aufirst%3DS.%2BP.%26aulast%3DBarnes%26aufirst%3DW.%2BS.%26aulast%3DWintjens%26aufirst%3DR.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DAlonso%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DOh%26aufirst%3DS.%26aulast%3DOh%26aufirst%3DT.%26aulast%3DNehrbass%26aufirst%3DU.%26aulast%3DHan%26aufirst%3DS.%2BJ.%26aulast%3DNo%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DBrodin%26aufirst%3DP.%26aulast%3DCho%26aufirst%3DS.%2BN.%26aulast%3DNam%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Q203%252C%2520a%2520potent%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520tuberculosis%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1157%26epage%3D1160%26doi%3D10.1038%2Fnm.3262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Kang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, R. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pethe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">No, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span> </span><span class="NLM_article-title">Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5293</span><span class="NLM_x">–</span> <span class="NLM_lpage">5305</span><span class="refDoi"> DOI: 10.1021/jm5003606</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5003606" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1Wqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5293-5305&author=S.+Kangauthor=R.+Y.+Kimauthor=M.+J.+Seoauthor=S.+Leeauthor=Y.+M.+Kimauthor=M.+Seoauthor=J.+J.+Seoauthor=Y.+Koauthor=I.+Choiauthor=J.+Jangauthor=J.+Namauthor=S.+Parkauthor=H.+Kangauthor=H.+J.+Kimauthor=J.+Kimauthor=S.+Ahnauthor=K.+Petheauthor=K.+Namauthor=Z.+Noauthor=J.+Kim&title=Lead+optimization+of+a+novel+series+of+imidazo%5B1%2C2-a%5Dpyridine+amides+leading+to+a+clinical+candidate+%28Q203%29+as+a+multi-+and+extensively-drug-resistant+anti-tuberculosis+agent&doi=10.1021%2Fjm5003606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization of a Novel Series of Imidazo[1,2-a]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent</span></div><div class="casAuthors">Kang, Sunhee; Kim, Ryang Yeo; Seo, Min Jung; Lee, Saeyeon; Kim, Young Mi; Seo, Mooyoung; Seo, Jeong Jea; Ko, Yoonae; Choi, Inhee; Jang, Jichan; Nam, Jiyoun; Park, Seijin; Kang, Hwankyu; Kim, Hyung Jun; Kim, Jungjun; Ahn, Sujin; Pethe, Kevin; Nam, Kiyean; No, Zaesung; Kim, Jaeseung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5293-5305</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A crit. unmet clin. need to combat the global tuberculosis epidemic is the development of potent agents capable of reducing the time of multi-drug-resistant (MDR) and extensively-drug-resistant (XDR) tuberculosis therapy.  In this paper, we report on the optimization of imidazo[1,2-a]pyridine amide (IPA) lead compd. I, which led to the design and synthesis of Q203 II (R1 = 6-Cl).  We found that the amide linker with IPA core is very important for activity against Mycobacterium tuberculosis H37Rv.  Linearity and lipophilicity of the amine part in the IPA series play a crit. role in improving in vitro and in vivo efficacy and pharmacokinetic profile.  The optimized IPAs II (R1 = 7-Cl, 6-Cl) showed not only excellent oral bioavailability (80.2% and 90.7%, resp.) with high exposure of the area under curve (AUC) but also displayed significant colony-forming unit (CFU) redn. (1.52 and 3.13 log10 redn. at 10 mg/kg dosing level, resp.) in mouse lung.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUtN4tIBVZU7Vg90H21EOLACvtfcHk0lhhZl5AiMs-tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1Wqtrg%253D&md5=377fc206a894d392a8394145c4019367</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm5003606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5003606%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DR.%2BY.%26aulast%3DSeo%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DY.%2BM.%26aulast%3DSeo%26aufirst%3DM.%26aulast%3DSeo%26aufirst%3DJ.%2BJ.%26aulast%3DKo%26aufirst%3DY.%26aulast%3DChoi%26aufirst%3DI.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DNam%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DKang%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DPethe%26aufirst%3DK.%26aulast%3DNam%26aufirst%3DK.%26aulast%3DNo%26aufirst%3DZ.%26aulast%3DKim%26aufirst%3DJ.%26atitle%3DLead%2520optimization%2520of%2520a%2520novel%2520series%2520of%2520imidazo%255B1%252C2-a%255Dpyridine%2520amides%2520leading%2520to%2520a%2520clinical%2520candidate%2520%2528Q203%2529%2520as%2520a%2520multi-%2520and%2520extensively-drug-resistant%2520anti-tuberculosis%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5293%26epage%3D5305%26doi%3D10.1021%2Fjm5003606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Palencia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, C. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Easom, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houston, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meewan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rock, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franzblau, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolhiser, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruppo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenaerts, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Malley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parish, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ioerger, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sacchettini, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rullas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angulo-Barturen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérez-Herrán, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendoza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barros, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cusack, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plattner, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alley, M. R. K.</span><span> </span><span class="NLM_article-title">Discovery of novel oral protein synthesis inhibitors of <i>Mycobacterium tuberculosis</i> that target leucyl-tRNA synthetase</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">6271</span><span class="NLM_x">–</span> <span class="NLM_lpage">6280</span><span class="refDoi"> DOI: 10.1128/AAC.01339-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1128%2FAAC.01339-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=27503647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=6271-6280&author=A.+Palenciaauthor=X.+Liauthor=W.+Buauthor=W.+Choiauthor=C.+Z.+Dingauthor=E.+E.+Easomauthor=L.+Fengauthor=V.+Hernandezauthor=P.+Houstonauthor=L.+Liuauthor=M.+Meewanauthor=M.+Mohanauthor=F.+L.+Rockauthor=H.+Sextonauthor=S.+Zhangauthor=Y.+Zhouauthor=B.+Wanauthor=Y.+Wangauthor=S.+G.+Franzblauauthor=L.+Woolhiserauthor=V.+Gruppoauthor=A.+J.+Lenaertsauthor=T.+O%E2%80%99Malleyauthor=T.+Parishauthor=C.+B.+Cooperauthor=M.+G.+Watersauthor=Z.+Maauthor=T.+R.+Ioergerauthor=J.+C.+Sacchettiniauthor=J.+Rullasauthor=I.+Angulo-Barturenauthor=E.+P%C3%A9rez-Herr%C3%A1nauthor=A.+Mendozaauthor=D.+Barrosauthor=S.+Cusackauthor=J.+J.+Plattnerauthor=M.+R.+K.+Alley&title=Discovery+of+novel+oral+protein+synthesis+inhibitors+of+Mycobacterium+tuberculosis+that+target+leucyl-tRNA+synthetase&doi=10.1128%2FAAC.01339-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel oral protein synthesis inhibitors of Mycobacterium tuberculosis that target leucyl-tRNA synthetase</span></div><div class="casAuthors">Palencia, Andres; Li, Xianfeng; Bu, Wei; Choi, Wai; Ding, Charles Z.; Easom, Eric E.; Feng, Lisa; Hernandez, Vincent; Houston, Paul; Liu, Liang; Meewan, Maliwan; Mohan, Manisha; Rock, Fernando L.; Sexton, Holly; Zhang, Suoming; Zhou, Yasheen; Wan, Baojie; Wang, Yuehong; Franzblau, Scott G.; Woolhiser, Lisa; Gruppo, Veronica; Lenaerts, Anne J.; O'Malley, Theresa; Parish, Tanya; Cooper, Christopher B.; Gerard, Waters M.; Ma, Zhenkun; Ioerger, Thomas R.; Sacchettini, James C.; Rullas, Joaquin; Angulo-Barturen, Inigo; Perez-Herran, Esther; Mendoza, Alfonso; Barros, David; Cusack, Stephen; Plattner, Jacob J.; Alley, M. R. K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6271-6280</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The recent development and spread of extensively drug-resistant and totally drug-resistant resistant (TDR) strains of Mycobacterium tuberculosis highlight the need for new antitubercular drugs.  Protein synthesis inhibitors have played an important role in the treatment of tuberculosis (TB) starting with the inclusion of streptomycin in the first combination therapies.  Although parenteral aminoglycosides are a key component of therapy for multidrug-resistant TB, the oxazolidinone linezolid is the only orally available protein synthesis inhibitor that is effective against TB.  Small-mol. inhibitors of aminoacyl-tRNA synthetases (AARSs), which are known to be excellent antibacterial protein synthesis targets, are orally bioavailable and effective against M. tuberculosis in TB mouse infection models.  The authors applied the oxaborole tRNA-trapping (OBORT) mechanism, which was first developed to target fungal cytoplasmic leucyl-tRNA synthetase (LeuRS), to M. tuberculosis LeuRS.  X-ray crystallog. was used to guide the design of LeuRS inhibitors that have good biochem. potency and excellent whole-cell activity against M. tuberculosis.  Importantly, their good oral bioavailability translates into in vivo efficacy in both the acute and chronic mouse models of TB with potency comparable to that of the frontline drug isoniazid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXJzF8QHuHLbVg90H21EOLACvtfcHk0ljTF8O28cQd-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKktb4%253D&md5=539a0a2039474285a7d243f972bc3a63</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1128%2FAAC.01339-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01339-16%26sid%3Dliteratum%253Aachs%26aulast%3DPalencia%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DBu%26aufirst%3DW.%26aulast%3DChoi%26aufirst%3DW.%26aulast%3DDing%26aufirst%3DC.%2BZ.%26aulast%3DEasom%26aufirst%3DE.%2BE.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DHernandez%26aufirst%3DV.%26aulast%3DHouston%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMeewan%26aufirst%3DM.%26aulast%3DMohan%26aufirst%3DM.%26aulast%3DRock%26aufirst%3DF.%2BL.%26aulast%3DSexton%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWan%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DWoolhiser%26aufirst%3DL.%26aulast%3DGruppo%26aufirst%3DV.%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DT.%26aulast%3DParish%26aufirst%3DT.%26aulast%3DCooper%26aufirst%3DC.%2BB.%26aulast%3DWaters%26aufirst%3DM.%2BG.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DIoerger%26aufirst%3DT.%2BR.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26aulast%3DRullas%26aufirst%3DJ.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DP%25C3%25A9rez-Herr%25C3%25A1n%26aufirst%3DE.%26aulast%3DMendoza%26aufirst%3DA.%26aulast%3DBarros%26aufirst%3DD.%26aulast%3DCusack%26aufirst%3DS.%26aulast%3DPlattner%26aufirst%3DJ.%2BJ.%26aulast%3DAlley%26aufirst%3DM.%2BR.%2BK.%26atitle%3DDiscovery%2520of%2520novel%2520oral%2520protein%2520synthesis%2520inhibitors%2520of%2520Mycobacterium%2520tuberculosis%2520that%2520target%2520leucyl-tRNA%2520synthetase%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D6271%26epage%3D6280%26doi%3D10.1128%2FAAC.01339-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Alley, M. R. K.; Hernandez, V.; Plattner, J. J.; Li, X.; Barros-Aguirre, D.; Giordano, I.</span><span> </span><span class="NLM_article-title">Tricyclic benzoxaborole compounds and uses thereof</span>. WO 2015/021396 A9, February 12,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=M.+R.+K.+Alley&author=V.+Hernandez&author=J.+J.+Plattner&author=X.+Li&author=D.+Barros-Aguirre&author=I.+Giordano&title=Tricyclic+benzoxaborole+compounds+and+uses+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlley%26aufirst%3DM.%2BR.%2BK.%26atitle%3DTricyclic%2520benzoxaborole%2520compounds%2520and%2520uses%2520thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Alley, M. R. K.; Barros-Aguirre, D.; Giordano, I.; Hernandez, V.; Li, X.; Plattner, J. J.</span><span> </span><span class="NLM_article-title">Benzoxaborole compounds and uses thereof</span>. WO 2016/128949 A1, August 18,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+R.+K.+Alley&author=D.+Barros-Aguirre&author=I.+Giordano&author=V.+Hernandez&author=X.+Li&author=J.+J.+Plattner&title=Benzoxaborole+compounds+and+uses+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlley%26aufirst%3DM.%2BR.%2BK.%26atitle%3DBenzoxaborole%2520compounds%2520and%2520uses%2520thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Hernandez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crépin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palencia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cusack, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freund, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meewan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rock, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheoran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nieman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anugula, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keramane, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savariraj, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subedi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Leary, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Marsh, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mushtaq, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livermore, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alley, M. R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plattner, J. J.</span><span> </span><span class="NLM_article-title">Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1394</span><span class="NLM_x">–</span> <span class="NLM_lpage">1403</span><span class="refDoi"> DOI: 10.1128/AAC.02058-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1128%2FAAC.02058-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=23295920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltV2htLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=1394-1403&author=V.+Hernandezauthor=T.+Cr%C3%A9pinauthor=A.+Palenciaauthor=S.+Cusackauthor=T.+Akamaauthor=S.+J.+Bakerauthor=W.+Buauthor=L.+Fengauthor=Y.+R.+Freundauthor=L.+Liuauthor=M.+Meewanauthor=M.+Mohanauthor=W.+Maoauthor=F.+L.+Rockauthor=H.+Sextonauthor=A.+Sheoranauthor=Y.+Zhangauthor=Y.+K.+Zhangauthor=Y.+Zhouauthor=J.+A.+Niemanauthor=M.+R.+Anugulaauthor=E.+M.+Keramaneauthor=K.+Savarirajauthor=D.+S.+Reddyauthor=R.+Sharmaauthor=R.+Subediauthor=R.+Singhauthor=A.+O%E2%80%99Learyauthor=N.+L.+Simonauthor=P.+L.+De+Marshauthor=S.+Mushtaqauthor=M.+Warnerauthor=D.+M.+Livermoreauthor=M.+R.+K.+Alleyauthor=J.+J.+Plattner&title=Discovery+of+a+novel+class+of+boron-based+antibacterials+with+activity+against+gram-negative+bacteria&doi=10.1128%2FAAC.02058-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel class of boron-based antibacterials with activity against Gram-negative bacteria</span></div><div class="casAuthors">Hernandez, Vincent; Crepin, Thibaut; Palencia, Andres; Cusack, Stephen; Akama, Tsutomu; Baker, Stephen J.; Bu, Wei; Feng, Lisa; Freund, Yvonne R.; Liu, Liang; Meewan, Maliwan; Mohan, Manisha; Mao, Weimin; Rock, Fernando L.; Sexton, Holly; Sheoran, Anita; Zhang, Yanchen; Zhang, Yong-Kang; Zhou, Yasheen; Nieman, James A.; Anugula, Mahipal Reddy; Keramane, El Mehdi; Savariraj, Kingsley; Reddy, D. Shekhar; Sharma, Rashmi; Subedi, Rajendra; Singh, Rajeshwar; O'Leary, Ann; Simon, Nerissa L.; De Marsh, Peter L.; Mushtaq, Shazad; Warner, Marina; Livermore, David M.; Alley, M. R. K.; Plattner, Jacob J.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1394-1403</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Gram-neg. bacteria cause approx. 70% of the infections in intensive care units.  A growing no. of bacterial isolates responsible for these infections are resistant to currently available antibiotics and to many in development.  Most agents under development are modifications of existing drug classes, which only partially overcome existing resistance mechanisms.  Therefore, new classes of Gram-neg. antibacterials with truly novel modes of action are needed to circumvent these existing resistance mechanisms.  We have previously identified a new a way to inhibit an aminoacyl-tRNA synthetase, leucyl-tRNA synthetase (LeuRS), in fungi via the oxaborole tRNA trapping (OBORT) mechanism.  Herein, we show how we have modified the OBORT mechanism using a structure-guided approach to develop a new boron-based antibiotic class, the aminomethylbenzoxaboroles, which inhibit bacterial leucyl-tRNA synthetase and have activity against Gram-neg. bacteria by largely evading the main efflux mechanisms in Escherichia coli and Pseudomonas aeruginosa.  The lead analog, AN3365, is active against Gram-neg. bacteria, including Enterobacteriaceae bearing NDM-1 and KPC carbapenemases, as well as P. aeruginosa.  This novel boron-based antibacterial, AN3365, has good mouse pharmacokinetics and was efficacious against E. coli and P. aeruginosa in murine thigh infection models, which suggest that this novel class of antibacterials has the potential to address this unmet medical need.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWl5Oj0jzVnLVg90H21EOLACvtfcHk0liWmeNsX4YFpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltV2htLg%253D&md5=7ed74bde2bacfa4ae20abb50b745c57d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1128%2FAAC.02058-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02058-12%26sid%3Dliteratum%253Aachs%26aulast%3DHernandez%26aufirst%3DV.%26aulast%3DCr%25C3%25A9pin%26aufirst%3DT.%26aulast%3DPalencia%26aufirst%3DA.%26aulast%3DCusack%26aufirst%3DS.%26aulast%3DAkama%26aufirst%3DT.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DBu%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DFreund%26aufirst%3DY.%2BR.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMeewan%26aufirst%3DM.%26aulast%3DMohan%26aufirst%3DM.%26aulast%3DMao%26aufirst%3DW.%26aulast%3DRock%26aufirst%3DF.%2BL.%26aulast%3DSexton%26aufirst%3DH.%26aulast%3DSheoran%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DNieman%26aufirst%3DJ.%2BA.%26aulast%3DAnugula%26aufirst%3DM.%2BR.%26aulast%3DKeramane%26aufirst%3DE.%2BM.%26aulast%3DSavariraj%26aufirst%3DK.%26aulast%3DReddy%26aufirst%3DD.%2BS.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DSubedi%26aufirst%3DR.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Leary%26aufirst%3DA.%26aulast%3DSimon%26aufirst%3DN.%2BL.%26aulast%3DDe%2BMarsh%26aufirst%3DP.%2BL.%26aulast%3DMushtaq%26aufirst%3DS.%26aulast%3DWarner%26aufirst%3DM.%26aulast%3DLivermore%26aufirst%3DD.%2BM.%26aulast%3DAlley%26aufirst%3DM.%2BR.%2BK.%26aulast%3DPlattner%26aufirst%3DJ.%2BJ.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520class%2520of%2520boron-based%2520antibacterials%2520with%2520activity%2520against%2520gram-negative%2520bacteria%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D1394%26epage%3D1403%26doi%3D10.1128%2FAAC.02058-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Conde, J. J.; Kowalski, A. J.; Zajac, M. A.</span><span> </span><span class="NLM_article-title">Process for preparing benzoxaboroles</span>. WO 2011/127143 A1, October 13,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+J.+Conde&author=A.+J.+Kowalski&author=M.+A.+Zajac&title=Process+for+preparing+benzoxaboroles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DConde%26aufirst%3DJ.%2BJ.%26atitle%3DProcess%2520for%2520preparing%2520benzoxaboroles%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Vshyvenko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clapson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, D. G.</span><span> </span><span class="NLM_article-title">Characterization of the dynamic equilibrium between closed and open forms of the benzoxaborole pharmacophore</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1097</span><span class="NLM_x">–</span> <span class="NLM_lpage">1101</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00300</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00300" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFGhsLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1097-1101&author=S.+Vshyvenkoauthor=M.+L.+Clapsonauthor=I.+Suzukiauthor=D.+G.+Hall&title=Characterization+of+the+dynamic+equilibrium+between+closed+and+open+forms+of+the+benzoxaborole+pharmacophore&doi=10.1021%2Facsmedchemlett.6b00300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Dynamic Equilibrium between Closed and Open Forms of the Benzoxaborole Pharmacophore</span></div><div class="casAuthors">Vshyvenko, Sergey; Clapson, Marissa L.; Suzuki, Itaru; Hall, Dennis G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1097-1101</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Benzoxaboroles are a class of five-membered hemiboronic acids that recently attracted significant attention as a new pharmacophore on account of their unique structural and physicochem. properties and their ability to interact selectively with biomols.  Their structural behavior in water and its effect on their physiol. properties remain unclear, esp. the question of dynamic hydrolytic equil. of the oxaborole ring.  Herein, we used NMR spectroscopy, in mixed aq.-org. solvent, to confirm the strong preference for the closed form of benzoxaborole and its six- and seven-membered homologues over the open boronic acid form.  Only with the eight-membered homolog does the cyclic form become unfavorable.  Using dynamic VT-NMR studies with designed probe compd. 20, we demonstrate that the oxaborole ring undergoes rapid hydrolytic ring closing-opening at ambient temp. at a rate of >100 Hz via a mechanism featuring rate-limiting proton-transfer steps.  This knowledge can help provide a better understanding of the behavior of benzoxaboroles in biol. systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzXVZHWiwlXbVg90H21EOLACvtfcHk0liWmeNsX4YFpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFGhsLfO&md5=81864340ccb800c9414f2d1dc0f41a89</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00300%26sid%3Dliteratum%253Aachs%26aulast%3DVshyvenko%26aufirst%3DS.%26aulast%3DClapson%26aufirst%3DM.%2BL.%26aulast%3DSuzuki%26aufirst%3DI.%26aulast%3DHall%26aufirst%3DD.%2BG.%26atitle%3DCharacterization%2520of%2520the%2520dynamic%2520equilibrium%2520between%2520closed%2520and%2520open%2520forms%2520of%2520the%2520benzoxaborole%2520pharmacophore%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D1097%26epage%3D1101%26doi%3D10.1021%2Facsmedchemlett.6b00300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Lue, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, S. O.</span><span> </span><span class="NLM_article-title">An aminoacyl-tRNA synthetase with a defunct editing site</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3010</span><span class="NLM_x">–</span> <span class="NLM_lpage">3016</span><span class="refDoi"> DOI: 10.1021/bi047901v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi047901v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2005&pages=3010-3016&author=S.+W.+Lueauthor=S.+O.+Kelley&title=An+aminoacyl-tRNA+synthetase+with+a+defunct+editing+site&doi=10.1021%2Fbi047901v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fbi047901v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi047901v%26sid%3Dliteratum%253Aachs%26aulast%3DLue%26aufirst%3DS.%2BW.%26aulast%3DKelley%26aufirst%3DS.%2BO.%26atitle%3DAn%2520aminoacyl-tRNA%2520synthetase%2520with%2520a%2520defunct%2520editing%2520site%26jtitle%3DBiochemistry%26date%3D2005%26volume%3D44%26spage%3D3010%26epage%3D3016%26doi%3D10.1021%2Fbi047901v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Blanco-Ruano, D.; Roberts, D. M.; Gonzalez-Del-Rio, R.; Alvarez, D.; Rebollo, M. J.; Perez-Herran, E.; Mendoza, A.</span><span> </span><span class="NLM_article-title">Antimicrobial Susceptibility Testing for Mycobacterium sp.</span> In  <span class="citation_source-book">Mycobacteria Protocols</span>; <span class="NLM_contrib-group">Parish, T.; Roberts, D. M.</span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Hatfield, Hertfordshire, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">257</span><span class="NLM_x">–</span> <span class="NLM_lpage">268</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1007%2F978-1-4939-2450-9_15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=257-268&author=D.+Blanco-Ruano&author=D.+M.+Roberts&author=R.+Gonzalez-Del-Rio&author=D.+Alvarez&author=M.+J.+Rebollo&author=E.+Perez-Herran&author=A.+Mendozaauthor=T.+Parish&author=D.+M.+Roberts&title=Mycobacteria+Protocols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-2450-9_15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4939-2450-9_15%26sid%3Dliteratum%253Aachs%26aulast%3DBlanco-Ruano%26aufirst%3DD.%26atitle%3DAntimicrobial%2520Susceptibility%2520Testing%2520for%2520Mycobacterium%2520sp.%26btitle%3DMycobacteria%2520Protocols%26aulast%3DParish%26aufirst%3DT.%26pub%3DSpringer%26date%3D2015%26spage%3D257%26epage%3D268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Rullas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beltrán, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardona, P.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cáceres, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García Bustos, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angulo-Barturen, I.</span><span> </span><span class="NLM_article-title">Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2262</span><span class="NLM_x">–</span> <span class="NLM_lpage">2264</span><span class="refDoi"> DOI: 10.1128/AAC.01423-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1128%2FAAC.01423-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=20160054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtFeltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=2262-2264&author=J.+Rullasauthor=J.+I.+Garc%C3%ADaauthor=M.+Beltr%C3%A1nauthor=P.-J.+Cardonaauthor=N.+C%C3%A1ceresauthor=J.+F.+Garc%C3%ADa+Bustosauthor=I.+Angulo-Barturen&title=Fast+standardized+therapeutic-efficacy+assay+for+drug+discovery+against+tuberculosis&doi=10.1128%2FAAC.01423-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis</span></div><div class="casAuthors">Rullas, Joaquin; Garcia, Juan Ignacio; Beltran, Manuela; Cardona, Pere-Joan; Caceres, Neus; Garcia-Bustos, Jose Francisco; Angulo-Barturen, Inigo</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2262-2264</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Murine models of Mycobacterium tuberculosis infection are essential tools in drug discovery.  Here we describe a fast standardized 9-day acute assay intended to measure the efficacy of drugs against M. tuberculosis growing in the lungs of immunocompetent mice.  This assay is highly reproducible, allows good throughput, and was validated for drug lead optimization using isoniazid, rifampin, ethambutol, pyrazinamide, linezolid, and moxifloxacin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpajX5TwxQ_E7Vg90H21EOLACvtfcHk0ljMjjRU_6ttig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtFeltLo%253D&md5=c923fae175b34eab3778a0e4d8d51878</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1128%2FAAC.01423-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01423-09%26sid%3Dliteratum%253Aachs%26aulast%3DRullas%26aufirst%3DJ.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DJ.%2BI.%26aulast%3DBeltr%25C3%25A1n%26aufirst%3DM.%26aulast%3DCardona%26aufirst%3DP.-J.%26aulast%3DC%25C3%25A1ceres%26aufirst%3DN.%26aulast%3DGarc%25C3%25ADa%2BBustos%26aufirst%3DJ.%2BF.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26atitle%3DFast%2520standardized%2520therapeutic-efficacy%2520assay%2520for%2520drug%2520discovery%2520against%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D2262%26epage%3D2264%26doi%3D10.1128%2FAAC.01423-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24a','cit24b'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 59 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Haonan Sun, Yunjian Yu, Yufei Zhang, Jie Li, Yijie Cheng, Siyuan Huang, Wenbo Wang, <span class="NLM_string-name hlFld-ContribAuthor">Xinge Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Glycosylated Nanotherapeutics with β-Lactamase Reversible Competitive Inhibitory Activity Reinvigorates Antibiotics against Gram-Negative Bacteria. </span><span class="cited-content_cbyCitation_journal-name">Biomacromolecules</span><span> <strong>2021,</strong> <em>22 </em>
                                    (7)
                                     , 2834-2849. <a href="https://doi.org/10.1021/acs.biomac.1c00231" title="DOI URL">https://doi.org/10.1021/acs.biomac.1c00231</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biomac.1c00231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biomac.1c00231%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomacromolecules%26atitle%3DGlycosylated%252BNanotherapeutics%252Bwith%252B%2525CE%2525B2-Lactamase%252BReversible%252BCompetitive%252BInhibitory%252BActivity%252BReinvigorates%252BAntibiotics%252Bagainst%252BGram-Negative%252BBacteria%26aulast%3DSun%26aufirst%3DHaonan%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D19022021%26date%3D14042021%26date%3D24062021%26volume%3D22%26issue%3D7%26spage%3D2834%26epage%3D2849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jiong Zhang, Jinyi Zhang, Guiyun Hao, Weixiang Xin, Fei Yang, Mingyan Zhu, <span class="NLM_string-name hlFld-ContribAuthor">Huchen Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Structure–Activity Relationship of 7-Propanamide Benzoxaboroles as Potent Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (14)
                                     , 6765-6784. <a href="https://doi.org/10.1021/acs.jmedchem.9b00736" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00736</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00736%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationship%252Bof%252B7-Propanamide%252BBenzoxaboroles%252Bas%252BPotent%252BAnticancer%252BAgents%26aulast%3DZhang%26aufirst%3DJiong%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D05052019%26date%3D02072019%26date%3D20062019%26volume%3D62%26issue%3D14%26spage%3D6765%26epage%3D6784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Robert T. Jacobs, Christopher S. Lunde, Yvonne R. Freund, Vincent Hernandez, Xianfeng Li, Yi Xia, David S. Carter, Pamela W. Berry, Jason Halladay, Fernando Rock, Rianna Stefanakis, Eric Easom, Jacob J. Plattner, Louise Ford, Kelly L. Johnston, Darren A. N. Cook, Rachel Clare, Andrew Cassidy, Laura Myhill, Hayley Tyrer, Joanne Gamble, Ana F. Guimaraes, Andrew Steven, Franziska Lenz, Alexandra Ehrens, Stefan J. Frohberger, Marianne Koschel, Achim Hoerauf, Marc P. Hübner, Case W. McNamara, Malina A. Bakowski, Joseph D. Turner, Mark J. Taylor, <span class="NLM_string-name hlFld-ContribAuthor">Stephen A. Ward</span>. </span><span class="cited-content_cbyCitation_article-title">Boron-Pleuromutilins as Anti-Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (5)
                                     , 2521-2540. <a href="https://doi.org/10.1021/acs.jmedchem.8b01854" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01854</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01854%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBoron-Pleuromutilins%252Bas%252BAnti-Wolbachia%252BAgents%252Bwith%252BPotential%252Bfor%252BTreatment%252Bof%252BOnchocerciasis%252Band%252BLymphatic%252BFilariasis%26aulast%3DJacobs%26aufirst%3DRobert%2BT.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D27112018%26date%3D26022019%26date%3D07022019%26volume%3D62%26issue%3D5%26spage%3D2521%26epage%3D2540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Frédéric St-Jean, Katarzyna A. Piechowicz, Lauren E. Sirois, Rémy Angelaud, <span class="NLM_string-name hlFld-ContribAuthor">Francis Gosselin</span>. </span><span class="cited-content_cbyCitation_article-title">Study of a Competing Hydrodefluorination Reaction During the Directed ortho-Lithiation/Borylation of 2-Fluorobenzaldehyde. </span><span class="cited-content_cbyCitation_journal-name">Organometallics</span><span> <strong>2019,</strong> <em>38 </em>
                                    (1)
                                     , 119-128. <a href="https://doi.org/10.1021/acs.organomet.8b00730" title="DOI URL">https://doi.org/10.1021/acs.organomet.8b00730</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.organomet.8b00730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.organomet.8b00730%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganometallics%26atitle%3DStudy%252Bof%252Ba%252BCompeting%252BHydrodefluorination%252BReaction%252BDuring%252Bthe%252BDirected%252Bortho-Lithiation%25252FBorylation%252Bof%252B2-Fluorobenzaldehyde%26aulast%3DSt-Jean%26aufirst%3DFr%25C3%25A9d%25C3%25A9ric%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D08102018%26date%3D20122018%26volume%3D38%26issue%3D1%26spage%3D119%26epage%3D128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas Boström</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Courtney C. Aldrich, , <span class="NLM_string-name hlFld-ContribAuthor">Félix Calderón</span>. </span><span class="cited-content_cbyCitation_article-title">2nd SCI/RSC Symposium on Medicinal Chemistry for Global Health: A Unique Opportunity for the Field. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2018,</strong> <em>4 </em>
                                    (4)
                                     , 424-428. <a href="https://doi.org/10.1021/acsinfecdis.8b00022" title="DOI URL">https://doi.org/10.1021/acsinfecdis.8b00022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.8b00022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.8b00022%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3D2nd%252BSCI%25252FRSC%252BSymposium%252Bon%252BMedicinal%252BChemistry%252Bfor%252BGlobal%252BHealth%25253A%252BA%252BUnique%252BOpportunity%252Bfor%252Bthe%252BField%26aulast%3DAldrich%26aufirst%3DCourtney%2BC.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D23012018%26volume%3D4%26issue%3D4%26spage%3D424%26epage%3D428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tianao  Yuan</span> and <span class="hlFld-ContribAuthor ">Nicole S.  Sampson</span>  . </span><span class="cited-content_cbyCitation_article-title">Hit Generation in TB Drug Discovery: From Genome to Granuloma. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2018,</strong> <em>118 </em>
                                    (4)
                                     , 1887-1916. <a href="https://doi.org/10.1021/acs.chemrev.7b00602" title="DOI URL">https://doi.org/10.1021/acs.chemrev.7b00602</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.7b00602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.7b00602%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DHit%252BGeneration%252Bin%252BTB%252BDrug%252BDiscovery%25253A%252BFrom%252BGenome%252Bto%252BGranuloma%26aulast%3DYuan%26aufirst%3DTianao%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D01102017%26date%3D31012018%26date%3D28022018%26volume%3D118%26issue%3D4%26spage%3D1887%26epage%3D1916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Umar  Ndagi</span>, <span class="hlFld-ContribAuthor ">Hezekiel M.  Kumalo</span>, <span class="hlFld-ContribAuthor ">Ndumiso N.  Mhlongo</span>. </span><span class="cited-content_cbyCitation_article-title">A consequence of drug targeting of aminoacyl‐tRNA synthetases in
              Mycobacterium
              tuberculosis. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2021,</strong> <em>10 </em><a href="https://doi.org/10.1111/cbdd.13865" title="DOI URL">https://doi.org/10.1111/cbdd.13865</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13865%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DA%252Bconsequence%252Bof%252Bdrug%252Btargeting%252Bof%252Baminoacyl%2525E2%252580%252590tRNA%252Bsynthetases%252Bin%252BMycobacterium%252Btuberculosis%26aulast%3DNdagi%26aufirst%3DUmar%26date%3D2021%26date%3D2021%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Egorova</span>, <span class="hlFld-ContribAuthor ">Mary  Jackson</span>, <span class="hlFld-ContribAuthor ">Victor  Gavrilyuk</span>, <span class="hlFld-ContribAuthor ">Vadim  Makarov</span>. </span><span class="cited-content_cbyCitation_article-title">Pipeline of anti‐
              Mycobacterium abscessus
              small molecules: Repurposable drugs and promising novel chemical entities. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2021,</strong> <em>41 </em>
                                    (4)
                                     , 2350-2387. <a href="https://doi.org/10.1002/med.21798" title="DOI URL">https://doi.org/10.1002/med.21798</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21798%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DPipeline%252Bof%252Banti%2525E2%252580%252590%252BMycobacterium%252Babscessus%252Bsmall%252Bmolecules%25253A%252BRepurposable%252Bdrugs%252Band%252Bpromising%252Bnovel%252Bchemical%252Bentities%26aulast%3DEgorova%26aufirst%3DAnna%26date%3D2021%26date%3D2021%26volume%3D41%26issue%3D4%26spage%3D2350%26epage%3D2387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paolo Saul  Coghi</span>, <span class="hlFld-ContribAuthor ">Yinghuai  Zhu</span>, <span class="hlFld-ContribAuthor ">Hongming  Xie</span>, <span class="hlFld-ContribAuthor ">Narayan S.  Hosmane</span>, <span class="hlFld-ContribAuthor ">Yingjun  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Organoboron Compounds: Effective Antibacterial and Antiparasitic Agents. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (11)
                                     , 3309. <a href="https://doi.org/10.3390/molecules26113309" title="DOI URL">https://doi.org/10.3390/molecules26113309</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26113309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26113309%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DOrganoboron%252BCompounds%25253A%252BEffective%252BAntibacterial%252Band%252BAntiparasitic%252BAgents%26aulast%3DCoghi%26aufirst%3DPaolo%2BSaul%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D11%26spage%3D3309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karolina  Michalska</span>, <span class="hlFld-ContribAuthor ">Robert  Jedrzejczak</span>, <span class="hlFld-ContribAuthor ">Jacek  Wower</span>, <span class="hlFld-ContribAuthor ">Changsoo  Chang</span>, <span class="hlFld-ContribAuthor ">Beatriz  Baragaña</span>, <span class="hlFld-ContribAuthor ">Ian H  Gilbert</span>, <span class="hlFld-ContribAuthor ">Barbara  Forte</span>, <span class="hlFld-ContribAuthor ">Andrzej  Joachimiak</span>. </span><span class="cited-content_cbyCitation_article-title">Mycobacterium tuberculosis
              Phe-tRNA synthetase: structural insights into tRNA recognition and aminoacylation. </span><span class="cited-content_cbyCitation_journal-name">Nucleic Acids Research</span><span> <strong>2021,</strong> <em>49 </em>
                                    (9)
                                     , 5351-5368. <a href="https://doi.org/10.1093/nar/gkab272" title="DOI URL">https://doi.org/10.1093/nar/gkab272</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/nar/gkab272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fnar%2Fgkab272%26sid%3Dliteratum%253Aachs%26jtitle%3DNucleic%2520Acids%2520Research%26atitle%3DMycobacterium%252Btuberculosis%252BPhe-tRNA%252Bsynthetase%25253A%252Bstructural%252Binsights%252Binto%252BtRNA%252Brecognition%252Band%252Baminoacylation%26aulast%3DMichalska%26aufirst%3DKarolina%26date%3D2021%26date%3D2021%26volume%3D49%26issue%3D9%26spage%3D5351%26epage%3D5368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhammad M.  Hasan</span>, <span class="hlFld-ContribAuthor ">Erin E.  Stebbins</span>, <span class="hlFld-ContribAuthor ">Robert K. M.  Choy</span>, <span class="hlFld-ContribAuthor ">J. Robert  Gillespie</span>, <span class="hlFld-ContribAuthor ">Eugenio L.  de Hostos</span>, <span class="hlFld-ContribAuthor ">Peter  Miller</span>, <span class="hlFld-ContribAuthor ">Aisha  Mushtaq</span>, <span class="hlFld-ContribAuthor ">Ranae M.  Ranade</span>, <span class="hlFld-ContribAuthor ">José E.  Teixeira</span>, <span class="hlFld-ContribAuthor ">Christophe L. M. J.  Verlinde</span>, <span class="hlFld-ContribAuthor ">Adam  Sateriale</span>, <span class="hlFld-ContribAuthor ">Zhongsheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Damon M.  Osbourn</span>, <span class="hlFld-ContribAuthor ">David W.  Griggs</span>, <span class="hlFld-ContribAuthor ">Erkang  Fan</span>, <span class="hlFld-ContribAuthor ">Frederick S.  Buckner</span>, <span class="hlFld-ContribAuthor ">Christopher D.  Huston</span>. </span><span class="cited-content_cbyCitation_article-title">Spontaneous Selection of
              Cryptosporidium
              Drug Resistance in a Calf Model of Infection. </span><span class="cited-content_cbyCitation_journal-name">Antimicrobial Agents and Chemotherapy</span><span> <strong>2021,</strong> <em>65 </em>
                                    (6)
                                     <a href="https://doi.org/10.1128/AAC.00023-21" title="DOI URL">https://doi.org/10.1128/AAC.00023-21</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/AAC.00023-21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FAAC.00023-21%26sid%3Dliteratum%253Aachs%26jtitle%3DAntimicrobial%2520Agents%2520and%2520Chemotherapy%26atitle%3DSpontaneous%252BSelection%252Bof%252BCryptosporidium%252BDrug%252BResistance%252Bin%252Ba%252BCalf%252BModel%252Bof%252BInfection%26aulast%3DHasan%26aufirst%3DMuhammad%2BM.%26date%3D2021%26volume%3D65%26issue%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Klaudia T.  Angula</span>, <span class="hlFld-ContribAuthor ">Lesetja J.  Legoabe</span>, <span class="hlFld-ContribAuthor ">Richard M.  Beteck</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010–2020 Review. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2021,</strong> <em>14 </em>
                                    (5)
                                     , 461. <a href="https://doi.org/10.3390/ph14050461" title="DOI URL">https://doi.org/10.3390/ph14050461</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph14050461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph14050461%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DChemical%252BClasses%252BPresenting%252BNovel%252BAntituberculosis%252BAgents%252BCurrently%252Bin%252BDifferent%252BPhases%252Bof%252BDrug%252BDevelopment%25253A%252BA%252B2010%2525E2%252580%2525932020%252BReview%26aulast%3DAngula%26aufirst%3DKlaudia%2BT.%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D5%26spage%3D461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ghada  Bouz</span>, <span class="hlFld-ContribAuthor ">Jan  Zitko</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors of aminoacyl-tRNA synthetases as antimycobacterial compounds: An up-to-date review. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>110 </em>, 104806. <a href="https://doi.org/10.1016/j.bioorg.2021.104806" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104806</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104806%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DInhibitors%252Bof%252Baminoacyl-tRNA%252Bsynthetases%252Bas%252Bantimycobacterial%252Bcompounds%25253A%252BAn%252Bup-to-date%252Breview%26aulast%3DBouz%26aufirst%3DGhada%26date%3D2021%26volume%3D110%26spage%3D104806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Uday S.  Ganapathy</span>, <span class="hlFld-ContribAuthor ">Rubén  González del Rio</span>, <span class="hlFld-ContribAuthor ">Mónica  Cacho-Izquierdo</span>, <span class="hlFld-ContribAuthor ">Fátima  Ortega</span>, <span class="hlFld-ContribAuthor ">Joël  Lelièvre</span>, <span class="hlFld-ContribAuthor ">David  Barros-Aguirre</span>, <span class="hlFld-ContribAuthor ">Marissa  Lindman</span>, <span class="hlFld-ContribAuthor ">Véronique  Dartois</span>, <span class="hlFld-ContribAuthor ">Martin  Gengenbacher</span>, <span class="hlFld-ContribAuthor ">Thomas  Dick</span>. </span><span class="cited-content_cbyCitation_article-title">A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Antimycobacterial Activity. </span><span class="cited-content_cbyCitation_journal-name">Antimicrobial Agents and Chemotherapy</span><span> <strong>2021,</strong> <em>65 </em>
                                    (5)
                                     <a href="https://doi.org/10.1128/AAC.02420-20" title="DOI URL">https://doi.org/10.1128/AAC.02420-20</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/AAC.02420-20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FAAC.02420-20%26sid%3Dliteratum%253Aachs%26jtitle%3DAntimicrobial%2520Agents%2520and%2520Chemotherapy%26atitle%3DA%252BLeucyl-tRNA%252BSynthetase%252BInhibitor%252Bwith%252BBroad-Spectrum%252BAntimycobacterial%252BActivity%26aulast%3DGanapathy%26aufirst%3DUday%2BS.%26date%3D2021%26volume%3D65%26issue%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Babita  Kushwaha</span>, <span class="hlFld-ContribAuthor ">Narva Deshwar  Kushwaha</span>, <span class="hlFld-ContribAuthor ">Tanya  Parish</span>, <span class="hlFld-ContribAuthor ">Junitta  Guzman</span>, <span class="hlFld-ContribAuthor ">Afsana  Kajee</span>, <span class="hlFld-ContribAuthor ">Mahamadhanif S.  Shaikh</span>, <span class="hlFld-ContribAuthor ">Idowu  Kehinde</span>, <span class="hlFld-ContribAuthor ">Vincent A.  Obakachi</span>, <span class="hlFld-ContribAuthor ">Tabasum Khan  Pathan</span>, <span class="hlFld-ContribAuthor ">Suraj Raosaheb  Shinde</span>, <span class="hlFld-ContribAuthor ">Rajshekhar  Karpoormath</span>. </span><span class="cited-content_cbyCitation_article-title">A New Class of Linezolid‐Based Molecules as Potential Antimicrobial and Antitubercular Agents: A Rational Approach. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (13)
                                     , 3065-3074. <a href="https://doi.org/10.1002/slct.202100493" title="DOI URL">https://doi.org/10.1002/slct.202100493</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202100493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202100493%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DA%252BNew%252BClass%252Bof%252BLinezolid%2525E2%252580%252590Based%252BMolecules%252Bas%252BPotential%252BAntimicrobial%252Band%252BAntitubercular%252BAgents%25253A%252BA%252BRational%252BApproach%26aulast%3DKushwaha%26aufirst%3DBabita%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D13%26spage%3D3065%26epage%3D3074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marta  Acebrón-García-de-Eulate</span>, <span class="hlFld-ContribAuthor ">Tom L.  Blundell</span>, <span class="hlFld-ContribAuthor ">Sundeep Chaitanya  Vedithi</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies for drug target identification in Mycobacterium leprae. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2021,</strong> <em>4 </em><a href="https://doi.org/10.1016/j.drudis.2021.03.026" title="DOI URL">https://doi.org/10.1016/j.drudis.2021.03.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2021.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2021.03.026%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DStrategies%252Bfor%252Bdrug%252Btarget%252Bidentification%252Bin%252BMycobacterium%252Bleprae%26aulast%3DAcebr%25C3%25B3n-Garc%25C3%25ADa-de-Eulate%26aufirst%3DMarta%26date%3D2021%26volume%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elizabeth  Fullam</span>, <span class="hlFld-ContribAuthor ">Robert J.  Young</span>. </span><span class="cited-content_cbyCitation_article-title">Physicochemical properties and
              Mycobacterium tuberculosis
              transporters: keys to efficacious antitubercular drugs?. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     , 43-56. <a href="https://doi.org/10.1039/D0MD00265H" title="DOI URL">https://doi.org/10.1039/D0MD00265H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00265H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00265H%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DPhysicochemical%252Bproperties%252Band%252BMycobacterium%252Btuberculosis%252Btransporters%25253A%252Bkeys%252Bto%252Befficacious%252Bantitubercular%252Bdrugs%25253F%26aulast%3DFullam%26aufirst%3DElizabeth%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D1%26spage%3D43%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Komal  G Sangu</span>, <span class="hlFld-ContribAuthor ">Akash  U Shinde</span>, <span class="hlFld-ContribAuthor ">Sidharth  Chopra</span>, <span class="hlFld-ContribAuthor ">Haridas  B Rode</span>. </span><span class="cited-content_cbyCitation_article-title">Evading antimicrobial resistance using boron-containing therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2021,</strong> <em>13 </em>
                                    (3)
                                     , 229-232. <a href="https://doi.org/10.4155/fmc-2020-0161" title="DOI URL">https://doi.org/10.4155/fmc-2020-0161</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2020-0161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2020-0161%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DEvading%252Bantimicrobial%252Bresistance%252Busing%252Bboron-containing%252Btherapeutics%26aulast%3DG%25C2%25A0Sangu%26aufirst%3DKomal%26date%3D2021%26volume%3D13%26issue%3D3%26spage%3D229%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tanjore S.  Balganesh</span>, <span class="hlFld-ContribAuthor ">Jagadeesh J.  Bhat</span>, <span class="hlFld-ContribAuthor ">Bheemarao  Ugarkar</span>. </span><span class="cited-content_cbyCitation_article-title">Modern Drug Discovery and Development for TB: The India Narrative. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 37-61. <a href="https://doi.org/10.1007/978-981-15-8002-4_2" title="DOI URL">https://doi.org/10.1007/978-981-15-8002-4_2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-15-8002-4_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-15-8002-4_2%26sid%3Dliteratum%253Aachs%26atitle%3DModern%252BDrug%252BDiscovery%252Band%252BDevelopment%252Bfor%252BTB%25253A%252BThe%252BIndia%252BNarrative%26aulast%3DBalganesh%26aufirst%3DTanjore%2BS.%26date%3D2021%26date%3D2021%26spage%3D37%26epage%3D61%26pub%3DSpringer%2520Singapore%26atitle%3DDrug%252BDiscovery%252Band%252BDrug%252BDevelopment%26aulast%3DDikshit%26aufirst%3DMadhu%26date%3D2021%26volume%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shu  Song</span>, <span class="hlFld-ContribAuthor ">Ping  Gao</span>, <span class="hlFld-ContribAuthor ">Lin  Sun</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments in the medicinal chemistry of single boron atom-containing compounds. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>73 </em><a href="https://doi.org/10.1016/j.apsb.2021.01.010" title="DOI URL">https://doi.org/10.1016/j.apsb.2021.01.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2021.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2021.01.010%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DRecent%252Bdevelopments%252Bin%252Bthe%252Bmedicinal%252Bchemistry%252Bof%252Bsingle%252Bboron%252Batom-containing%252Bcompounds%26aulast%3DSong%26aufirst%3DShu%26date%3D2021%26volume%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">R. Alan  Aitken</span>, <span class="hlFld-ContribAuthor ">Dheirya K.  Sonecha</span>. </span><span class="cited-content_cbyCitation_article-title">Five-membered Rings With Two Adjacent Heteroatoms With at Least One Boron. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00111-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00111-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00111-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00111-6%26sid%3Dliteratum%253Aachs%26atitle%3DFive-membered%252BRings%252BWith%252BTwo%252BAdjacent%252BHeteroatoms%252BWith%252Bat%252BLeast%252BOne%252BBoron%26aulast%3DAitken%26aufirst%3DR.%2BAlan%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2021%26volume%3D694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samanvai Reddy  Tetali</span>, <span class="hlFld-ContribAuthor ">Eswar  Kunapaeddi</span>, <span class="hlFld-ContribAuthor ">Raghu Prasad  Mailavaram</span>, <span class="hlFld-ContribAuthor ">Vinayak  Singh</span>, <span class="hlFld-ContribAuthor ">Pobitra  Borah</span>, <span class="hlFld-ContribAuthor ">Pran Kishore  Deb</span>, <span class="hlFld-ContribAuthor ">Katharigatta N.  Venugopala</span>, <span class="hlFld-ContribAuthor ">Wafa  Hourani</span>, <span class="hlFld-ContribAuthor ">Rakesh Kumar  Tekade</span>. </span><span class="cited-content_cbyCitation_article-title">Current advances in the clinical development of anti-tubercular agents. </span><span class="cited-content_cbyCitation_journal-name">Tuberculosis</span><span> <strong>2020,</strong> <em>125 </em>, 101989. <a href="https://doi.org/10.1016/j.tube.2020.101989" title="DOI URL">https://doi.org/10.1016/j.tube.2020.101989</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tube.2020.101989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tube.2020.101989%26sid%3Dliteratum%253Aachs%26jtitle%3DTuberculosis%26atitle%3DCurrent%252Badvances%252Bin%252Bthe%252Bclinical%252Bdevelopment%252Bof%252Banti-tubercular%252Bagents%26aulast%3DTetali%26aufirst%3DSamanvai%2BReddy%26date%3D2020%26volume%3D125%26spage%3D101989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Soong-Hyun  Kim</span>, <span class="hlFld-ContribAuthor ">Seri  Bae</span>, <span class="hlFld-ContribAuthor ">Minsoo  Song</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Development of Aminoacyl-tRNA Synthetase Inhibitors for Human Diseases: A Future Perspective. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2020,</strong> <em>10 </em>
                                    (12)
                                     , 1625. <a href="https://doi.org/10.3390/biom10121625" title="DOI URL">https://doi.org/10.3390/biom10121625</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom10121625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom10121625%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DRecent%252BDevelopment%252Bof%252BAminoacyl-tRNA%252BSynthetase%252BInhibitors%252Bfor%252BHuman%252BDiseases%25253A%252BA%252BFuture%252BPerspective%26aulast%3DKim%26aufirst%3DSoong-Hyun%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D12%26spage%3D1625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pedro F.  Dalberto</span>, <span class="hlFld-ContribAuthor ">Eduardo V.  de Souza</span>, <span class="hlFld-ContribAuthor ">Bruno L.  Abbadi</span>, <span class="hlFld-ContribAuthor ">Christiano E.  Neves</span>, <span class="hlFld-ContribAuthor ">Raoní S.  Rambo</span>, <span class="hlFld-ContribAuthor ">Alessandro S.  Ramos</span>, <span class="hlFld-ContribAuthor ">Fernanda S.  Macchi</span>, <span class="hlFld-ContribAuthor ">Pablo  Machado</span>, <span class="hlFld-ContribAuthor ">Cristiano V.  Bizarro</span>, <span class="hlFld-ContribAuthor ">Luiz A.  Basso</span>. </span><span class="cited-content_cbyCitation_article-title">Handling the Hurdles on the Way to Anti-tuberculosis Drug Development. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2020,</strong> <em>8 </em><a href="https://doi.org/10.3389/fchem.2020.586294" title="DOI URL">https://doi.org/10.3389/fchem.2020.586294</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2020.586294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2020.586294%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DHandling%252Bthe%252BHurdles%252Bon%252Bthe%252BWay%252Bto%252BAnti-tuberculosis%252BDrug%252BDevelopment%26aulast%3DDalberto%26aufirst%3DPedro%2BF.%26date%3D2020%26date%3D2020%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Théoneste  Umumararungu</span>, <span class="hlFld-ContribAuthor ">Marie Jeanne  Mukazayire</span>, <span class="hlFld-ContribAuthor ">Matabishi  Mpenda</span>, <span class="hlFld-ContribAuthor ">Marie Françoise  Mukanyangezi</span>, <span class="hlFld-ContribAuthor ">Jean Bosco  Nkuranga</span>, <span class="hlFld-ContribAuthor ">Janvier  Mukiza</span>, <span class="hlFld-ContribAuthor ">Emmanuel Oladayo  Olawode</span>. </span><span class="cited-content_cbyCitation_article-title">A review of recent advances in anti-tubercular drug development. </span><span class="cited-content_cbyCitation_journal-name">Indian Journal of Tuberculosis</span><span> <strong>2020,</strong> <em>67 </em>
                                    (4)
                                     , 539-559. <a href="https://doi.org/10.1016/j.ijtb.2020.07.017" title="DOI URL">https://doi.org/10.1016/j.ijtb.2020.07.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijtb.2020.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijtb.2020.07.017%26sid%3Dliteratum%253Aachs%26jtitle%3DIndian%2520Journal%2520of%2520Tuberculosis%26atitle%3DA%252Breview%252Bof%252Brecent%252Badvances%252Bin%252Banti-tubercular%252Bdrug%252Bdevelopment%26aulast%3DUmumararungu%26aufirst%3DTh%25C3%25A9oneste%26date%3D2020%26volume%3D67%26issue%3D4%26spage%3D539%26epage%3D559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher  Burke</span>, <span class="hlFld-ContribAuthor ">Monika  Jankute</span>, <span class="hlFld-ContribAuthor ">Patrick  Moynihan</span>, <span class="hlFld-ContribAuthor ">Ruben  Gonzalez del Rio</span>, <span class="hlFld-ContribAuthor ">Xiaojun  Li</span>, <span class="hlFld-ContribAuthor ">Jorge  Esquivias</span>, <span class="hlFld-ContribAuthor ">Joël  Lelièvre</span>, <span class="hlFld-ContribAuthor ">Jonathan A. G.  Cox</span>, <span class="hlFld-ContribAuthor ">James  Sacchettini</span>, <span class="hlFld-ContribAuthor ">Gurdyal S.  Besra</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a novel secondary phenotypic screen to identify hits within the mycobacterial protein synthesis pipeline. </span><span class="cited-content_cbyCitation_journal-name">FASEB BioAdvances</span><span> <strong>2020,</strong> <em>2 </em>
                                    (10)
                                     , 600-612. <a href="https://doi.org/10.1096/fba.2020-00022" title="DOI URL">https://doi.org/10.1096/fba.2020-00022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1096/fba.2020-00022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1096%2Ffba.2020-00022%26sid%3Dliteratum%253Aachs%26jtitle%3DFASEB%2520BioAdvances%26atitle%3DDevelopment%252Bof%252Ba%252Bnovel%252Bsecondary%252Bphenotypic%252Bscreen%252Bto%252Bidentify%252Bhits%252Bwithin%252Bthe%252Bmycobacterial%252Bprotein%252Bsynthesis%252Bpipeline%26aulast%3DBurke%26aufirst%3DChristopher%26date%3D2020%26date%3D2020%26volume%3D2%26issue%3D10%26spage%3D600%26epage%3D612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mariana Pereira  Silva</span>, <span class="hlFld-ContribAuthor ">Lucília  Saraiva</span>, <span class="hlFld-ContribAuthor ">Madalena  Pinto</span>, <span class="hlFld-ContribAuthor ">Maria Emília  Sousa</span>. </span><span class="cited-content_cbyCitation_article-title">Boronic Acids and Their Derivatives in Medicinal Chemistry: Synthesis and Biological Applications. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (18)
                                     , 4323. <a href="https://doi.org/10.3390/molecules25184323" title="DOI URL">https://doi.org/10.3390/molecules25184323</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25184323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25184323%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBoronic%252BAcids%252Band%252BTheir%252BDerivatives%252Bin%252BMedicinal%252BChemistry%25253A%252BSynthesis%252Band%252BBiological%252BApplications%26aulast%3DSilva%26aufirst%3DMariana%2BPereira%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D18%26spage%3D4323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sergey V.  Melnikov</span>, <span class="hlFld-ContribAuthor ">David L.  Stevens</span>, <span class="hlFld-ContribAuthor ">Xian  Fu</span>, <span class="hlFld-ContribAuthor ">Hui Si  Kwok</span>, <span class="hlFld-ContribAuthor ">Jin-Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Yue  Shen</span>, <span class="hlFld-ContribAuthor ">Jeffery  Sabina</span>, <span class="hlFld-ContribAuthor ">Kevin  Lee</span>, <span class="hlFld-ContribAuthor ">Harry  Lee</span>, <span class="hlFld-ContribAuthor ">Dieter  Söll</span>. </span><span class="cited-content_cbyCitation_article-title">Exploiting evolutionary trade-offs for posttreatment management of drug-resistant populations. </span><span class="cited-content_cbyCitation_journal-name">Proceedings of the National Academy of Sciences</span><span> <strong>2020,</strong> <em>117 </em>
                                    (30)
                                     , 17924-17931. <a href="https://doi.org/10.1073/pnas.2003132117" title="DOI URL">https://doi.org/10.1073/pnas.2003132117</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1073/pnas.2003132117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1073%2Fpnas.2003132117%26sid%3Dliteratum%253Aachs%26jtitle%3DProceedings%2520of%2520the%2520National%2520Academy%2520of%2520Sciences%26atitle%3DExploiting%252Bevolutionary%252Btrade-offs%252Bfor%252Bposttreatment%252Bmanagement%252Bof%252Bdrug-resistant%252Bpopulations%26aulast%3DMelnikov%26aufirst%3DSergey%2BV.%26date%3D2020%26date%3D2020%26volume%3D117%26issue%3D30%26spage%3D17924%26epage%3D17931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jessica  Plescia</span>, <span class="hlFld-ContribAuthor ">Nicolas  Moitessier</span>. </span><span class="cited-content_cbyCitation_article-title">Design and discovery of boronic acid drugs. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>195 </em>, 112270. <a href="https://doi.org/10.1016/j.ejmech.2020.112270" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112270</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112270%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bdiscovery%252Bof%252Bboronic%252Bacid%252Bdrugs%26aulast%3DPlescia%26aufirst%3DJessica%26date%3D2020%26volume%3D195%26spage%3D112270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gauri S.  Shetye</span>, <span class="hlFld-ContribAuthor ">Scott G.  Franzblau</span>, <span class="hlFld-ContribAuthor ">Sanghyun  Cho</span>. </span><span class="cited-content_cbyCitation_article-title">New tuberculosis drug targets, their inhibitors, and potential therapeutic impact. </span><span class="cited-content_cbyCitation_journal-name">Translational Research</span><span> <strong>2020,</strong> <em>220 </em>, 68-97. <a href="https://doi.org/10.1016/j.trsl.2020.03.007" title="DOI URL">https://doi.org/10.1016/j.trsl.2020.03.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.trsl.2020.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.trsl.2020.03.007%26sid%3Dliteratum%253Aachs%26jtitle%3DTranslational%2520Research%26atitle%3DNew%252Btuberculosis%252Bdrug%252Btargets%25252C%252Btheir%252Binhibitors%25252C%252Band%252Bpotential%252Btherapeutic%252Bimpact%26aulast%3DShetye%26aufirst%3DGauri%2BS.%26date%3D2020%26volume%3D220%26spage%3D68%26epage%3D97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark S.  Butler</span>, <span class="hlFld-ContribAuthor ">David L.  Paterson</span>. </span><span class="cited-content_cbyCitation_article-title">Antibiotics in the clinical pipeline in October 2019. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Antibiotics</span><span> <strong>2020,</strong> <em>73 </em>
                                    (6)
                                     , 329-364. <a href="https://doi.org/10.1038/s41429-020-0291-8" title="DOI URL">https://doi.org/10.1038/s41429-020-0291-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41429-020-0291-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41429-020-0291-8%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Antibiotics%26atitle%3DAntibiotics%252Bin%252Bthe%252Bclinical%252Bpipeline%252Bin%252BOctober%252B2019%26aulast%3DButler%26aufirst%3DMark%2BS.%26date%3D2020%26date%3D2020%26volume%3D73%26issue%3D6%26spage%3D329%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stanislav  Huszár</span>, <span class="hlFld-ContribAuthor ">Kelly  Chibale</span>, <span class="hlFld-ContribAuthor ">Vinayak  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">The quest for the holy grail: new antitubercular chemical entities, targets and strategies. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2020,</strong> <em>25 </em>
                                    (4)
                                     , 772-780. <a href="https://doi.org/10.1016/j.drudis.2020.02.003" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.02.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.02.003%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DThe%252Bquest%252Bfor%252Bthe%252Bholy%252Bgrail%25253A%252Bnew%252Bantitubercular%252Bchemical%252Bentities%25252C%252Btargets%252Band%252Bstrategies%26aulast%3DHusz%25C3%25A1r%26aufirst%3DStanislav%26date%3D2020%26volume%3D25%26issue%3D4%26spage%3D772%26epage%3D780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dong  Cai</span>, <span class="hlFld-ContribAuthor ">Tai  Li</span>, <span class="hlFld-ContribAuthor ">Qian  Xie</span>, <span class="hlFld-ContribAuthor ">Xiaofei  Yu</span>, <span class="hlFld-ContribAuthor ">Wei  Xu</span>, <span class="hlFld-ContribAuthor ">Yu  Chen</span>, <span class="hlFld-ContribAuthor ">Zhe  Jin</span>, <span class="hlFld-ContribAuthor ">Chun  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Characterization, and Biological Evaluation of Novel 7-Oxo-7H-thiazolo[3,2-b]-1,2,4-triazine-2-carboxylic Acid Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (6)
                                     , 1307. <a href="https://doi.org/10.3390/molecules25061307" title="DOI URL">https://doi.org/10.3390/molecules25061307</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25061307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25061307%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%25252C%252BCharacterization%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252B7-Oxo-7H-thiazolo%25255B3%25252C2-b%25255D-1%25252C2%25252C4-triazine-2-carboxylic%252BAcid%252BDerivatives%26aulast%3DCai%26aufirst%3DDong%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D6%26spage%3D1307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenzhu  Dong</span>, <span class="hlFld-ContribAuthor ">Shanshan  Li</span>, <span class="hlFld-ContribAuthor ">Shu’an  Wen</span>, <span class="hlFld-ContribAuthor ">Wei  Jing</span>, <span class="hlFld-ContribAuthor ">Jin  Shi</span>, <span class="hlFld-ContribAuthor ">Yifeng  Ma</span>, <span class="hlFld-ContribAuthor ">Fengmin  Huo</span>, <span class="hlFld-ContribAuthor ">Fei  Gao</span>, <span class="hlFld-ContribAuthor ">Yu  Pang</span>, <span class="hlFld-ContribAuthor ">Jie  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">In Vitro
              Susceptibility Testing of GSK656 against
              Mycobacterium
              Species. </span><span class="cited-content_cbyCitation_journal-name">Antimicrobial Agents and Chemotherapy</span><span> <strong>2020,</strong> <em>64 </em>
                                    (2)
                                     <a href="https://doi.org/10.1128/AAC.01577-19" title="DOI URL">https://doi.org/10.1128/AAC.01577-19</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/AAC.01577-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FAAC.01577-19%26sid%3Dliteratum%253Aachs%26jtitle%3DAntimicrobial%2520Agents%2520and%2520Chemotherapy%26atitle%3DIn%252BVitro%252BSusceptibility%252BTesting%252Bof%252BGSK656%252Bagainst%252BMycobacterium%252BSpecies%26aulast%3DDong%26aufirst%3DWenzhu%26date%3D2020%26volume%3D64%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramandeep  Singh</span>, <span class="hlFld-ContribAuthor ">Pradeep  Kumar</span>, <span class="hlFld-ContribAuthor ">Kapil  Tahlan</span>. </span><span class="cited-content_cbyCitation_article-title">Drugs against Mycobacterium tuberculosis. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 139-170. <a href="https://doi.org/10.1016/B978-0-12-818480-6.00006-0" title="DOI URL">https://doi.org/10.1016/B978-0-12-818480-6.00006-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818480-6.00006-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818480-6.00006-0%26sid%3Dliteratum%253Aachs%26atitle%3DDrugs%252Bagainst%252BMycobacterium%252Btuberculosis%26aulast%3DSingh%26aufirst%3DRamandeep%26date%3D2020%26spage%3D139%26epage%3D170%26pub%3DElsevier%26atitle%3DDrug%252BDiscovery%252BTargeting%252BDrug-Resistant%252BBacteria%26date%3D2020%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yolanda  Gonzalez</span>, <span class="hlFld-ContribAuthor ">Silvia  Guzmán-Beltrán</span>, <span class="hlFld-ContribAuthor ">Laura E.  Carreto-Binaghi</span>, <span class="hlFld-ContribAuthor ">Esmeralda  Juárez</span>. </span><span class="cited-content_cbyCitation_article-title">Translational research for therapy against tuberculosis. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 53-73. <a href="https://doi.org/10.1016/B978-0-12-819811-7.00004-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-819811-7.00004-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-819811-7.00004-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-819811-7.00004-7%26sid%3Dliteratum%253Aachs%26atitle%3DTranslational%252Bresearch%252Bfor%252Btherapy%252Bagainst%252Btuberculosis%26aulast%3DGonzalez%26aufirst%3DYolanda%26date%3D2020%26spage%3D53%26epage%3D73%26pub%3DElsevier%26atitle%3DNanotechnology%252BBased%252BApproaches%252Bfor%252BTuberculosis%252BTreatment%26date%3D2020%26volume%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria  Lukarska</span>, <span class="hlFld-ContribAuthor ">Andrés  Palencia</span>. </span><span class="cited-content_cbyCitation_article-title">Aminoacyl-tRNA synthetases as drug targets. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 321-350. <a href="https://doi.org/10.1016/bs.enz.2020.07.001" title="DOI URL">https://doi.org/10.1016/bs.enz.2020.07.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.enz.2020.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.enz.2020.07.001%26sid%3Dliteratum%253Aachs%26atitle%3DAminoacyl-tRNA%252Bsynthetases%252Bas%252Bdrug%252Btargets%26aulast%3DLukarska%26aufirst%3DMaria%26date%3D2020%26spage%3D321%26epage%3D350%26pub%3DElsevier%26atitle%3DBiology%252Bof%252BAminoacyl-tRNA%252BSynthetases%26date%3D2020%26volume%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Ren</span>, <span class="hlFld-ContribAuthor ">Wei  Shi</span>, <span class="hlFld-ContribAuthor ">Damin  Zhao</span>, <span class="hlFld-ContribAuthor ">Qinglin  Wang</span>, <span class="hlFld-ContribAuthor ">Xiayun  Chang</span>, <span class="hlFld-ContribAuthor ">Xiangyi  He</span>, <span class="hlFld-ContribAuthor ">Xiaojin  Wang</span>, <span class="hlFld-ContribAuthor ">Yong  Gao</span>, <span class="hlFld-ContribAuthor ">Peng  Lu</span>, <span class="hlFld-ContribAuthor ">Xiquan  Zhang</span>, <span class="hlFld-ContribAuthor ">Hongjiang  Xu</span>, <span class="hlFld-ContribAuthor ">Yinsheng  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (2)
                                     , 115236. <a href="https://doi.org/10.1016/j.bmc.2019.115236" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.115236</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.115236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.115236%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bboron-containing%252Bdiphenylpyrimidines%252Bas%252Bpotent%252BBTK%252Band%252BJAK3%252Bdual%252Binhibitors%26aulast%3DRen%26aufirst%3DJing%26date%3D2020%26volume%3D28%26issue%3D2%26spage%3D115236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anzheng  Nie</span>, <span class="hlFld-ContribAuthor ">Bao  Sun</span>, <span class="hlFld-ContribAuthor ">Zhihui  Fu</span>, <span class="hlFld-ContribAuthor ">Dongsheng  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Roles of aminoacyl-tRNA synthetases in immune regulation and immune diseases. </span><span class="cited-content_cbyCitation_journal-name">Cell Death & Disease</span><span> <strong>2019,</strong> <em>10 </em>
                                    (12)
                                     <a href="https://doi.org/10.1038/s41419-019-2145-5" title="DOI URL">https://doi.org/10.1038/s41419-019-2145-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41419-019-2145-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41419-019-2145-5%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Death%2520%2526%2520Disease%26atitle%3DRoles%252Bof%252Baminoacyl-tRNA%252Bsynthetases%252Bin%252Bimmune%252Bregulation%252Band%252Bimmune%252Bdiseases%26aulast%3DNie%26aufirst%3DAnzheng%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Collette S.  Guy</span>, <span class="hlFld-ContribAuthor ">Kathryn  Murray</span>, <span class="hlFld-ContribAuthor ">Matthew I.  Gibson</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Fullam</span>. </span><span class="cited-content_cbyCitation_article-title">Dimeric benzoboroxoles for targeted activity against
              Mycobacterium tuberculosis. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (43)
                                     , 9524-9528. <a href="https://doi.org/10.1039/C9OB02222H" title="DOI URL">https://doi.org/10.1039/C9OB02222H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9OB02222H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9OB02222H%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DDimeric%252Bbenzoboroxoles%252Bfor%252Btargeted%252Bactivity%252Bagainst%252BMycobacterium%252Btuberculosis%26aulast%3DGuy%26aufirst%3DCollette%2BS.%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D43%26spage%3D9524%26epage%3D9528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Galyna P.  Volynets</span>, <span class="hlFld-ContribAuthor ">Sergiy A.  Starosyla</span>, <span class="hlFld-ContribAuthor ">Mariia Yu.  Rybak</span>, <span class="hlFld-ContribAuthor ">Volodymyr G.  Bdzhola</span>, <span class="hlFld-ContribAuthor ">Oksana P.  Kovalenko</span>, <span class="hlFld-ContribAuthor ">Vasyl S.  Vdovin</span>, <span class="hlFld-ContribAuthor ">Sergiy M.  Yarmoluk</span>, <span class="hlFld-ContribAuthor ">Michail A.  Tukalo</span>. </span><span class="cited-content_cbyCitation_article-title">Dual-targeted hit identification using pharmacophore screening. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computer-Aided Molecular Design</span><span> <strong>2019,</strong> <em>33 </em>
                                    (11)
                                     , 955-964. <a href="https://doi.org/10.1007/s10822-019-00245-5" title="DOI URL">https://doi.org/10.1007/s10822-019-00245-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10822-019-00245-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10822-019-00245-5%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computer-Aided%2520Molecular%2520Design%26atitle%3DDual-targeted%252Bhit%252Bidentification%252Busing%252Bpharmacophore%252Bscreening%26aulast%3DVolynets%26aufirst%3DGalyna%2BP.%26date%3D2019%26date%3D2019%26volume%3D33%26issue%3D11%26spage%3D955%26epage%3D964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guilherme Felipe Santos  Fernandes</span>, <span class="hlFld-ContribAuthor ">William Alexander  Denny</span>, <span class="hlFld-ContribAuthor ">Jean Leandro  Dos Santos</span>. </span><span class="cited-content_cbyCitation_article-title">Boron in drug design: Recent advances in the development of new therapeutic agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>179 </em>, 791-804. <a href="https://doi.org/10.1016/j.ejmech.2019.06.092" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.092</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.092%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBoron%252Bin%252Bdrug%252Bdesign%25253A%252BRecent%252Badvances%252Bin%252Bthe%252Bdevelopment%252Bof%252Bnew%252Btherapeutic%252Bagents%26aulast%3DFernandes%26aufirst%3DGuilherme%2BFelipe%2BSantos%26date%3D2019%26volume%3D179%26spage%3D791%26epage%3D804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amanda  Mabhula</span>, <span class="hlFld-ContribAuthor ">Vinayak  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">Drug-resistance in
              Mycobacterium tuberculosis
              : where we stand. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2019,</strong> <em>10 </em>
                                    (8)
                                     , 1342-1360. <a href="https://doi.org/10.1039/C9MD00057G" title="DOI URL">https://doi.org/10.1039/C9MD00057G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9MD00057G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9MD00057G%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DDrug-resistance%252Bin%252BMycobacterium%252Btuberculosis%252B%25253A%252Bwhere%252Bwe%252Bstand%26aulast%3DMabhula%26aufirst%3DAmanda%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D8%26spage%3D1342%26epage%3D1360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Panpan  Zhang</span>, <span class="hlFld-ContribAuthor ">Shutao  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Recent development of leucyl-tRNA synthetase inhibitors as antimicrobial agents. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2019,</strong> <em>10 </em>
                                    (8)
                                     , 1329-1341. <a href="https://doi.org/10.1039/C9MD00139E" title="DOI URL">https://doi.org/10.1039/C9MD00139E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9MD00139E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9MD00139E%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DRecent%252Bdevelopment%252Bof%252Bleucyl-tRNA%252Bsynthetase%252Binhibitors%252Bas%252Bantimicrobial%252Bagents%26aulast%3DZhang%26aufirst%3DPanpan%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D8%26spage%3D1329%26epage%3D1341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nam Hoon  Kwon</span>, <span class="hlFld-ContribAuthor ">Paul L.  Fox</span>, <span class="hlFld-ContribAuthor ">Sunghoon  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Aminoacyl-tRNA synthetases as therapeutic targets. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2019,</strong> <em>18 </em>
                                    (8)
                                     , 629-650. <a href="https://doi.org/10.1038/s41573-019-0026-3" title="DOI URL">https://doi.org/10.1038/s41573-019-0026-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41573-019-0026-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41573-019-0026-3%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DAminoacyl-tRNA%252Bsynthetases%252Bas%252Btherapeutic%252Btargets%26aulast%3DKwon%26aufirst%3DNam%2BHoon%26date%3D2019%26date%3D2019%26volume%3D18%26issue%3D8%26spage%3D629%26epage%3D650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David  Tenero</span>, <span class="hlFld-ContribAuthor ">Geo  Derimanov</span>, <span class="hlFld-ContribAuthor ">Alex  Carlton</span>, <span class="hlFld-ContribAuthor ">John  Tonkyn</span>, <span class="hlFld-ContribAuthor ">Matt  Davies</span>, <span class="hlFld-ContribAuthor ">Simon  Cozens</span>, <span class="hlFld-ContribAuthor ">Stephanie  Gresham</span>, <span class="hlFld-ContribAuthor ">Alison  Gaudion</span>, <span class="hlFld-ContribAuthor ">Adeep  Puri</span>, <span class="hlFld-ContribAuthor ">Morris  Muliaditan</span>, <span class="hlFld-ContribAuthor ">Joaquin  Rullas-Trincado</span>, <span class="hlFld-ContribAuthor ">Alfonso  Mendoza-Losana</span>, <span class="hlFld-ContribAuthor ">Andrew  Skingsley</span>, <span class="hlFld-ContribAuthor ">David  Barros-Aguirre</span>. </span><span class="cited-content_cbyCitation_article-title">First-Time-in-Human Study and Prediction of Early Bactericidal Activity for GSK3036656, a Potent Leucyl-tRNA Synthetase Inhibitor for Tuberculosis Treatment. </span><span class="cited-content_cbyCitation_journal-name">Antimicrobial Agents and Chemotherapy</span><span> <strong>2019,</strong> <em>63 </em>
                                    (8)
                                     <a href="https://doi.org/10.1128/AAC.00240-19" title="DOI URL">https://doi.org/10.1128/AAC.00240-19</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/AAC.00240-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FAAC.00240-19%26sid%3Dliteratum%253Aachs%26jtitle%3DAntimicrobial%2520Agents%2520and%2520Chemotherapy%26atitle%3DFirst-Time-in-Human%252BStudy%252Band%252BPrediction%252Bof%252BEarly%252BBactericidal%252BActivity%252Bfor%252BGSK3036656%25252C%252Ba%252BPotent%252BLeucyl-tRNA%252BSynthetase%252BInhibitor%252Bfor%252BTuberculosis%252BTreatment%26aulast%3DTenero%26aufirst%3DDavid%26date%3D2019%26volume%3D63%26issue%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eveline  Torfs</span>, <span class="hlFld-ContribAuthor ">Tatiana  Piller</span>, <span class="hlFld-ContribAuthor ">Paul  Cos</span>, <span class="hlFld-ContribAuthor ">Davie  Cappoen</span>. </span><span class="cited-content_cbyCitation_article-title">Opportunities for Overcoming Mycobacterium tuberculosis Drug Resistance: Emerging Mycobacterial Targets and Host-Directed Therapy. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (12)
                                     , 2868. <a href="https://doi.org/10.3390/ijms20122868" title="DOI URL">https://doi.org/10.3390/ijms20122868</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20122868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20122868%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DOpportunities%252Bfor%252BOvercoming%252BMycobacterium%252Btuberculosis%252BDrug%252BResistance%25253A%252BEmerging%252BMycobacterial%252BTargets%252Band%252BHost-Directed%252BTherapy%26aulast%3DTorfs%26aufirst%3DEveline%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D12%26spage%3D2868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hawra  Al-Ghafli</span>, <span class="hlFld-ContribAuthor ">Sahal  Al-Hajoj</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical Management of Drug-resistant Mycobacterium tuberculosis Strains: Pathogen-targeted Versus Host-directed Treatment Approaches. </span><span class="cited-content_cbyCitation_journal-name">Current Pharmaceutical Biotechnology</span><span> <strong>2019,</strong> <em>20 </em>
                                    (4)
                                     , 272-284. <a href="https://doi.org/10.2174/1389201019666180731120544" title="DOI URL">https://doi.org/10.2174/1389201019666180731120544</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1389201019666180731120544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1389201019666180731120544%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Pharmaceutical%2520Biotechnology%26atitle%3DClinical%252BManagement%252Bof%252BDrug-resistant%252BMycobacterium%252Btuberculosis%252BStrains%25253A%252BPathogen-targeted%252BVersus%252BHost-directed%252BTreatment%252BApproaches%26aulast%3DAl-Ghafli%26aufirst%3DHawra%26date%3D2019%26volume%3D20%26issue%3D4%26spage%3D272%26epage%3D284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simon F.K.  Lee</span>, <span class="hlFld-ContribAuthor ">Barbara E.  Laughon</span>, <span class="hlFld-ContribAuthor ">Timothy D.  McHugh</span>, <span class="hlFld-ContribAuthor ">Marc  Lipman</span>. </span><span class="cited-content_cbyCitation_article-title">New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Pulmonary Medicine</span><span> <strong>2019,</strong> <em>25 </em>
                                    (3)
                                     , 271-280. <a href="https://doi.org/10.1097/MCP.0000000000000570" title="DOI URL">https://doi.org/10.1097/MCP.0000000000000570</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/MCP.0000000000000570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FMCP.0000000000000570%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Pulmonary%2520Medicine%26atitle%3DNew%252Bdrugs%252Bto%252Btreat%252Bdifficult%252Btuberculous%252Band%252Bnontuberculous%252Bmycobacterial%252Bpulmonary%252Bdisease%26aulast%3DLee%26aufirst%3DSimon%2BF.K.%26date%3D2019%26volume%3D25%26issue%3D3%26spage%3D271%26epage%3D280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Frederick S.  Buckner</span>, <span class="hlFld-ContribAuthor ">Ranae M.  Ranade</span>, <span class="hlFld-ContribAuthor ">J. Robert  Gillespie</span>, <span class="hlFld-ContribAuthor ">Sayaka  Shibata</span>, <span class="hlFld-ContribAuthor ">Matthew A.  Hulverson</span>, <span class="hlFld-ContribAuthor ">Zhongsheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Wenlin  Huang</span>, <span class="hlFld-ContribAuthor ">Ryan  Choi</span>, <span class="hlFld-ContribAuthor ">Christophe L. M. J.  Verlinde</span>, <span class="hlFld-ContribAuthor ">Wim G. J.  Hol</span>, <span class="hlFld-ContribAuthor ">Atsuko  Ochida</span>, <span class="hlFld-ContribAuthor ">Yuichiro  Akao</span>, <span class="hlFld-ContribAuthor ">Robert K. M.  Choy</span>, <span class="hlFld-ContribAuthor ">Wesley C.  Van Voorhis</span>, <span class="hlFld-ContribAuthor ">Sam L. M.  Arnold</span>, <span class="hlFld-ContribAuthor ">Rajiv S.  Jumani</span>, <span class="hlFld-ContribAuthor ">Christopher D.  Huston</span>, <span class="hlFld-ContribAuthor ">Erkang  Fan</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization of Methionyl tRNA-Synthetase Inhibitors for Treatment of
              Cryptosporidium
              Infection. </span><span class="cited-content_cbyCitation_journal-name">Antimicrobial Agents and Chemotherapy</span><span> <strong>2019,</strong> <em>63 </em>
                                    (4)
                                     <a href="https://doi.org/10.1128/AAC.02061-18" title="DOI URL">https://doi.org/10.1128/AAC.02061-18</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/AAC.02061-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FAAC.02061-18%26sid%3Dliteratum%253Aachs%26jtitle%3DAntimicrobial%2520Agents%2520and%2520Chemotherapy%26atitle%3DOptimization%252Bof%252BMethionyl%252BtRNA-Synthetase%252BInhibitors%252Bfor%252BTreatment%252Bof%252BCryptosporidium%252BInfection%26aulast%3DBuckner%26aufirst%3DFrederick%2BS.%26date%3D2019%26volume%3D63%26issue%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anju Choorakottayil  Pushkaran</span>, <span class="hlFld-ContribAuthor ">Raja  Biswas</span>, <span class="hlFld-ContribAuthor ">C. Gopi  Mohan</span>. </span><span class="cited-content_cbyCitation_article-title">Impact of Target-Based Drug Design in Anti-bacterial Drug Discovery for the Treatment of Tuberculosis. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 307-346. <a href="https://doi.org/10.1007/978-3-030-05282-9_10" title="DOI URL">https://doi.org/10.1007/978-3-030-05282-9_10</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-05282-9_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-05282-9_10%26sid%3Dliteratum%253Aachs%26atitle%3DImpact%252Bof%252BTarget-Based%252BDrug%252BDesign%252Bin%252BAnti-bacterial%252BDrug%252BDiscovery%252Bfor%252Bthe%252BTreatment%252Bof%252BTuberculosis%26aulast%3DPushkaran%26aufirst%3DAnju%2BChoorakottayil%26date%3D2019%26date%3D2019%26spage%3D307%26epage%3D346%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DStructural%252BBioinformatics%25253A%252BApplications%252Bin%252BPreclinical%252BDrug%252BDiscovery%252BProcess%26aulast%3DMohan%26aufirst%3DC.%2BGopi%26date%3D2019%26volume%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Steven J.  Berthel</span>, <span class="hlFld-ContribAuthor ">Christopher B.  Cooper</span>, <span class="hlFld-ContribAuthor ">Nader  Fotouhi</span>. </span><span class="cited-content_cbyCitation_article-title">Tuberculosis. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 1-25. <a href="https://doi.org/10.1016/bs.armc.2019.05.004" title="DOI URL">https://doi.org/10.1016/bs.armc.2019.05.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.armc.2019.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.armc.2019.05.004%26sid%3Dliteratum%253Aachs%26atitle%3DTuberculosis%26aulast%3DBerthel%26aufirst%3DSteven%2BJ.%26date%3D2019%26spage%3D1%26epage%3D25%26pub%3DElsevier%26atitle%3DMedicinal%252BChemistry%252BApproaches%252Bto%252BTuberculosis%252Band%252BTrypanosomiasis%26date%3D2019%26volume%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M Daben  J Libardo</span>, <span class="hlFld-ContribAuthor ">Helena IM  Boshoff</span>, <span class="hlFld-ContribAuthor ">Clifton E  Barry</span>. </span><span class="cited-content_cbyCitation_article-title">The present state of the tuberculosis drug development pipeline. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Pharmacology</span><span> <strong>2018,</strong> <em>42 </em>, 81-94. <a href="https://doi.org/10.1016/j.coph.2018.08.001" title="DOI URL">https://doi.org/10.1016/j.coph.2018.08.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.coph.2018.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.coph.2018.08.001%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Pharmacology%26atitle%3DThe%252Bpresent%252Bstate%252Bof%252Bthe%252Btuberculosis%252Bdrug%252Bdevelopment%252Bpipeline%26aulast%3DJ%2BLibardo%26aufirst%3DM%2BDaben%26date%3D2018%26volume%3D42%26spage%3D81%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joanna C  .Evans</span>, <span class="hlFld-ContribAuthor ">Valerie  Mizrahi</span>. </span><span class="cited-content_cbyCitation_article-title">Priming the tuberculosis drug pipeline: new antimycobacterial targets and agents. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Microbiology</span><span> <strong>2018,</strong> <em>45 </em>, 39-46. <a href="https://doi.org/10.1016/j.mib.2018.02.006" title="DOI URL">https://doi.org/10.1016/j.mib.2018.02.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.mib.2018.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.mib.2018.02.006%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Microbiology%26atitle%3DPriming%252Bthe%252Btuberculosis%252Bdrug%252Bpipeline%25253A%252Bnew%252Bantimycobacterial%252Btargets%252Band%252Bagents%26aulast%3D.Evans%26aufirst%3DJoanna%2BC%26date%3D2018%26volume%3D45%26spage%3D39%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manu  De Rycker</span>, <span class="hlFld-ContribAuthor ">Beatriz  Baragaña</span>, <span class="hlFld-ContribAuthor ">Suzanne L.  Duce</span>, <span class="hlFld-ContribAuthor ">Ian H.  Gilbert</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges and recent progress in drug discovery for tropical diseases. </span><span class="cited-content_cbyCitation_journal-name">Nature</span><span> <strong>2018,</strong> <em>559 </em>
                                    (7715)
                                     , 498-506. <a href="https://doi.org/10.1038/s41586-018-0327-4" title="DOI URL">https://doi.org/10.1038/s41586-018-0327-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41586-018-0327-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41586-018-0327-4%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%26atitle%3DChallenges%252Band%252Brecent%252Bprogress%252Bin%252Bdrug%252Bdiscovery%252Bfor%252Btropical%252Bdiseases%26aulast%3DDe%2BRycker%26aufirst%3DManu%26date%3D2018%26date%3D2018%26volume%3D559%26issue%3D7715%26spage%3D498%26epage%3D506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessio  Nocentini</span>, <span class="hlFld-ContribAuthor ">Claudiu T.  Supuran</span>, <span class="hlFld-ContribAuthor ">Jean-Yves  Winum</span>. </span><span class="cited-content_cbyCitation_article-title">Benzoxaborole compounds for therapeutic uses: a patent review (2010- 2018). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2018,</strong> <em>28 </em>
                                    (6)
                                     , 493-504. <a href="https://doi.org/10.1080/13543776.2018.1473379" title="DOI URL">https://doi.org/10.1080/13543776.2018.1473379</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2018.1473379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2018.1473379%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DBenzoxaborole%252Bcompounds%252Bfor%252Btherapeutic%252Buses%25253A%252Ba%252Bpatent%252Breview%252B%2525282010-%252B2018%252529%26aulast%3DNocentini%26aufirst%3DAlessio%26date%3D2018%26date%3D2018%26volume%3D28%26issue%3D6%26spage%3D493%26epage%3D504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gautam R.  Mereddy</span>, <span class="hlFld-ContribAuthor ">Anjali  Chakradhar</span>, <span class="hlFld-ContribAuthor ">Ryan M.  Rutkoski</span>, <span class="hlFld-ContribAuthor ">Subash C.  Jonnalagadda</span>. </span><span class="cited-content_cbyCitation_article-title">Benzoboroxoles: Synthesis and applications in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Organometallic Chemistry</span><span> <strong>2018,</strong> <em>865 </em>, 12-22. <a href="https://doi.org/10.1016/j.jorganchem.2018.03.017" title="DOI URL">https://doi.org/10.1016/j.jorganchem.2018.03.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jorganchem.2018.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jorganchem.2018.03.017%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Organometallic%2520Chemistry%26atitle%3DBenzoboroxoles%25253A%252BSynthesis%252Band%252Bapplications%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DMereddy%26aufirst%3DGautam%2BR.%26date%3D2018%26volume%3D865%26spage%3D12%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kai  Lv</span>, <span class="hlFld-ContribAuthor ">Zeyu  Tao</span>, <span class="hlFld-ContribAuthor ">Qian  Liu</span>, <span class="hlFld-ContribAuthor ">Lu  Yang</span>, <span class="hlFld-ContribAuthor ">Bin  Wang</span>, <span class="hlFld-ContribAuthor ">Shuo  Wu</span>, <span class="hlFld-ContribAuthor ">Apeng  Wang</span>, <span class="hlFld-ContribAuthor ">Menghao  Huang</span>, <span class="hlFld-ContribAuthor ">Mingliang  Liu</span>, <span class="hlFld-ContribAuthor ">Yu  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and antitubercular evaluation of benzothiazinones containing a piperidine moiety. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>151 </em>, 1-8. <a href="https://doi.org/10.1016/j.ejmech.2018.03.060" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.03.060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.03.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.03.060%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bantitubercular%252Bevaluation%252Bof%252Bbenzothiazinones%252Bcontaining%252Ba%252Bpiperidine%252Bmoiety%26aulast%3DLv%26aufirst%3DKai%26date%3D2018%26volume%3D151%26spage%3D1%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/medium/jm-2017-00631g_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00631&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/medium/jm-2017-00631g_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0001.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Bedaquiline, delamanid, and selected TB drug candidates in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00631&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/medium/jm-2017-00631g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. 3-Aminomethyl 4-halogen benzoxaborole inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00631&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/medium/jm-2017-00631g_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0004.jpeg" id="rightTab-GRAPHIC-d97e1604-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00631&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) when R = alkyl, alkyl bromide or alkyl iodide, K<sub>2</sub>CO<sub>3</sub>, DMF, heat; when R = aryl, arylboronic acid, Cu(OAc)<sub>2</sub>, TEA, DCM; (b) (Pin)<sub>2</sub>B<sub>2</sub>, KOAc, PdCl<sub>2</sub>(dppf), THF, reflux; (c) CH<sub>3</sub>NO<sub>2</sub>, NaOH, water/THF; (d) ethylene glycol, TsOH, toluene, Dean–Stark apparatus, reflux; (e) (1) BuLi, B(OMe)<sub>3</sub>, THF, −78 °C; (2) 2 N HCl, rt; (f) CH<sub>3</sub>NO<sub>2</sub>, NaOH, water/THF; (g) (1) Raney Ni, H<sub>2</sub>, NH<sub>3</sub>/EtOH, then HCl/Et<sub>2</sub>O; (2) di-<i>tert</i>-butyl dicarbonate, TEA, DCM, 0 °C; (h) when X = Cl, NCS, DMF, heat or SO<sub>2</sub>Cl<sub>2</sub>, AcOH, rt; when X = Br, NBS, CH<sub>3</sub>CN, heat; (i) TFA, DCM, then HCl; (j) when X = Cl, NCS, DMF, heat; when X = Br, NBS, CH<sub>3</sub>CN, heat; (k) Raney Ni, H<sub>2</sub>, NH<sub>3</sub>/EtOH, then HCl/Et<sub>2</sub>O; (l) chiral SFC separation.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/medium/jm-2017-00631g_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0005.jpeg" id="rightTab-GRAPHIC-d97e1767-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00631&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) di-<i>tert</i>-butyl dicarbonate, TEA, DCM, 0 °C; (b) (1) when X = Cl, NCS, DMF, heat; when X = Br, NBS, CH<sub>3</sub>CN, heat; (2) TFA, DCM, then HCl; (c) BBr<sub>3</sub>, DCM, −78 °C; (d) di-<i>tert</i>-butyl dicarbonate, TEA, DCM, 0 °C; (e) alkyl bromide, <i>t</i>-BuOK, DMSO, 90 °C; (f) (1) when X = Cl, NCS, DMF, heat or SO<sub>2</sub>Cl<sub>2</sub>, AcOH, rt; when X = Br, NBS, CH<sub>3</sub>CN, heat; (2) TFA, DCM, then HCl.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/medium/jm-2017-00631g_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0006.jpeg" id="rightTab-GRAPHIC-d97e1889-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00631&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) dihydropyran, PPTS (cat.), DCM; (b) Tf<sub>2</sub>O, pyridine, DCM, 0 °C; (c) (Pin)<sub>2</sub>B<sub>2</sub>, PdCl<sub>2</sub>(dppf), KOAc, THF, reflux; (d) CH<sub>3</sub>NO<sub>2</sub>, NaOH, THF; (e) conc HCl; (f) (1) Raney Ni, H<sub>2</sub>, NH<sub>3</sub>/EtOH, then HCl/EtOH; (2) di-<i>tert</i>-butyl dicarbonate, TEA, DCM, 0 °C; (g) alkyl bromide or alkyl iodide, K<sub>2</sub>CO<sub>3</sub>, DMF, heat; (h) TFA, DCM, then HCl.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/medium/jm-2017-00631g_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0007.jpeg" id="rightTab-GRAPHIC-d97e1936-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00631&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) alkyl bromide, K<sub>2</sub>CO<sub>3</sub>, DMF, heat; (b) CH(OMe)<sub>3</sub>, H<sub>2</sub>SO<sub>4</sub>, MeOH, reflux; (c) (1) BuLi, B(OMe)<sub>3</sub>, THF, −78 °C; (2) 2 N HCl, rt; (d) CH<sub>3</sub>NO<sub>2</sub>, NaOH, water/THF; (e) Raney Ni, H<sub>2</sub>, NH<sub>3</sub>/EtOH, then HCl/EtOH.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/medium/jm-2017-00631g_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0008.jpeg" id="rightTab-GRAPHIC-d97e2052-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00631&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) CH<sub>2</sub>Br<sub>2</sub> (<i>n</i> = 1) or BrCH<sub>2</sub>CH<sub>2</sub>Br (<i>n</i> = 2), K<sub>2</sub>CO<sub>3</sub>, DMF, heat; (b) (Pin)<sub>2</sub>B<sub>2</sub>, KOAc, PdCl<sub>2</sub>(dppf), dioxane, reflux; (c) CH<sub>3</sub>NO<sub>2</sub>, NaOH, THF; (d) when X = Cl, NCS, DMF, heat or SO<sub>2</sub>Cl<sub>2</sub>, AcOH, rt; when X = Br, NBS, CH<sub>3</sub>CN; (e) Raney Ni, H<sub>2</sub>, NH<sub>3</sub>/EtOH, then HCl/EtOH; (f) chiral SFC separation.</p></p></figure><figure data-id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/medium/jm-2017-00631g_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. 3-Aminomethyl 4-halogen benzoxaborole inhibitors <b>23a</b> and <b>24a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00631/20171006/images/large/jm-2017-00631g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00631&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i61">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85240" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85240" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 30 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">WHO</span><span class="NLM_x">. </span><span> </span><span class="NLM_article-title">Global Tuberculosis Report 2016</span>. <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.who.int/tb/publications/global_report/en/" class="extLink">http://www.who.int/tb/publications/global_report/en/</a> (accessed November 22, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=WHO.+Global+Tuberculosis+Report+2016.+World+Health+Organization%3A+Geneva%2C+2016%3B+http%3A%2F%2Fwww.who.int%2Ftb%2Fpublications%2Fglobal_report%2Fen%2F+%28accessed+November+22%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DGlobal%2520Tuberculosis%2520Report%25202016%26pub%3DWorld%2520Health%2520Organization%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Coker, R. J.</span><span> </span><span class="NLM_article-title">Multidrug-resistant tuberculosis: public health challenges</span> <span class="citation_source-journal">Trop. Med. Int. Health</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span><span class="refDoi"> DOI: 10.1046/j.1365-3156.2003.01156.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1046%2Fj.1365-3156.2003.01156.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=14728604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252FjtVyrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=25-40&author=R.+J.+Coker&title=Multidrug-resistant+tuberculosis%3A+public+health+challenges&doi=10.1046%2Fj.1365-3156.2003.01156.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Review: multidrug-resistant tuberculosis: public health challenges</span></div><div class="casAuthors">Coker Richard J</div><div class="citationInfo"><span class="NLM_cas:title">Tropical medicine & international health : TM & IH</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-40</span>
        ISSN:<span class="NLM_cas:issn">1360-2276</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHu6CcloILkzC850By6mxpfW6udTcc2eY24x9gzneKaLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252FjtVyrtw%253D%253D&md5=ff2e35bac2f25869857aa72fc7d77238</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-3156.2003.01156.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-3156.2003.01156.x%26sid%3Dliteratum%253Aachs%26aulast%3DCoker%26aufirst%3DR.%2BJ.%26atitle%3DMultidrug-resistant%2520tuberculosis%253A%2520public%2520health%2520challenges%26jtitle%3DTrop.%2520Med.%2520Int.%2520Health%26date%3D2004%26volume%3D9%26spage%3D25%26epage%3D40%26doi%3D10.1046%2Fj.1365-3156.2003.01156.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Esposito, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Ambrosio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadolini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaaf, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caminero Luna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Centis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matteelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blasi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliori, G. B.</span><span> </span><span class="NLM_article-title">ERS/WHO tuberculosis consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">811</span><span class="NLM_x">–</span> <span class="NLM_lpage">815</span><span class="refDoi"> DOI: 10.1183/09031936.00060414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1183%2F09031936.00060414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=24833763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A280%3ADC%252BC2cjjt1OmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2014&pages=811-815&author=S.+Espositoauthor=L.+D%E2%80%99Ambrosioauthor=M.+Tadoliniauthor=H.+S.+Schaafauthor=J.+Caminero+Lunaauthor=B.+Maraisauthor=R.+Centisauthor=M.+Daraauthor=A.+Matteelliauthor=F.+Blasiauthor=G.+B.+Migliori&title=ERS%2FWHO+tuberculosis+consilium+assistance+with+extensively+drug-resistant+tuberculosis+management+in+a+child%3A+case+study+of+compassionate+delamanid+use&doi=10.1183%2F09031936.00060414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use</span></div><div class="casAuthors">Esposito Susanna; D'Ambrosio Lia; Tadolini Marina; Schaaf H Simon; Caminero Luna Jose; Marais Ben; Centis Rosella; Migliori Giovanni Battista; Dara Masoud; Matteelli Alberto; Blasi Francesco</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">811-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrd6ehdbC4EjAyhZbj3lKdfW6udTcc2ea5_M2LHnJ72rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjjt1OmtA%253D%253D&md5=b6d47e209f05734b7ea318d13d119908</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1183%2F09031936.00060414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00060414%26sid%3Dliteratum%253Aachs%26aulast%3DEsposito%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Ambrosio%26aufirst%3DL.%26aulast%3DTadolini%26aufirst%3DM.%26aulast%3DSchaaf%26aufirst%3DH.%2BS.%26aulast%3DCaminero%2BLuna%26aufirst%3DJ.%26aulast%3DMarais%26aufirst%3DB.%26aulast%3DCentis%26aufirst%3DR.%26aulast%3DDara%26aufirst%3DM.%26aulast%3DMatteelli%26aufirst%3DA.%26aulast%3DBlasi%26aufirst%3DF.%26aulast%3DMigliori%26aufirst%3DG.%2BB.%26atitle%3DERS%252FWHO%2520tuberculosis%2520consilium%2520assistance%2520with%2520extensively%2520drug-resistant%2520tuberculosis%2520management%2520in%2520a%2520child%253A%2520case%2520study%2520of%2520compassionate%2520delamanid%2520use%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2014%26volume%3D44%26spage%3D811%26epage%3D815%26doi%3D10.1183%2F09031936.00060414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Udwadia, Z. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amale, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajbani, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, C.</span><span> </span><span class="NLM_article-title">Totally drug-resistant tuberculosis in India</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">–</span> <span class="NLM_lpage">581</span><span class="refDoi"> DOI: 10.1093/cid/cir889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1093%2Fcid%2Fcir889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=22190562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A280%3ADC%252BC387ptF2hsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2012&pages=579-581&author=Z.+F.+Udwadiaauthor=R.+A.+Amaleauthor=K.+K.+Ajbaniauthor=C.+Rodrigues&title=Totally+drug-resistant+tuberculosis+in+India&doi=10.1093%2Fcid%2Fcir889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Totally drug-resistant tuberculosis in India</span></div><div class="casAuthors">Udwadia Zarir F; Amale Rohit A; Ajbani Kanchan K; Rodrigues Camilla</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">579-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT2_G3WsdaydUbxh97K6Vt6fW6udTcc2ea5_M2LHnJ72rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387ptF2hsQ%253D%253D&md5=237f5c180e0daee51adf5df45a93d428</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcir889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcir889%26sid%3Dliteratum%253Aachs%26aulast%3DUdwadia%26aufirst%3DZ.%2BF.%26aulast%3DAmale%26aufirst%3DR.%2BA.%26aulast%3DAjbani%26aufirst%3DK.%2BK.%26aulast%3DRodrigues%26aufirst%3DC.%26atitle%3DTotally%2520drug-resistant%2520tuberculosis%2520in%2520India%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2012%26volume%3D54%26spage%3D579%26epage%3D581%26doi%3D10.1093%2Fcid%2Fcir889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Hoagland, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. E.</span><span> </span><span class="NLM_article-title">New agents for the treatment of drug-resistant Mycobacterium tuberculosis</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span><span class="refDoi"> DOI: 10.1016/j.addr.2016.04.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1016%2Fj.addr.2016.04.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=27151308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlSns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2016&pages=55-72&author=D.+T.+Hoaglandauthor=J.+Liuauthor=R.+B.+Leeauthor=R.+E.+Lee&title=New+agents+for+the+treatment+of+drug-resistant+Mycobacterium+tuberculosis&doi=10.1016%2Fj.addr.2016.04.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">New agents for the treatment of drug-resistant Mycobacterium tuberculosis</span></div><div class="casAuthors">Hoagland, Daniel T.; Liu, Jiuyu; Lee, Robin B.; Lee, Richard E.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">55-72</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inadequate dosing and incomplete treatment regimens, coupled with the ability of the tuberculosis bacilli to cause latent infections that are tolerant of currently used drugs, have fueled the rise of multidrug-resistant tuberculosis (MDR-TB).  Treatment of MDR-TB infections is a major clin. challenge that has few viable or effective solns.; therefore patients face a poor prognosis and years of treatment.  This review focuses on emerging drug classes that have the potential for treating MDR-TB and highlights their particular strengths as leads including their mode of action, in vivo efficacy, and key medicinal chem. properties.  Examples include the newly approved drugs bedaquiline and delaminid, and other agents in clin. and late preclin. development pipeline for the treatment of MDR-TB.  Herein, we discuss the challenges to developing drugs to treat tuberculosis and how the field has adapted to these difficulties, with an emphasis on drug discovery approaches that might produce more effective agents and treatment regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBEswjNcHj27Vg90H21EOLACvtfcHk0lg3aJS8CYnylQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlSns7c%253D&md5=7c8ca15b9b493cceaf3d51d93b9afcec</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.04.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.04.026%26sid%3Dliteratum%253Aachs%26aulast%3DHoagland%26aufirst%3DD.%2BT.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BB.%26aulast%3DLee%26aufirst%3DR.%2BE.%26atitle%3DNew%2520agents%2520for%2520the%2520treatment%2520of%2520drug-resistant%2520Mycobacterium%2520tuberculosis%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2016%26volume%3D102%26spage%3D55%26epage%3D72%26doi%3D10.1016%2Fj.addr.2016.04.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Zumla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nahid, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, S. T.</span><span> </span><span class="NLM_article-title">Advances in the development of new tuberculosis drugs and treatment regimens</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">388</span><span class="NLM_x">–</span> <span class="NLM_lpage">404</span><span class="refDoi"> DOI: 10.1038/nrd4001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1038%2Fnrd4001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=23629506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Kmsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=388-404&author=A.+Zumlaauthor=P.+Nahidauthor=S.+T.+Cole&title=Advances+in+the+development+of+new+tuberculosis+drugs+and+treatment+regimens&doi=10.1038%2Fnrd4001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the development of new tuberculosis drugs and treatment regimens</span></div><div class="casAuthors">Zumla, Alimuddin; Nahid, Payam; Cole, Stewart T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">388-404</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid, rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to cause considerable morbidity and mortality worldwide.  For the first time since the 1960s, new and novel drugs and regimens for all forms of TB are emerging.  Such regimens are likely to utilize both repurposed drugs and new chem. entities, and several of these regimens are now progressing through clin. trials.  This article covers current concepts and recent advances in TB drug discovery and development, including an update of ongoing TB treatment trials, newer clin. trial designs, TB biomarkers and adjunct host-directed therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs_a1A-oQwcrVg90H21EOLACvtfcHk0lh9kwGJ631v8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Kmsrk%253D&md5=fbf12f867a19ffff4d7fb74a98699682</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrd4001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4001%26sid%3Dliteratum%253Aachs%26aulast%3DZumla%26aufirst%3DA.%26aulast%3DNahid%26aufirst%3DP.%26aulast%3DCole%26aufirst%3DS.%2BT.%26atitle%3DAdvances%2520in%2520the%2520development%2520of%2520new%2520tuberculosis%2520drugs%2520and%2520treatment%2520regimens%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D388%26epage%3D404%26doi%3D10.1038%2Fnrd4001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Gutierrez-Lugo, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bewley, C. A.</span><span> </span><span class="NLM_article-title">Natural products, small molecules, and genetics in tuberculosis drug development</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2606</span><span class="NLM_x">–</span> <span class="NLM_lpage">2612</span><span class="refDoi"> DOI: 10.1021/jm070719i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070719i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2606-2612&author=M.+T.+Gutierrez-Lugoauthor=C.+A.+Bewley&title=Natural+products%2C+small+molecules%2C+and+genetics+in+tuberculosis+drug+development&doi=10.1021%2Fjm070719i"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm070719i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070719i%26sid%3Dliteratum%253Aachs%26aulast%3DGutierrez-Lugo%26aufirst%3DM.%2BT.%26aulast%3DBewley%26aufirst%3DC.%2BA.%26atitle%3DNatural%2520products%252C%2520small%2520molecules%252C%2520and%2520genetics%2520in%2520tuberculosis%2520drug%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2606%26epage%3D2612%26doi%3D10.1021%2Fjm070719i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Ma, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lienhardt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIlleron, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunn, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span> </span><span class="NLM_article-title">Global tuberculosis drug development pipeline: the need and the reality</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">375</span><span class="NLM_x">, </span> <span class="NLM_fpage">2100</span><span class="NLM_x">–</span> <span class="NLM_lpage">2109</span><span class="refDoi"> DOI: 10.1016/S0140-6736(10)60359-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1016%2FS0140-6736%2810%2960359-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2010&pages=2100-2109&author=Z.+Maauthor=C.+Lienhardtauthor=H.+McIlleronauthor=A.+J.+Nunnauthor=X.+Wang&title=Global+tuberculosis+drug+development+pipeline%3A+the+need+and+the+reality&doi=10.1016%2FS0140-6736%2810%2960359-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2960359-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252960359-9%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DLienhardt%26aufirst%3DC.%26aulast%3DMcIlleron%26aufirst%3DH.%26aulast%3DNunn%26aufirst%3DA.%2BJ.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DGlobal%2520tuberculosis%2520drug%2520development%2520pipeline%253A%2520the%2520need%2520and%2520the%2520reality%26jtitle%3DLancet%26date%3D2010%26volume%3D375%26spage%3D2100%26epage%3D2109%26doi%3D10.1016%2FS0140-6736%2810%2960359-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Cohen, J.</span><span> </span><span class="NLM_article-title">Infectious disease. Approval of novel TB drug celebrated–with restraint</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">339</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="refDoi"> DOI: 10.1126/science.339.6116.130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1126%2Fscience.339.6116.130" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2013&pages=130&author=J.+Cohen&title=Infectious+disease.+Approval+of+novel+TB+drug+celebrated%E2%80%93with+restraint&doi=10.1126%2Fscience.339.6116.130"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1126%2Fscience.339.6116.130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.339.6116.130%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DJ.%26atitle%3DInfectious%2520disease.%2520Approval%2520of%2520novel%2520TB%2520drug%2520celebrated%25E2%2580%2593with%2520restraint%26jtitle%3DScience%26date%3D2013%26volume%3D339%26spage%3D130%26doi%3D10.1126%2Fscience.339.6116.130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Ryan, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, J. H.</span><span> </span><span class="NLM_article-title">Delamanid: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1041</span><span class="NLM_x">–</span> <span class="NLM_lpage">1045</span><span class="refDoi"> DOI: 10.1007/s40265-014-0241-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1007%2Fs40265-014-0241-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=24923253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVagsb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1041-1045&author=N.+J.+Ryanauthor=J.+H.+Lo&title=Delamanid%3A+first+global+approval&doi=10.1007%2Fs40265-014-0241-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Delamanid: First Global Approval</span></div><div class="casAuthors">Ryan, Nicola J.; Lo, Jin Han</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1041-1045</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Delamanid, a nitro-dihydro-imidazooxazole deriv., has been developed by Otsuka Pharmaceutical for the treatment of multidrug-resistant tuberculosis (MDR-TB).  Delamanid received its first global approval for the treatment of MDR-TB in the European Union (EU), for use in combination with optimized background therapy.  It is also under review for marketing in Japan for MDR-TB, the first drug application filed in Japan for this indication.  Delamanid has been granted orphan drug status in both the EU and Japan.  This article summarizes the milestones in the development of delamanid leading to this first approval for MDR-TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxJsQP29JADrVg90H21EOLACvtfcHk0lh9kwGJ631v8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVagsb%252FJ&md5=1cce5f24a66b3cd98abaa95466023fc0</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0241-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0241-5%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DN.%2BJ.%26aulast%3DLo%26aufirst%3DJ.%2BH.%26atitle%3DDelamanid%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D1041%26epage%3D1045%26doi%3D10.1007%2Fs40265-014-0241-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Andries, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhasselt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillemont, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Göhlmann, H. W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neefs, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Gestel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timmerman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Chaffoy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huitric, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cambau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truffot-Pernot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lounis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarlier, V.</span><span> </span><span class="NLM_article-title">A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">307</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span><span class="refDoi"> DOI: 10.1126/science.1106753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1126%2Fscience.1106753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=15591164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVKkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=223-227&author=K.+Andriesauthor=P.+Verhasseltauthor=J.+Guillemontauthor=H.+W.+H.+G%C3%B6hlmannauthor=J.-M.+Neefsauthor=H.+Winklerauthor=J.+Van+Gestelauthor=P.+Timmermanauthor=M.+Zhuauthor=E.+Leeauthor=P.+Williamsauthor=D.+de+Chaffoyauthor=E.+Huitricauthor=S.+Hoffnerauthor=E.+Cambauauthor=C.+Truffot-Pernotauthor=N.+Lounisauthor=V.+Jarlier&title=A+diarylquinoline+drug+active+on+the+ATP+synthase+of+Mycobacterium+tuberculosis&doi=10.1126%2Fscience.1106753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis</span></div><div class="casAuthors">Andries, Koen; Verhasselt, Peter; Guillemont, Jerome; Goehlmann, Hinrich W. H.; Neefs, Jean-Marc; Winkler, Hans; Van Gestel, Jef; Timmerman, Philip; Zhu, Min; Lee, Ennis; Williams, Peter; de Chaffoy, Didier; Huitric, Emma; Hoffner, Sven; Cambau, Emmanuelle; Truffot-Pernot, Chantal; Lounis, Nacer; Jarlier, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5707</span>),
    <span class="NLM_cas:pages">223-227</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The incidence of tuberculosis has been increasing substantially on a worldwide basis over the past decade, but no tuberculosis-specific drugs have been discovered in 40 years.  We identified a diarylquinoline, R207910, that potently inhibits both drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro (min. inhibitory concn. 0.06 μg/mL).  In mice, R207910 exceeded the bactericidal activities of isoniazid and rifampin by at least 1 log unit.  Substitution of drugs included in the World Health Organization's first-line tuberculosis treatment regimen (rifampin, isoniazid, and pyrazinamide) with R207910 accelerated bactericidal activity, leading to complete culture conversion after 2 mo of treatment in some combinations.  A single dose of R207910 inhibited mycobacterial growth for 1 wk.  Plasma levels assocd. with efficacy in mice were well tolerated in healthy human volunteers.  Mutants selected in vitro suggest that the drug targets the proton pump of ATP (ATP) synthase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9LY7RSAIXUrVg90H21EOLACvtfcHk0lgvTvEC6X0aqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVKkug%253D%253D&md5=099b643f173bb77e70cf1aa6e9871ffe</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1126%2Fscience.1106753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1106753%26sid%3Dliteratum%253Aachs%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DVerhasselt%26aufirst%3DP.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DG%25C3%25B6hlmann%26aufirst%3DH.%2BW.%2BH.%26aulast%3DNeefs%26aufirst%3DJ.-M.%26aulast%3DWinkler%26aufirst%3DH.%26aulast%3DVan%2BGestel%26aufirst%3DJ.%26aulast%3DTimmerman%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DWilliams%26aufirst%3DP.%26aulast%3Dde%2BChaffoy%26aufirst%3DD.%26aulast%3DHuitric%26aufirst%3DE.%26aulast%3DHoffner%26aufirst%3DS.%26aulast%3DCambau%26aufirst%3DE.%26aulast%3DTruffot-Pernot%26aufirst%3DC.%26aulast%3DLounis%26aufirst%3DN.%26aulast%3DJarlier%26aufirst%3DV.%26atitle%3DA%2520diarylquinoline%2520drug%2520active%2520on%2520the%2520ATP%2520synthase%2520of%2520Mycobacterium%2520tuberculosis%26jtitle%3DScience%26date%3D2005%26volume%3D307%26spage%3D223%26epage%3D227%26doi%3D10.1126%2Fscience.1106753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Matsumoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashizume, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomishige, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsubouchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimokawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komatsu, M.</span><span> </span><span class="NLM_article-title">OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">e466</span><span class="refDoi"> DOI: 10.1371/journal.pmed.0030466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1371%2Fjournal.pmed.0030466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=17132069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A280%3ADC%252BD28npsFKgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=e466&author=M.+Matsumotoauthor=H.+Hashizumeauthor=T.+Tomishigeauthor=M.+Kawasakiauthor=H.+Tsubouchiauthor=H.+Sasakiauthor=Y.+Shimokawaauthor=M.+Komatsu&title=OPC-67683%2C+a+nitro-dihydro-imidazooxazole+derivative+with+promising+action+against+tuberculosis+in+vitro+and+in+mice&doi=10.1371%2Fjournal.pmed.0030466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice</span></div><div class="casAuthors">Matsumoto Makoto; Hashizume Hiroyuki; Tomishige Tatsuo; Kawasaki Masanori; Tsubouchi Hidetsugu; Sasaki Hirofumi; Shimokawa Yoshihiko; Komatsu Makoto</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e466</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Tuberculosis (TB) is still a leading cause of death worldwide.  Almost a third of the world's population is infected with TB bacilli, and each year approximately 8 million people develop active TB and 2 million die as a result.  Today's TB treatment, which dates back to the 1970s, is long and burdensome, requiring at least 6 mo of multidrug chemotherapy.  The situation is further compounded by the emergence of multidrug-resistant TB (MDR-TB) and by the infection's lethal synergy with HIV/AIDS.  Global health and philanthropic organizations are now pleading for new drug interventions that can address these unmet needs in TB treatment.  METHODS AND FINDINGS:  Here we report OPC-67683, a nitro-dihydro-imidazooxazole derivative that was screened to help combat the unmet needs in TB treatment.  The compound is a mycolic acid biosynthesis inhibitor found to be free of mutagenicity and to possess highly potent activity against TB, including MDR-TB, as shown by its exceptionally low minimum inhibitory concentration (MIC) range of 0.006-0.024 microg/ml in vitro and highly effective therapeutic activity at low doses in vivo.  Additionally, the results of the post-antibiotic effect of OPC-67683 on intracellular Mycobacterium tuberculosis showed the agent to be highly and dose-dependently active also against intracellular M. tuberculosis H37Rv after a 4-h pulsed exposure, and this activity at a concentration of 0.1 microg/ml was similar to that of the first-line drug rifampicin (RFP) at a concentration of 3 microg/ml.  The combination of OPC-67683 with RFP and pyrazinamide (PZA) exhibited a remarkably quicker eradication (by at least 2 mo) of viable TB bacilli in the lung in comparison with the standard regimen consisting of RFP, isoniazid (INH), ethambutol (EB), and PZA.  Furthermore, OPC-67683 was not affected by nor did it affect the activity of liver microsome enzymes, suggesting the possibility for OPC-67683 to be used in combination with drugs, including anti-retrovirals, that induce or are metabolized by cytochrome P450 enzymes.  CONCLUSIONS:  We concluded that based on these properties OPC-67683 has the potential to be used as a TB drug to help combat the unmet needs in TB treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSF0z_BNLNYeRS7coPn-RtfW6udTcc2eY0yjaJSwVOJLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28npsFKgug%253D%253D&md5=8a80560cc653b1c76ff4d47430317d18</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0030466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0030466%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumoto%26aufirst%3DM.%26aulast%3DHashizume%26aufirst%3DH.%26aulast%3DTomishige%26aufirst%3DT.%26aulast%3DKawasaki%26aufirst%3DM.%26aulast%3DTsubouchi%26aufirst%3DH.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DShimokawa%26aufirst%3DY.%26aulast%3DKomatsu%26aufirst%3DM.%26atitle%3DOPC-67683%252C%2520a%2520nitro-dihydro-imidazooxazole%2520derivative%2520with%2520promising%2520action%2520against%2520tuberculosis%2520in%2520vitro%2520and%2520in%2520mice%26jtitle%3DPLoS%2520Med.%26date%3D2006%26volume%3D3%26spage%3De466%26doi%3D10.1371%2Fjournal.pmed.0030466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Fox, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzies, D.</span><span> </span><span class="NLM_article-title">A review of the evidence for using bedaquiline (TMC207) to treat multi-drug resistant tuberculosis</span> <span class="citation_source-journal">Infect. Dis. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span><span class="refDoi"> DOI: 10.1007/s40121-013-0009-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1007%2Fs40121-013-0009-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=25134476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FjtV2rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=123-144&author=G.+J.+Foxauthor=D.+Menzies&title=A+review+of+the+evidence+for+using+bedaquiline+%28TMC207%29+to+treat+multi-drug+resistant+tuberculosis&doi=10.1007%2Fs40121-013-0009-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis</span></div><div class="casAuthors">Fox Gregory J; Menzies Dick</div><div class="citationInfo"><span class="NLM_cas:title">Infectious diseases and therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-44</span>
        ISSN:<span class="NLM_cas:issn">2193-8229</span>.
    </div><div class="casAbstract">Existing therapies for multi-drug resistant tuberculosis (MDR-TB) have substantial limitations, in terms of their effectiveness, side-effect profile, and complexity of administration.  Bedaquiline is a novel diarylquinoline antibiotic that has recently been investigated as an adjunct to existing therapies for MDR-TB.  Currently, limited clinical data are available to evaluate the drug's safety and effectiveness.  In two small randomized-controlled clinical studies, bedaquiline given for 8 or 24 weeks has been shown to improve surrogate microbiological markers of treatment response, but trials have not yet evaluated its impact on clinical failure and relapse.  Safety concerns include an increased mortality in the bedaquiline arm of one study, an increased incidence of QT segment prolongation on electrocardiogram, and hepatotoxicity.  Until further research data are available, the use of bedaquiline should be confined to settings where carefully selected patients can be closely monitored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTlWFOQsVg1oaNc3HjJRoFAfW6udTcc2eY0yjaJSwVOJLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FjtV2rtg%253D%253D&md5=0cd964c385e6bc327878d5c5203b3f06</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs40121-013-0009-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40121-013-0009-3%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DG.%2BJ.%26aulast%3DMenzies%26aufirst%3DD.%26atitle%3DA%2520review%2520of%2520the%2520evidence%2520for%2520using%2520bedaquiline%2520%2528TMC207%2529%2520to%2520treat%2520multi-drug%2520resistant%2520tuberculosis%26jtitle%3DInfect.%2520Dis.%2520Ther.%26date%3D2013%26volume%3D2%26spage%3D123%26epage%3D144%26doi%3D10.1007%2Fs40121-013-0009-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Field, S. K.</span><span> </span><span class="NLM_article-title">Safety and efficacy of delamanid in the treatment of multidrug-resistant tuberculosis (MDR-TB)</span> <span class="citation_source-journal">Clin. Med. Insights: Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">–</span> <span class="NLM_lpage">149</span><span class="refDoi"> DOI: 10.4137/CMT.S11675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.4137%2FCMT.S11675" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWgsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=137-149&author=S.+K.+Field&title=Safety+and+efficacy+of+delamanid+in+the+treatment+of+multidrug-resistant+tuberculosis+%28MDR-TB%29&doi=10.4137%2FCMT.S11675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of delamanid in the treatment of multidrug-resistant tuberculosis (MDR-TB)</span></div><div class="casAuthors">Field, Stephen K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Medicine Insights: Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">137-149</span>CODEN:
                <span class="NLM_cas:coden">CMITB2</span>;
        ISSN:<span class="NLM_cas:issn">1179-559X</span>.
    
            (<span class="NLM_cas:orgname">Libertas Academica</span>)
        </div><div class="casAbstract">A review.  Globally, the incidence of tuberculosis (TB) is declining but the proportion of drug-resistant cases has increased.  Strains resistant to both isoniazid and rifampin, and possibly other antibiotics, called multidrug-resistant (MDR), are particularly difficult to treat.  Poorer outcomes, including increased mortality, occur in patients infected with MDR strains and the costs assocd. with treatment of MDR-TB are substantially greater.  The recent recognition of MDR-TB and strains with more complex resistance patterns has stimulated the development of new TB medications including fluoroquinolones, oxazolidinones, diarylquinolines, nitroimidazopyrans, ethylenediamines, and benzothiazinones.  Bedaquiline, a diarylquinoline, was approved for the treatment of MDR-TB in 2012.  Addn. of delamanid to WHO-approved treatment improved outcomes for MDR-TB and for extensively drug-resistant TB in a large randomized, controlled phase II clin. trial and is undergoing evaluation in a large international phase III study.  This review will focus on MDR-TB and the role of delamanid in its treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptmzp9Cx13ArVg90H21EOLACvtfcHk0liMgwtxG2z4eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWgsbfJ&md5=1187f7711003c1af26605d015f4676b3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.4137%2FCMT.S11675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4137%252FCMT.S11675%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DS.%2BK.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520delamanid%2520in%2520the%2520treatment%2520of%2520multidrug-resistant%2520tuberculosis%2520%2528MDR-TB%2529%26jtitle%3DClin.%2520Med.%2520Insights%253A%2520Ther.%26date%3D2013%26volume%3D5%26spage%3D137%26epage%3D149%26doi%3D10.4137%2FCMT.S11675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Hartkoorn, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uplekar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, S. T.</span><span> </span><span class="NLM_article-title">Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2979</span><span class="NLM_x">–</span> <span class="NLM_lpage">2981</span><span class="refDoi"> DOI: 10.1128/AAC.00037-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1128%2FAAC.00037-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=24590481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovV2qsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=2979-2981&author=R.+C.+Hartkoornauthor=S.+Uplekarauthor=S.+T.+Cole&title=Cross-resistance+between+clofazimine+and+bedaquiline+through+upregulation+of+MmpL5+in+Mycobacterium+tuberculosis&doi=10.1128%2FAAC.00037-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis</span></div><div class="casAuthors">Hartkoorn, Ruben C.; Uplekar, Swapna; Cole, Stewart T.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2979-2981, 4 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The antileprosy drug clofazimine is also of interest for the treatment of multidrug-resistant tuberculosis.  To understand possible resistance mechanisms, clofazimine-resistant Mycobacterium tuberculosis mutants were isolated in vitro, and, unexpectedly, found to be cross-resistant to bedaquiline.  Mutations in the transcriptional regulator Rv0678, with concomitant upregulation of the multisubstrate efflux pump, MmpL5, accounted for this cross-resistance.  Mutation in Rv0678 should therefore be considered a confounding factor for the treatment of tuberculosis with clofazimine or bedaquiline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIT-1_Uz5-a7Vg90H21EOLACvtfcHk0liMgwtxG2z4eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovV2qsLk%253D&md5=ca70e96eceab1d9a8717082ab46d1745</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FAAC.00037-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00037-14%26sid%3Dliteratum%253Aachs%26aulast%3DHartkoorn%26aufirst%3DR.%2BC.%26aulast%3DUplekar%26aufirst%3DS.%26aulast%3DCole%26aufirst%3DS.%2BT.%26atitle%3DCross-resistance%2520between%2520clofazimine%2520and%2520bedaquiline%2520through%2520upregulation%2520of%2520MmpL5%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D2979%26epage%3D2981%26doi%3D10.1128%2FAAC.00037-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Stinson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurepina, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shashkina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreiswirth, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geiter, L.</span><span> </span><span class="NLM_article-title">MIC of delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">3316</span><span class="NLM_x">–</span> <span class="NLM_lpage">3322</span><span class="refDoi"> DOI: 10.1128/AAC.03014-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1128%2FAAC.03014-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=26976868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1entrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=3316-3322&author=K.+Stinsonauthor=N.+Kurepinaauthor=A.+Venterauthor=M.+Fujiwaraauthor=M.+Kawasakiauthor=J.+Timmauthor=E.+Shashkinaauthor=B.+N.+Kreiswirthauthor=Y.+Liuauthor=M.+Matsumotoauthor=L.+Geiter&title=MIC+of+delamanid+%28OPC-67683%29+against+Mycobacterium+tuberculosis+clinical+isolates+and+a+proposed+critical+concentration&doi=10.1128%2FAAC.03014-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">MIC of delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration</span></div><div class="casAuthors">Stinson, Kelly; Kurepina, Natalia; Venter, Amour; Fujiwara, Mamoru; Kawasaki, Masanori; Timm, Juliano; Shashkina, Elena; Kreiswirth, Barry N.; Liu, Yongge; Matsumoto, Makoto; Geiter, Lawrence</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3316-3322</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The increasing global burden of multidrug-resistant tuberculosis (MDR-TB) requires reliable drug susceptibility testing that accurately characterizes susceptibility and resistance of pathogenic bacteria to effectively treat patients with this deadly disease.  Delamanid is an anti-TB agent first approved in the European Union in 2014 for the treatment of pulmonary MDR-TB in adults.  Using the agar proportion method, delamanid MIC was detd. for 460 isolates: 316 from patients enrolled in a phase 2 global clin. trial, 76 from two phase 2 early bactericidal activity trials conducted in South Africa, and 68 isolates obtained outside clin. trials (45 from Japanese patients and 23 from South African patients).  With the exception of two isolates, MICs ranged from 0.001 to 0.05 μg/mL, resulting in an MIC50 of 0.004 μg/mL and an MIC90 of 0.012 μg/mL.  Various degrees of resistance to other anti-TB drugs did not affect the distribution of MICs, nor did origin of isolates from regions/countries other than South Africa.  A crit. concn./breakpoint of 0.2 μg/mL can be used to define susceptible and resistant isolates based on the distribution of MICs and available pharmacokinetic data.  Thus, clin. isolates from delamanid-naive patients with tuberculosis have a very low MIC for delamanid and baseline resistance is rare, demonstrating the potential potency of delamanid and supporting its use in an optimized background treatment regimen for MDR-TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot2O44cdNSm7Vg90H21EOLACvtfcHk0liMgwtxG2z4eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1entrrL&md5=9a69303ff8d63f8aa0e73c8dd5f068cb</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FAAC.03014-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03014-15%26sid%3Dliteratum%253Aachs%26aulast%3DStinson%26aufirst%3DK.%26aulast%3DKurepina%26aufirst%3DN.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DFujiwara%26aufirst%3DM.%26aulast%3DKawasaki%26aufirst%3DM.%26aulast%3DTimm%26aufirst%3DJ.%26aulast%3DShashkina%26aufirst%3DE.%26aulast%3DKreiswirth%26aufirst%3DB.%2BN.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMatsumoto%26aufirst%3DM.%26aulast%3DGeiter%26aufirst%3DL.%26atitle%3DMIC%2520of%2520delamanid%2520%2528OPC-67683%2529%2520against%2520Mycobacterium%2520tuberculosis%2520clinical%2520isolates%2520and%2520a%2520proposed%2520critical%2520concentration%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D3316%26epage%3D3322%26doi%3D10.1128%2FAAC.03014-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Martínez-Hoyos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Herran, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulten, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Encinas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Álvarez-Gómez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrer-Bazaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Pérez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortega, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angulo-Barturen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rullas-Trincado, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanco Ruano, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castañeda, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernández Menéndez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">González Del Valle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barros, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Signorino-Gelo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKinney, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Bustos, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavandera, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sacchettini, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martín-Casabona, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro-Pichel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendoza-Losana, A.</span><span> </span><span class="NLM_article-title">Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor</span> <span class="citation_source-journal">EBioMedicine.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span><span class="refDoi"> DOI: 10.1016/j.ebiom.2016.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1016%2Fj.ebiom.2016.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=27428438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A280%3ADC%252BC2s3hvVWksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=291-301&author=M.+Mart%C3%ADnez-Hoyosauthor=E.+Perez-Herranauthor=G.+Gultenauthor=L.+Encinasauthor=D.+%C3%81lvarez-G%C3%B3mezauthor=E.+Alvarezauthor=S.+Ferrer-Bazagaauthor=A.+Garc%C3%ADa-P%C3%A9rezauthor=F.+Ortegaauthor=I.+Angulo-Barturenauthor=J.+Rullas-Trincadoauthor=D.+Blanco+Ruanoauthor=P.+Torresauthor=P.+Casta%C3%B1edaauthor=S.+Hussauthor=R.+Fern%C3%A1ndez+Men%C3%A9ndezauthor=S.+Gonz%C3%A1lez+Del+Valleauthor=L.+Ballellauthor=D.+Barrosauthor=S.+Modhaauthor=N.+Dharauthor=F.+Signorino-Geloauthor=J.+D.+McKinneyauthor=J.+F.+Garc%C3%ADa-Bustosauthor=J.+L.+Lavanderaauthor=J.+C.+Sacchettiniauthor=M.+S.+Jimenezauthor=N.+Mart%C3%ADn-Casabonaauthor=J.+Castro-Pichelauthor=A.+Mendoza-Losana&title=Antitubercular+drugs+for+an+old+target%3A+GSK693+as+a+promising+InhA+direct+inhibitor&doi=10.1016%2Fj.ebiom.2016.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor</span></div><div class="casAuthors">Martinez-Hoyos Maria; Perez-Herran Esther; Encinas Lourdes; Alvarez-Gomez Daniel; Alvarez Emilio; Ferrer-Bazaga Santiago; Garcia-Perez Adolfo; Ortega Fatima; Angulo-Barturen Inigo; Rullas-Trincado Joaquin; Blanco Ruano Delia; Torres Pedro; Castaneda Pablo; Huss Sophie; Fernandez Menendez Raquel; Gonzalez Del Valle Silvia; Ballell Lluis; Barros David; Garcia-Bustos Jose Francisco; Lavandera Jose Luis; Castro-Pichel Julia; Gulten Gulcin; Sacchettini James C; Modha Sundip; Signorino-Gelo Francois; McKinney John D; Dhar Neeraj; Jimenez M Soledad; Martin-Casabona Nuria; Mendoza-Losana Alfonso</div><div class="citationInfo"><span class="NLM_cas:title">EBioMedicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">291-301</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Despite being one of the first antitubercular agents identified, isoniazid (INH) is still the most prescribed drug for prophylaxis and tuberculosis (TB) treatment and, together with rifampicin, the pillars of current chemotherapy.  A high percentage of isoniazid resistance is linked to mutations in the pro-drug activating enzyme KatG, so the discovery of direct inhibitors (DI) of the enoyl-ACP reductase (InhA) has been pursued by many groups leading to the identification of different enzyme inhibitors, active against Mycobacterium tuberculosis (Mtb), but with poor physicochemical properties to be considered as preclinical candidates.  Here, we present a series of InhA DI active against multidrug (MDR) and extensively (XDR) drug-resistant clinical isolates as well as in TB murine models when orally dosed that can be a promising foundation for a future treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBKqsJCl5WvbZpSb_XWfMrfW6udTcc2eYp2kjtjRKXqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3hvVWksg%253D%253D&md5=21f1dbf20ad29185ba9c322829755ebb</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ebiom.2016.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ebiom.2016.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25ADnez-Hoyos%26aufirst%3DM.%26aulast%3DPerez-Herran%26aufirst%3DE.%26aulast%3DGulten%26aufirst%3DG.%26aulast%3DEncinas%26aufirst%3DL.%26aulast%3D%25C3%2581lvarez-G%25C3%25B3mez%26aufirst%3DD.%26aulast%3DAlvarez%26aufirst%3DE.%26aulast%3DFerrer-Bazaga%26aufirst%3DS.%26aulast%3DGarc%25C3%25ADa-P%25C3%25A9rez%26aufirst%3DA.%26aulast%3DOrtega%26aufirst%3DF.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DRullas-Trincado%26aufirst%3DJ.%26aulast%3DBlanco%2BRuano%26aufirst%3DD.%26aulast%3DTorres%26aufirst%3DP.%26aulast%3DCasta%25C3%25B1eda%26aufirst%3DP.%26aulast%3DHuss%26aufirst%3DS.%26aulast%3DFern%25C3%25A1ndez%2BMen%25C3%25A9ndez%26aufirst%3DR.%26aulast%3DGonz%25C3%25A1lez%2BDel%2BValle%26aufirst%3DS.%26aulast%3DBallell%26aufirst%3DL.%26aulast%3DBarros%26aufirst%3DD.%26aulast%3DModha%26aufirst%3DS.%26aulast%3DDhar%26aufirst%3DN.%26aulast%3DSignorino-Gelo%26aufirst%3DF.%26aulast%3DMcKinney%26aufirst%3DJ.%2BD.%26aulast%3DGarc%25C3%25ADa-Bustos%26aufirst%3DJ.%2BF.%26aulast%3DLavandera%26aufirst%3DJ.%2BL.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26aulast%3DJimenez%26aufirst%3DM.%2BS.%26aulast%3DMart%25C3%25ADn-Casabona%26aufirst%3DN.%26aulast%3DCastro-Pichel%26aufirst%3DJ.%26aulast%3DMendoza-Losana%26aufirst%3DA.%26atitle%3DAntitubercular%2520drugs%2520for%2520an%2520old%2520target%253A%2520GSK693%2520as%2520a%2520promising%2520InhA%2520direct%2520inhibitor%26jtitle%3DEBioMedicine.%26date%3D2016%26volume%3D8%26spage%3D291%26epage%3D301%26doi%3D10.1016%2Fj.ebiom.2016.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Šink, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosič, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Živec, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Férnandez-Menéndez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turk, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pajk, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Álvarez-Gómez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Román, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales-Cortez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rullas-Triconado, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angulo-Barturen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barros, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballell-Pages, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Encinas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobec, S.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of new thiadiazole-based direct inhibitors of enoyl acyl carrier protein reductase (InhA) for the treatment of tuberculosis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">613</span><span class="NLM_x">–</span> <span class="NLM_lpage">624</span><span class="refDoi"> DOI: 10.1021/jm501029r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501029r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOgsL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=613-624&author=R.+%C5%A0inkauthor=I.+Sosi%C4%8Dauthor=M.+%C5%BDivecauthor=R.+F%C3%A9rnandez-Men%C3%A9ndezauthor=S.+Turkauthor=S.+Pajkauthor=D.+%C3%81lvarez-G%C3%B3mezauthor=E.+M.+Lopez-Rom%C3%A1nauthor=C.+Gonzales-Cortezauthor=J.+Rullas-Triconadoauthor=I.+Angulo-Barturenauthor=D.+Barrosauthor=L.+Ballell-Pagesauthor=R.+J.+Youngauthor=L.+Encinasauthor=S.+Gobec&title=Design%2C+synthesis%2C+and+evaluation+of+new+thiadiazole-based+direct+inhibitors+of+enoyl+acyl+carrier+protein+reductase+%28InhA%29+for+the+treatment+of+tuberculosis&doi=10.1021%2Fjm501029r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of New Thiadiazole-Based Direct Inhibitors of Enoyl Acyl Carrier Protein Reductase (InhA) for the Treatment of Tuberculosis</span></div><div class="casAuthors">Sink, Roman; Sosic, Izidor; Zivec, Matej; Fernandez-Menendez, Raquel; Turk, Samo; Pajk, Stane; Alvarez-Gomez, Daniel; Lopez-Roman, Eva Maria; Gonzales-Cortez, Carolina; Rullas-Triconado, Joaquin; Angulo-Barturen, Inigo; Barros, David; Ballell-Pages, Lluis; Young, Robert J.; Encinas, Lourdes; Gobec, Stanislav</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">613-624</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mycobacterial enoyl acyl carrier protein reductase (InhA) is a clin. validated target for the treatment of tuberculosis infections, a disease that still causes the death of at least a million people annually.  A known class of potent, direct, and competitive InhA inhibitors based on a tetracyclic thiadiazole structure has been shown to have in vivo activity in murine models of tuberculosis infection.  On the basis of this template, we have here explored the medicinal chem. of truncated analogs that have only three arom. rings.  In particular, compds. I [Aryl = 6-methyl-2-pyridyl, 6-bromo-2-pyridyl (8d), 6-(trifluoromethyl)-2-pyridyl, 5-bromo-2-pyridyl and 5-bromo-6-(trifluoromethyl)-2-pyridyl] show interesting features, including low nanomolar InhA IC50, submicromolar antimycobacterial potency, and improved physicochem. profiles in comparison with the tetracyclic analogs.  From this series, 8d is identified as having the best balance of potency and properties, whereby the resolved 8d S-enantiomer shows encouraging in vivo efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMhr0INTijhLVg90H21EOLACvtfcHk0li2kT_V_I6-NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOgsL3O&md5=01311420c022fc076432829c1b1896c8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm501029r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501029r%26sid%3Dliteratum%253Aachs%26aulast%3D%25C5%25A0ink%26aufirst%3DR.%26aulast%3DSosi%25C4%258D%26aufirst%3DI.%26aulast%3D%25C5%25BDivec%26aufirst%3DM.%26aulast%3DF%25C3%25A9rnandez-Men%25C3%25A9ndez%26aufirst%3DR.%26aulast%3DTurk%26aufirst%3DS.%26aulast%3DPajk%26aufirst%3DS.%26aulast%3D%25C3%2581lvarez-G%25C3%25B3mez%26aufirst%3DD.%26aulast%3DLopez-Rom%25C3%25A1n%26aufirst%3DE.%2BM.%26aulast%3DGonzales-Cortez%26aufirst%3DC.%26aulast%3DRullas-Triconado%26aufirst%3DJ.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DBarros%26aufirst%3DD.%26aulast%3DBallell-Pages%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DEncinas%26aufirst%3DL.%26aulast%3DGobec%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520new%2520thiadiazole-based%2520direct%2520inhibitors%2520of%2520enoyl%2520acyl%2520carrier%2520protein%2520reductase%2520%2528InhA%2529%2520for%2520the%2520treatment%2520of%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D613%26epage%3D624%26doi%3D10.1021%2Fjm501029r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Stec, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onajole, O. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lun, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merenbloom, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vistoli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishai, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Indole-2-carboxamide-based MmpL3 Inhibitors show exceptional antitubercular activity in an animal model of tuberculosis infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">6232</span><span class="NLM_x">–</span> <span class="NLM_lpage">6247</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00415</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00415" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVCltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6232-6247&author=J.+Stecauthor=O.+K.+Onajoleauthor=S.+Lunauthor=H.+Guoauthor=B.+Merenbloomauthor=G.+Vistoliauthor=W.+R.+Bishaiauthor=A.+P.+Kozikowski&title=Indole-2-carboxamide-based+MmpL3+Inhibitors+show+exceptional+antitubercular+activity+in+an+animal+model+of+tuberculosis+infection&doi=10.1021%2Facs.jmedchem.6b00415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection</span></div><div class="casAuthors">Stec, Jozef; Onajole, Oluseye K.; Lun, Shichun; Guo, Haidan; Merenbloom, Benjamin; Vistoli, Giulio; Bishai, William R.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6232-6247</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Our team had previously identified certain indolecarboxamides that represented a new chem. scaffold that showed promising anti-TB activity at both an in vitro and in vivo level.  Based on mutational anal. using bacteria found resistant to one of these indolecarboxamides, we identified the trehalose monomycolate transporter MmpL3 as the likely target of these compds.  In the present work, we now further elaborate on the SAR of these compds., which has led in turn to the identification of a new analog, 4,6-difluoro-N-((1R,2R,3R,5S)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-yl)-1H-indole-2-carboxamide (26), that shows excellent activity against drug-sensitive (MIC = 0.012 μM; SI ≥ 16000), multidrug-resistant (MDR), and extensively drug-resistant (XDR) Mycobacterium tuberculosis strains, has superior ADMET properties, and shows excellent activity in the TB aerosol lung infection model.  Compd. 26 is also shown to work in synergy with rifampin.  Because of these properties, we believe that indolecarboxamide 26 is a possible candidate for advancement to human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg0h9TR-VL5rVg90H21EOLACvtfcHk0li2kT_V_I6-NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVCltb8%253D&md5=f9e3d545a65f85deb3f97054dca77c1f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00415%26sid%3Dliteratum%253Aachs%26aulast%3DStec%26aufirst%3DJ.%26aulast%3DOnajole%26aufirst%3DO.%2BK.%26aulast%3DLun%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DMerenbloom%26aufirst%3DB.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DBishai%26aufirst%3DW.%2BR.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DIndole-2-carboxamide-based%2520MmpL3%2520Inhibitors%2520show%2520exceptional%2520antitubercular%2520activity%2520in%2520an%2520animal%2520model%2520of%2520tuberculosis%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6232%26epage%3D6247%26doi%3D10.1021%2Facs.jmedchem.6b00415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Couturier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lair, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellet, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cogo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menegotto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheiper, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagrange, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacqué, E.</span><span> </span><span class="NLM_article-title">Identification and optimization of a new series of anti-tubercular quinazolinones</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">5290</span><span class="NLM_x">–</span> <span class="NLM_lpage">5299</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.09.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1016%2Fj.bmcl.2016.09.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=27671498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFyntbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5290-5299&author=C.+Couturierauthor=C.+Lairauthor=A.+Pelletauthor=A.+Uptonauthor=T.+Kanekoauthor=C.+Perronauthor=E.+Cogoauthor=J.+Menegottoauthor=A.+Bauerauthor=B.+Scheiperauthor=S.+Lagrangeauthor=E.+Bacqu%C3%A9&title=Identification+and+optimization+of+a+new+series+of+anti-tubercular+quinazolinones&doi=10.1016%2Fj.bmcl.2016.09.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and optimization of a new series of anti-tubercular quinazolinones</span></div><div class="casAuthors">Couturier, Cedric; Lair, Christine; Pellet, Alain; Upton, Anna; Kaneko, Takushi; Perron, Corinne; Cogo, Eric; Menegotto, Jerome; Bauer, Armin; Scheiper, Bodo; Lagrange, Sophie; Bacque, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5290-5299</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A high throughput phenotypic screening against Mycobacterium smegmatis led us to the discovery of a new class of bacteriostatic, highly hydrophobic antitubercular quinazolinones that potently inhibited the in vitro growth of either extracellular or intramacrophagic M. tuberculosis (Mtb), via modulation of an unidentified but yet novel target.  Optimization of the initial hit compd. culminated in the identification of potent but poorly sol. Mtb growth inhibitors, three of which were progressed to in vivo efficacy studies.  Despite nanomolar in vitro potency and attractive PK properties, none of these compds. was convincingly potent in the in vivo mouse tuberculosis models.  This lack of efficacy may be linked to the poor drug-likeness of the test mols. and/or to the properties of the target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZQPkqXJ5moLVg90H21EOLACvtfcHk0lhluXRfNhN92Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFyntbzK&md5=95392a67ae9d357cbf44431057268dde</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.09.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.09.043%26sid%3Dliteratum%253Aachs%26aulast%3DCouturier%26aufirst%3DC.%26aulast%3DLair%26aufirst%3DC.%26aulast%3DPellet%26aufirst%3DA.%26aulast%3DUpton%26aufirst%3DA.%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DPerron%26aufirst%3DC.%26aulast%3DCogo%26aufirst%3DE.%26aulast%3DMenegotto%26aufirst%3DJ.%26aulast%3DBauer%26aufirst%3DA.%26aulast%3DScheiper%26aufirst%3DB.%26aulast%3DLagrange%26aufirst%3DS.%26aulast%3DBacqu%25C3%25A9%26aufirst%3DE.%26atitle%3DIdentification%2520and%2520optimization%2520of%2520a%2520new%2520series%2520of%2520anti-tubercular%2520quinazolinones%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D5290%26epage%3D5299%26doi%3D10.1016%2Fj.bmcl.2016.09.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Pethe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiricek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeon, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cechetto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christophe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kempf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenaerts, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pham, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yim, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chua, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanjundappa, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wintjens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonso, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nehrbass, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">No, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span> </span><span class="NLM_article-title">Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1157</span><span class="NLM_x">–</span> <span class="NLM_lpage">1160</span><span class="refDoi"> DOI: 10.1038/nm.3262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1038%2Fnm.3262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=23913123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1WhtrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1157-1160&author=K.+Petheauthor=P.+Bifaniauthor=J.+Jangauthor=S.+Kangauthor=S.+Parkauthor=S.+Ahnauthor=J.+Jiricekauthor=J.+Jungauthor=H.+K.+Jeonauthor=J.+Cechettoauthor=T.+Christopheauthor=H.+Leeauthor=M.+Kempfauthor=M.+Jacksonauthor=A.+J.+Lenaertsauthor=H.+Phamauthor=V.+Jonesauthor=M.+J.+Seoauthor=Y.+M.+Kimauthor=M.+Seoauthor=J.+J.+Seoauthor=D.+Parkauthor=Y.+Koauthor=I.+Choiauthor=R.+Kimauthor=S.+Y.+Kimauthor=S.+Limauthor=S.+A.+Yimauthor=J.+Namauthor=H.+Kangauthor=H.+Kwonauthor=C.+T.+Ohauthor=Y.+Choauthor=Y.+Jangauthor=J.+Kimauthor=A.+Chuaauthor=B.+H.+Tanauthor=M.+B.+Nanjundappaauthor=S.+P.+Raoauthor=W.+S.+Barnesauthor=R.+Wintjensauthor=J.+R.+Walkerauthor=S.+Alonsoauthor=S.+Leeauthor=J.+Kimauthor=S.+Ohauthor=T.+Ohauthor=U.+Nehrbassauthor=S.+J.+Hanauthor=Z.+Noauthor=J.+Leeauthor=P.+Brodinauthor=S.+N.+Choauthor=K.+Namauthor=J.+Kim&title=Discovery+of+Q203%2C+a+potent+clinical+candidate+for+the+treatment+of+tuberculosis&doi=10.1038%2Fnm.3262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis</span></div><div class="casAuthors">Pethe, Kevin; Bifani, Pablo; Jang, Jichan; Kang, Sunhee; Park, Seijin; Ahn, Sujin; Jiricek, Jan; Jung, Juyoung; Jeon, Hee Kyoung; Cechetto, Jonathan; Christophe, Thierry; Lee, Honggun; Kempf, Marie; Jackson, Mary; Lenaerts, Anne J.; Pham, Ha; Jones, Victoria; Seo, Min Jung; Kim, Young Mi; Seo, Mooyoung; Seo, Jeong Jea; Park, Dongsik; Ko, Yoonae; Choi, Inhee; Kim, Ryangyeo; Kim, Se Yeon; Lim, Seung Bin; Yim, Seung-Ae; Nam, Jiyoun; Kang, Hwankyu; Kwon, Haejin; Oh, Chun-Taek; Cho, Yoojin; Jang, Yunhee; Kim, Junghwan; Chua, Adeline; Tan, Bee Huat; Nanjundappa, Mahesh B.; Rao, Srinivasa P. S.; Barnes, Whitney S.; Wintjens, Rene; Walker, John R.; Alonso, Sylvie; Lee, Saeyeon; Kim, Jungjun; Oh, Soohyun; Oh, Taegwon; Nehrbass, Ulf; Han, Sung-Jun; No, Zaesung; Lee, Jinhwa; Brodin, Priscille; Cho, Sang-Nae; Nam, Kiyean; Kim, Jaeseung</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1157-1160</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">New therapeutic strategies are needed to combat the tuberculosis pandemic and the spread of multidrug-resistant (MDR) and extensively drug-resistant (XDR) forms of the disease, which remain a serious public health challenge worldwide.  The most urgent clin. need is to discover potent agents capable of reducing the duration of MDR and XDR tuberculosis therapy with a success rate comparable to that of current therapies for drug-susceptible tuberculosis.  The last decade has seen the discovery of new agent classes for the management of tuberculosis, several of which are currently in clin. trials.  However, given the high attrition rate of drug candidates during clin. development and the emergence of drug resistance, the discovery of addnl. clin. candidates is clearly needed.  Here, we report on a promising class of imidazopyridine amide (IPA) compds. that block Mycobacterium tuberculosis growth by targeting the respiratory cytochrome bc1 complex.  The optimized IPA compd. Q203 inhibited the growth of MDR and XDR M. tuberculosis clin. isolates in culture broth medium in the low nanomolar range and was efficacious in a mouse model of tuberculosis at a dose less than 1 mg per kg body wt., which highlights the potency of this compd.  In addn., Q203 displays pharmacokinetic and safety profiles compatible with once-daily dosing.  Together, our data indicate that Q203 is a promising new clin. candidate for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqNkAj8BKYybVg90H21EOLACvtfcHk0lhluXRfNhN92Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1WhtrzK&md5=b865009db53f5b4bc15948ded64ef064</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnm.3262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3262%26sid%3Dliteratum%253Aachs%26aulast%3DPethe%26aufirst%3DK.%26aulast%3DBifani%26aufirst%3DP.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DJiricek%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DJ.%26aulast%3DJeon%26aufirst%3DH.%2BK.%26aulast%3DCechetto%26aufirst%3DJ.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DKempf%26aufirst%3DM.%26aulast%3DJackson%26aufirst%3DM.%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DPham%26aufirst%3DH.%26aulast%3DJones%26aufirst%3DV.%26aulast%3DSeo%26aufirst%3DM.%2BJ.%26aulast%3DKim%26aufirst%3DY.%2BM.%26aulast%3DSeo%26aufirst%3DM.%26aulast%3DSeo%26aufirst%3DJ.%2BJ.%26aulast%3DPark%26aufirst%3DD.%26aulast%3DKo%26aufirst%3DY.%26aulast%3DChoi%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DLim%26aufirst%3DS.%26aulast%3DYim%26aufirst%3DS.%2BA.%26aulast%3DNam%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DH.%26aulast%3DKwon%26aufirst%3DH.%26aulast%3DOh%26aufirst%3DC.%2BT.%26aulast%3DCho%26aufirst%3DY.%26aulast%3DJang%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DChua%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DB.%2BH.%26aulast%3DNanjundappa%26aufirst%3DM.%2BB.%26aulast%3DRao%26aufirst%3DS.%2BP.%26aulast%3DBarnes%26aufirst%3DW.%2BS.%26aulast%3DWintjens%26aufirst%3DR.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DAlonso%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DOh%26aufirst%3DS.%26aulast%3DOh%26aufirst%3DT.%26aulast%3DNehrbass%26aufirst%3DU.%26aulast%3DHan%26aufirst%3DS.%2BJ.%26aulast%3DNo%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DBrodin%26aufirst%3DP.%26aulast%3DCho%26aufirst%3DS.%2BN.%26aulast%3DNam%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Q203%252C%2520a%2520potent%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520tuberculosis%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1157%26epage%3D1160%26doi%3D10.1038%2Fnm.3262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Kang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, R. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pethe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">No, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span> </span><span class="NLM_article-title">Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5293</span><span class="NLM_x">–</span> <span class="NLM_lpage">5305</span><span class="refDoi"> DOI: 10.1021/jm5003606</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5003606" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1Wqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5293-5305&author=S.+Kangauthor=R.+Y.+Kimauthor=M.+J.+Seoauthor=S.+Leeauthor=Y.+M.+Kimauthor=M.+Seoauthor=J.+J.+Seoauthor=Y.+Koauthor=I.+Choiauthor=J.+Jangauthor=J.+Namauthor=S.+Parkauthor=H.+Kangauthor=H.+J.+Kimauthor=J.+Kimauthor=S.+Ahnauthor=K.+Petheauthor=K.+Namauthor=Z.+Noauthor=J.+Kim&title=Lead+optimization+of+a+novel+series+of+imidazo%5B1%2C2-a%5Dpyridine+amides+leading+to+a+clinical+candidate+%28Q203%29+as+a+multi-+and+extensively-drug-resistant+anti-tuberculosis+agent&doi=10.1021%2Fjm5003606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization of a Novel Series of Imidazo[1,2-a]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent</span></div><div class="casAuthors">Kang, Sunhee; Kim, Ryang Yeo; Seo, Min Jung; Lee, Saeyeon; Kim, Young Mi; Seo, Mooyoung; Seo, Jeong Jea; Ko, Yoonae; Choi, Inhee; Jang, Jichan; Nam, Jiyoun; Park, Seijin; Kang, Hwankyu; Kim, Hyung Jun; Kim, Jungjun; Ahn, Sujin; Pethe, Kevin; Nam, Kiyean; No, Zaesung; Kim, Jaeseung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5293-5305</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A crit. unmet clin. need to combat the global tuberculosis epidemic is the development of potent agents capable of reducing the time of multi-drug-resistant (MDR) and extensively-drug-resistant (XDR) tuberculosis therapy.  In this paper, we report on the optimization of imidazo[1,2-a]pyridine amide (IPA) lead compd. I, which led to the design and synthesis of Q203 II (R1 = 6-Cl).  We found that the amide linker with IPA core is very important for activity against Mycobacterium tuberculosis H37Rv.  Linearity and lipophilicity of the amine part in the IPA series play a crit. role in improving in vitro and in vivo efficacy and pharmacokinetic profile.  The optimized IPAs II (R1 = 7-Cl, 6-Cl) showed not only excellent oral bioavailability (80.2% and 90.7%, resp.) with high exposure of the area under curve (AUC) but also displayed significant colony-forming unit (CFU) redn. (1.52 and 3.13 log10 redn. at 10 mg/kg dosing level, resp.) in mouse lung.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUtN4tIBVZU7Vg90H21EOLACvtfcHk0lhinbTBMWaoPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1Wqtrg%253D&md5=377fc206a894d392a8394145c4019367</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm5003606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5003606%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DR.%2BY.%26aulast%3DSeo%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DY.%2BM.%26aulast%3DSeo%26aufirst%3DM.%26aulast%3DSeo%26aufirst%3DJ.%2BJ.%26aulast%3DKo%26aufirst%3DY.%26aulast%3DChoi%26aufirst%3DI.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DNam%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DKang%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DPethe%26aufirst%3DK.%26aulast%3DNam%26aufirst%3DK.%26aulast%3DNo%26aufirst%3DZ.%26aulast%3DKim%26aufirst%3DJ.%26atitle%3DLead%2520optimization%2520of%2520a%2520novel%2520series%2520of%2520imidazo%255B1%252C2-a%255Dpyridine%2520amides%2520leading%2520to%2520a%2520clinical%2520candidate%2520%2528Q203%2529%2520as%2520a%2520multi-%2520and%2520extensively-drug-resistant%2520anti-tuberculosis%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5293%26epage%3D5305%26doi%3D10.1021%2Fjm5003606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Palencia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, C. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Easom, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houston, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meewan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rock, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franzblau, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolhiser, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruppo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenaerts, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Malley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parish, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ioerger, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sacchettini, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rullas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angulo-Barturen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérez-Herrán, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendoza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barros, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cusack, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plattner, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alley, M. R. K.</span><span> </span><span class="NLM_article-title">Discovery of novel oral protein synthesis inhibitors of <i>Mycobacterium tuberculosis</i> that target leucyl-tRNA synthetase</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">6271</span><span class="NLM_x">–</span> <span class="NLM_lpage">6280</span><span class="refDoi"> DOI: 10.1128/AAC.01339-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1128%2FAAC.01339-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=27503647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=6271-6280&author=A.+Palenciaauthor=X.+Liauthor=W.+Buauthor=W.+Choiauthor=C.+Z.+Dingauthor=E.+E.+Easomauthor=L.+Fengauthor=V.+Hernandezauthor=P.+Houstonauthor=L.+Liuauthor=M.+Meewanauthor=M.+Mohanauthor=F.+L.+Rockauthor=H.+Sextonauthor=S.+Zhangauthor=Y.+Zhouauthor=B.+Wanauthor=Y.+Wangauthor=S.+G.+Franzblauauthor=L.+Woolhiserauthor=V.+Gruppoauthor=A.+J.+Lenaertsauthor=T.+O%E2%80%99Malleyauthor=T.+Parishauthor=C.+B.+Cooperauthor=M.+G.+Watersauthor=Z.+Maauthor=T.+R.+Ioergerauthor=J.+C.+Sacchettiniauthor=J.+Rullasauthor=I.+Angulo-Barturenauthor=E.+P%C3%A9rez-Herr%C3%A1nauthor=A.+Mendozaauthor=D.+Barrosauthor=S.+Cusackauthor=J.+J.+Plattnerauthor=M.+R.+K.+Alley&title=Discovery+of+novel+oral+protein+synthesis+inhibitors+of+Mycobacterium+tuberculosis+that+target+leucyl-tRNA+synthetase&doi=10.1128%2FAAC.01339-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel oral protein synthesis inhibitors of Mycobacterium tuberculosis that target leucyl-tRNA synthetase</span></div><div class="casAuthors">Palencia, Andres; Li, Xianfeng; Bu, Wei; Choi, Wai; Ding, Charles Z.; Easom, Eric E.; Feng, Lisa; Hernandez, Vincent; Houston, Paul; Liu, Liang; Meewan, Maliwan; Mohan, Manisha; Rock, Fernando L.; Sexton, Holly; Zhang, Suoming; Zhou, Yasheen; Wan, Baojie; Wang, Yuehong; Franzblau, Scott G.; Woolhiser, Lisa; Gruppo, Veronica; Lenaerts, Anne J.; O'Malley, Theresa; Parish, Tanya; Cooper, Christopher B.; Gerard, Waters M.; Ma, Zhenkun; Ioerger, Thomas R.; Sacchettini, James C.; Rullas, Joaquin; Angulo-Barturen, Inigo; Perez-Herran, Esther; Mendoza, Alfonso; Barros, David; Cusack, Stephen; Plattner, Jacob J.; Alley, M. R. K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6271-6280</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The recent development and spread of extensively drug-resistant and totally drug-resistant resistant (TDR) strains of Mycobacterium tuberculosis highlight the need for new antitubercular drugs.  Protein synthesis inhibitors have played an important role in the treatment of tuberculosis (TB) starting with the inclusion of streptomycin in the first combination therapies.  Although parenteral aminoglycosides are a key component of therapy for multidrug-resistant TB, the oxazolidinone linezolid is the only orally available protein synthesis inhibitor that is effective against TB.  Small-mol. inhibitors of aminoacyl-tRNA synthetases (AARSs), which are known to be excellent antibacterial protein synthesis targets, are orally bioavailable and effective against M. tuberculosis in TB mouse infection models.  The authors applied the oxaborole tRNA-trapping (OBORT) mechanism, which was first developed to target fungal cytoplasmic leucyl-tRNA synthetase (LeuRS), to M. tuberculosis LeuRS.  X-ray crystallog. was used to guide the design of LeuRS inhibitors that have good biochem. potency and excellent whole-cell activity against M. tuberculosis.  Importantly, their good oral bioavailability translates into in vivo efficacy in both the acute and chronic mouse models of TB with potency comparable to that of the frontline drug isoniazid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXJzF8QHuHLbVg90H21EOLACvtfcHk0lixCz2wCx58vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKktb4%253D&md5=539a0a2039474285a7d243f972bc3a63</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1128%2FAAC.01339-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01339-16%26sid%3Dliteratum%253Aachs%26aulast%3DPalencia%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DBu%26aufirst%3DW.%26aulast%3DChoi%26aufirst%3DW.%26aulast%3DDing%26aufirst%3DC.%2BZ.%26aulast%3DEasom%26aufirst%3DE.%2BE.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DHernandez%26aufirst%3DV.%26aulast%3DHouston%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMeewan%26aufirst%3DM.%26aulast%3DMohan%26aufirst%3DM.%26aulast%3DRock%26aufirst%3DF.%2BL.%26aulast%3DSexton%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWan%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DWoolhiser%26aufirst%3DL.%26aulast%3DGruppo%26aufirst%3DV.%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DT.%26aulast%3DParish%26aufirst%3DT.%26aulast%3DCooper%26aufirst%3DC.%2BB.%26aulast%3DWaters%26aufirst%3DM.%2BG.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DIoerger%26aufirst%3DT.%2BR.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26aulast%3DRullas%26aufirst%3DJ.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DP%25C3%25A9rez-Herr%25C3%25A1n%26aufirst%3DE.%26aulast%3DMendoza%26aufirst%3DA.%26aulast%3DBarros%26aufirst%3DD.%26aulast%3DCusack%26aufirst%3DS.%26aulast%3DPlattner%26aufirst%3DJ.%2BJ.%26aulast%3DAlley%26aufirst%3DM.%2BR.%2BK.%26atitle%3DDiscovery%2520of%2520novel%2520oral%2520protein%2520synthesis%2520inhibitors%2520of%2520Mycobacterium%2520tuberculosis%2520that%2520target%2520leucyl-tRNA%2520synthetase%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D6271%26epage%3D6280%26doi%3D10.1128%2FAAC.01339-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Alley, M. R. K.; Hernandez, V.; Plattner, J. J.; Li, X.; Barros-Aguirre, D.; Giordano, I.</span><span> </span><span class="NLM_article-title">Tricyclic benzoxaborole compounds and uses thereof</span>. WO 2015/021396 A9, February 12,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=M.+R.+K.+Alley&author=V.+Hernandez&author=J.+J.+Plattner&author=X.+Li&author=D.+Barros-Aguirre&author=I.+Giordano&title=Tricyclic+benzoxaborole+compounds+and+uses+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlley%26aufirst%3DM.%2BR.%2BK.%26atitle%3DTricyclic%2520benzoxaborole%2520compounds%2520and%2520uses%2520thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Alley, M. R. K.; Barros-Aguirre, D.; Giordano, I.; Hernandez, V.; Li, X.; Plattner, J. J.</span><span> </span><span class="NLM_article-title">Benzoxaborole compounds and uses thereof</span>. WO 2016/128949 A1, August 18,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+R.+K.+Alley&author=D.+Barros-Aguirre&author=I.+Giordano&author=V.+Hernandez&author=X.+Li&author=J.+J.+Plattner&title=Benzoxaborole+compounds+and+uses+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlley%26aufirst%3DM.%2BR.%2BK.%26atitle%3DBenzoxaborole%2520compounds%2520and%2520uses%2520thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Hernandez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crépin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palencia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cusack, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freund, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meewan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rock, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheoran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nieman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anugula, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keramane, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savariraj, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subedi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Leary, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Marsh, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mushtaq, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livermore, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alley, M. R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plattner, J. J.</span><span> </span><span class="NLM_article-title">Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1394</span><span class="NLM_x">–</span> <span class="NLM_lpage">1403</span><span class="refDoi"> DOI: 10.1128/AAC.02058-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1128%2FAAC.02058-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=23295920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltV2htLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=1394-1403&author=V.+Hernandezauthor=T.+Cr%C3%A9pinauthor=A.+Palenciaauthor=S.+Cusackauthor=T.+Akamaauthor=S.+J.+Bakerauthor=W.+Buauthor=L.+Fengauthor=Y.+R.+Freundauthor=L.+Liuauthor=M.+Meewanauthor=M.+Mohanauthor=W.+Maoauthor=F.+L.+Rockauthor=H.+Sextonauthor=A.+Sheoranauthor=Y.+Zhangauthor=Y.+K.+Zhangauthor=Y.+Zhouauthor=J.+A.+Niemanauthor=M.+R.+Anugulaauthor=E.+M.+Keramaneauthor=K.+Savarirajauthor=D.+S.+Reddyauthor=R.+Sharmaauthor=R.+Subediauthor=R.+Singhauthor=A.+O%E2%80%99Learyauthor=N.+L.+Simonauthor=P.+L.+De+Marshauthor=S.+Mushtaqauthor=M.+Warnerauthor=D.+M.+Livermoreauthor=M.+R.+K.+Alleyauthor=J.+J.+Plattner&title=Discovery+of+a+novel+class+of+boron-based+antibacterials+with+activity+against+gram-negative+bacteria&doi=10.1128%2FAAC.02058-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel class of boron-based antibacterials with activity against Gram-negative bacteria</span></div><div class="casAuthors">Hernandez, Vincent; Crepin, Thibaut; Palencia, Andres; Cusack, Stephen; Akama, Tsutomu; Baker, Stephen J.; Bu, Wei; Feng, Lisa; Freund, Yvonne R.; Liu, Liang; Meewan, Maliwan; Mohan, Manisha; Mao, Weimin; Rock, Fernando L.; Sexton, Holly; Sheoran, Anita; Zhang, Yanchen; Zhang, Yong-Kang; Zhou, Yasheen; Nieman, James A.; Anugula, Mahipal Reddy; Keramane, El Mehdi; Savariraj, Kingsley; Reddy, D. Shekhar; Sharma, Rashmi; Subedi, Rajendra; Singh, Rajeshwar; O'Leary, Ann; Simon, Nerissa L.; De Marsh, Peter L.; Mushtaq, Shazad; Warner, Marina; Livermore, David M.; Alley, M. R. K.; Plattner, Jacob J.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1394-1403</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Gram-neg. bacteria cause approx. 70% of the infections in intensive care units.  A growing no. of bacterial isolates responsible for these infections are resistant to currently available antibiotics and to many in development.  Most agents under development are modifications of existing drug classes, which only partially overcome existing resistance mechanisms.  Therefore, new classes of Gram-neg. antibacterials with truly novel modes of action are needed to circumvent these existing resistance mechanisms.  We have previously identified a new a way to inhibit an aminoacyl-tRNA synthetase, leucyl-tRNA synthetase (LeuRS), in fungi via the oxaborole tRNA trapping (OBORT) mechanism.  Herein, we show how we have modified the OBORT mechanism using a structure-guided approach to develop a new boron-based antibiotic class, the aminomethylbenzoxaboroles, which inhibit bacterial leucyl-tRNA synthetase and have activity against Gram-neg. bacteria by largely evading the main efflux mechanisms in Escherichia coli and Pseudomonas aeruginosa.  The lead analog, AN3365, is active against Gram-neg. bacteria, including Enterobacteriaceae bearing NDM-1 and KPC carbapenemases, as well as P. aeruginosa.  This novel boron-based antibacterial, AN3365, has good mouse pharmacokinetics and was efficacious against E. coli and P. aeruginosa in murine thigh infection models, which suggest that this novel class of antibacterials has the potential to address this unmet medical need.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWl5Oj0jzVnLVg90H21EOLACvtfcHk0lhhfrXa0OPUbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltV2htLg%253D&md5=7ed74bde2bacfa4ae20abb50b745c57d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1128%2FAAC.02058-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02058-12%26sid%3Dliteratum%253Aachs%26aulast%3DHernandez%26aufirst%3DV.%26aulast%3DCr%25C3%25A9pin%26aufirst%3DT.%26aulast%3DPalencia%26aufirst%3DA.%26aulast%3DCusack%26aufirst%3DS.%26aulast%3DAkama%26aufirst%3DT.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DBu%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DFreund%26aufirst%3DY.%2BR.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMeewan%26aufirst%3DM.%26aulast%3DMohan%26aufirst%3DM.%26aulast%3DMao%26aufirst%3DW.%26aulast%3DRock%26aufirst%3DF.%2BL.%26aulast%3DSexton%26aufirst%3DH.%26aulast%3DSheoran%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DNieman%26aufirst%3DJ.%2BA.%26aulast%3DAnugula%26aufirst%3DM.%2BR.%26aulast%3DKeramane%26aufirst%3DE.%2BM.%26aulast%3DSavariraj%26aufirst%3DK.%26aulast%3DReddy%26aufirst%3DD.%2BS.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DSubedi%26aufirst%3DR.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Leary%26aufirst%3DA.%26aulast%3DSimon%26aufirst%3DN.%2BL.%26aulast%3DDe%2BMarsh%26aufirst%3DP.%2BL.%26aulast%3DMushtaq%26aufirst%3DS.%26aulast%3DWarner%26aufirst%3DM.%26aulast%3DLivermore%26aufirst%3DD.%2BM.%26aulast%3DAlley%26aufirst%3DM.%2BR.%2BK.%26aulast%3DPlattner%26aufirst%3DJ.%2BJ.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520class%2520of%2520boron-based%2520antibacterials%2520with%2520activity%2520against%2520gram-negative%2520bacteria%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D1394%26epage%3D1403%26doi%3D10.1128%2FAAC.02058-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Conde, J. J.; Kowalski, A. J.; Zajac, M. A.</span><span> </span><span class="NLM_article-title">Process for preparing benzoxaboroles</span>. WO 2011/127143 A1, October 13,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+J.+Conde&author=A.+J.+Kowalski&author=M.+A.+Zajac&title=Process+for+preparing+benzoxaboroles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DConde%26aufirst%3DJ.%2BJ.%26atitle%3DProcess%2520for%2520preparing%2520benzoxaboroles%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Vshyvenko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clapson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, D. G.</span><span> </span><span class="NLM_article-title">Characterization of the dynamic equilibrium between closed and open forms of the benzoxaborole pharmacophore</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1097</span><span class="NLM_x">–</span> <span class="NLM_lpage">1101</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00300</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00300" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFGhsLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1097-1101&author=S.+Vshyvenkoauthor=M.+L.+Clapsonauthor=I.+Suzukiauthor=D.+G.+Hall&title=Characterization+of+the+dynamic+equilibrium+between+closed+and+open+forms+of+the+benzoxaborole+pharmacophore&doi=10.1021%2Facsmedchemlett.6b00300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Dynamic Equilibrium between Closed and Open Forms of the Benzoxaborole Pharmacophore</span></div><div class="casAuthors">Vshyvenko, Sergey; Clapson, Marissa L.; Suzuki, Itaru; Hall, Dennis G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1097-1101</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Benzoxaboroles are a class of five-membered hemiboronic acids that recently attracted significant attention as a new pharmacophore on account of their unique structural and physicochem. properties and their ability to interact selectively with biomols.  Their structural behavior in water and its effect on their physiol. properties remain unclear, esp. the question of dynamic hydrolytic equil. of the oxaborole ring.  Herein, we used NMR spectroscopy, in mixed aq.-org. solvent, to confirm the strong preference for the closed form of benzoxaborole and its six- and seven-membered homologues over the open boronic acid form.  Only with the eight-membered homolog does the cyclic form become unfavorable.  Using dynamic VT-NMR studies with designed probe compd. 20, we demonstrate that the oxaborole ring undergoes rapid hydrolytic ring closing-opening at ambient temp. at a rate of >100 Hz via a mechanism featuring rate-limiting proton-transfer steps.  This knowledge can help provide a better understanding of the behavior of benzoxaboroles in biol. systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzXVZHWiwlXbVg90H21EOLACvtfcHk0lhhfrXa0OPUbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFGhsLfO&md5=81864340ccb800c9414f2d1dc0f41a89</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00300%26sid%3Dliteratum%253Aachs%26aulast%3DVshyvenko%26aufirst%3DS.%26aulast%3DClapson%26aufirst%3DM.%2BL.%26aulast%3DSuzuki%26aufirst%3DI.%26aulast%3DHall%26aufirst%3DD.%2BG.%26atitle%3DCharacterization%2520of%2520the%2520dynamic%2520equilibrium%2520between%2520closed%2520and%2520open%2520forms%2520of%2520the%2520benzoxaborole%2520pharmacophore%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D1097%26epage%3D1101%26doi%3D10.1021%2Facsmedchemlett.6b00300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Lue, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, S. O.</span><span> </span><span class="NLM_article-title">An aminoacyl-tRNA synthetase with a defunct editing site</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3010</span><span class="NLM_x">–</span> <span class="NLM_lpage">3016</span><span class="refDoi"> DOI: 10.1021/bi047901v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi047901v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2005&pages=3010-3016&author=S.+W.+Lueauthor=S.+O.+Kelley&title=An+aminoacyl-tRNA+synthetase+with+a+defunct+editing+site&doi=10.1021%2Fbi047901v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fbi047901v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi047901v%26sid%3Dliteratum%253Aachs%26aulast%3DLue%26aufirst%3DS.%2BW.%26aulast%3DKelley%26aufirst%3DS.%2BO.%26atitle%3DAn%2520aminoacyl-tRNA%2520synthetase%2520with%2520a%2520defunct%2520editing%2520site%26jtitle%3DBiochemistry%26date%3D2005%26volume%3D44%26spage%3D3010%26epage%3D3016%26doi%3D10.1021%2Fbi047901v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Blanco-Ruano, D.; Roberts, D. M.; Gonzalez-Del-Rio, R.; Alvarez, D.; Rebollo, M. J.; Perez-Herran, E.; Mendoza, A.</span><span> </span><span class="NLM_article-title">Antimicrobial Susceptibility Testing for Mycobacterium sp.</span> In  <span class="citation_source-book">Mycobacteria Protocols</span>; <span class="NLM_contrib-group">Parish, T.; Roberts, D. M.</span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Hatfield, Hertfordshire, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">257</span><span class="NLM_x">–</span> <span class="NLM_lpage">268</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1007%2F978-1-4939-2450-9_15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=257-268&author=D.+Blanco-Ruano&author=D.+M.+Roberts&author=R.+Gonzalez-Del-Rio&author=D.+Alvarez&author=M.+J.+Rebollo&author=E.+Perez-Herran&author=A.+Mendozaauthor=T.+Parish&author=D.+M.+Roberts&title=Mycobacteria+Protocols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-2450-9_15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4939-2450-9_15%26sid%3Dliteratum%253Aachs%26aulast%3DBlanco-Ruano%26aufirst%3DD.%26atitle%3DAntimicrobial%2520Susceptibility%2520Testing%2520for%2520Mycobacterium%2520sp.%26btitle%3DMycobacteria%2520Protocols%26aulast%3DParish%26aufirst%3DT.%26pub%3DSpringer%26date%3D2015%26spage%3D257%26epage%3D268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Rullas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beltrán, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardona, P.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cáceres, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García Bustos, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angulo-Barturen, I.</span><span> </span><span class="NLM_article-title">Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2262</span><span class="NLM_x">–</span> <span class="NLM_lpage">2264</span><span class="refDoi"> DOI: 10.1128/AAC.01423-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=10.1128%2FAAC.01423-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=20160054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtFeltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=2262-2264&author=J.+Rullasauthor=J.+I.+Garc%C3%ADaauthor=M.+Beltr%C3%A1nauthor=P.-J.+Cardonaauthor=N.+C%C3%A1ceresauthor=J.+F.+Garc%C3%ADa+Bustosauthor=I.+Angulo-Barturen&title=Fast+standardized+therapeutic-efficacy+assay+for+drug+discovery+against+tuberculosis&doi=10.1128%2FAAC.01423-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis</span></div><div class="casAuthors">Rullas, Joaquin; Garcia, Juan Ignacio; Beltran, Manuela; Cardona, Pere-Joan; Caceres, Neus; Garcia-Bustos, Jose Francisco; Angulo-Barturen, Inigo</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2262-2264</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Murine models of Mycobacterium tuberculosis infection are essential tools in drug discovery.  Here we describe a fast standardized 9-day acute assay intended to measure the efficacy of drugs against M. tuberculosis growing in the lungs of immunocompetent mice.  This assay is highly reproducible, allows good throughput, and was validated for drug lead optimization using isoniazid, rifampin, ethambutol, pyrazinamide, linezolid, and moxifloxacin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpajX5TwxQ_E7Vg90H21EOLACvtfcHk0lhhfrXa0OPUbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtFeltLo%253D&md5=c923fae175b34eab3778a0e4d8d51878</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1128%2FAAC.01423-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01423-09%26sid%3Dliteratum%253Aachs%26aulast%3DRullas%26aufirst%3DJ.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DJ.%2BI.%26aulast%3DBeltr%25C3%25A1n%26aufirst%3DM.%26aulast%3DCardona%26aufirst%3DP.-J.%26aulast%3DC%25C3%25A1ceres%26aufirst%3DN.%26aulast%3DGarc%25C3%25ADa%2BBustos%26aufirst%3DJ.%2BF.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26atitle%3DFast%2520standardized%2520therapeutic-efficacy%2520assay%2520for%2520drug%2520discovery%2520against%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D2262%26epage%3D2264%26doi%3D10.1128%2FAAC.01423-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00631&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-19%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00631%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00631" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799a69daf633c5e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
